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ABSTRACT

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a condition of lower urinary
tract (LUT) dysfunction, characterized by 6 ≤ weeks of LUT symptoms and pelvic pain or
discomfort, with other discernable causes excluded. Few treatments exist and more
therapeutic targets are needed. Progress is further compounded by the unknown etiology
of IC/BPS.
A subpopulation of interstitial cells has been recently identified in the urinary
bladder detrusor muscle and lamina propria (LP) and many express the platelet-derived
growth factor receptor alpha (PDGFRα). Functionally, LP interstitial cells are theorized
to act as intermediary sensors, transducing signals from the urothelium to the detrusor
and/or nerves, and the detrusor interstitial cells are theorized to regulate smooth muscle
excitability. Reports suggest urinary bladder interstitial cells may contribute to LUT
dysfunction; PDGFRα+ interstitial cells demonstrate altered chemical expression and
electrophysiological activity and are associated with bladder hyperactivity in human
patients and animal models with IC/BPS or OAB. Imatinib mesylate is a tyrosine kinase
inhibitor of the PDGFRα and -β, c-KIT, and BCR-ABL tyrosine kinases, and has been
previously used in the LUT to disrupt interstitial cell function. In models of LUT
dysfunction, imatinib has been shown to reduce interstitial cell marker expression,
detrusor contractile properties, and improve bladder function.
We hypothesize that urinary bladder PDGFRα interstitial cells contribute to
bladder dysfunction (e.g., decreased voiding frequency, decreased infused volume,
increased somatic sensitivity) by altering the inflammatory milieu of the micturition
reflex components (e.g., urinary bladder). In the first aim of this dissertation, we
investigated the effect of imatinib on functional LUT outcomes with a prevention and
treatment design, in a mouse model of cyclophosphamide (CYP)-induced cystitis. These
studies suggest that imatinib administration, by prevention or treatment, improves
cystometric LUT outcomes, but does not affect somatic sensitivity, in mice with acute
CYP-induced cystitis. In the second aim of this dissertation, we investigated potential
mechanism(s) of action by which imatinib mediates LUT improvements in acute CYPinduced cystitis. These studies suggest (1) imatinib prevention reduces urinary bladder
inflammatory mediator expression, (2) imatinib treatment acts by other, non-immune
mediated mechanism(s) or affects mediators other than those examined, and (3) imatinib
prevention and treatment reduces LP phosphorylated kinase expression in mice with
acute CYP-induced cystitis.
Collectively, these studies characterize the effects of imatinib on LUT at the
functional and cellular level, by two experimental designs, in a mouse model of CYPinduced cystitis, and demonstrate pre-clinical evidence, supporting imatinib as a potential
therapeutic option for LUT dysfunction. Ultimately, this work furthers our understanding
of imatinib mesylate on urinary bladder function, inflammatory mediators and signaling
mechanisms in a mouse model of CYP-induced cystitis.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW
1.1. Lower Urinary Tract (LUT) Anatomy and Function
1.1.1. LUT Anatomy
LUT Gross Anatomical Features
This section will review human LUT structures. The lower urinary tract (LUT) is a
part of the renal system and includes the urinary bladder and the urethra. The LUT is
contained within the lower abdominal viscera. It is positioned posterior to the pubic bone,
sitting within the bowl-shaped structure of the pelvic floor, ventral to the rectum. In
females, the LUT is ventral to the reproductive organs (Elbadawi, 1996).
The bladder is separated into four gross anatomical regions: the apex, body, base
(also referred to as fundus), and neck. The apex is the anterior, superior area of the bladder
which points toward the abdominal wall. The apex is attached to the fibrous cord, urachus,
which ascends through the extraperitoneal, abdominal tissues to connect with the
umbilicus. The urachus is an embryological remnant of a tube through which urine drains
from the fetus in the first trimester, known as the allantois (Shermadou et al., 2022).
Processed urine is transported from the kidneys to the bladder bilaterally, through smooth
muscle, tubular structures known as the ureters. The ureters attach to the distal, dorsal
surface of the bladder and delineate the bladder body and base. The bladder body is defined
as the region above the entrance of the ureters, while the bladder base (also referred to as
fundus) lies below. The bladder base additionally consists of the trigone, defined as the
region between the ureteral orifices and internal urethral inlet and bladder neck (Elbadawi,
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1996). The bladder neck is the region inferior to the base, at which the bladder begins to
taper and narrow, eventually leading to the urethra.
The urethra begins at the internal urethral meatus of the bladder neck and extends
to the external urethral meatus. In females, the urethra is 3-4 cm in length whereas the male
urethra is longer (18-20 cm) and wider in diameter than the female urethra, as it extends
more distally, traversing through the prostate gland and penis (Elbadawi, 1996; Mistry et
al., 2020). The rhabdosphincter (i.e., external urethral sphincter; EUS) is a striated muscle
located on the external, ventral aspect of the urethra, that surrounds the urethra
incompletely, in a circular, horseshoe like fashion. The EUS is present in both males and
females. In females, the EUS surrounds nearly the full-length of the urethra. The EUS
covers only a portion of the male urethra, extending from the bladder base through the
membranous section of the urethra (Abelson et al., 2018). The pelvic floor muscles (i.e.,
levator ani and coccygeus muscles) are striated muscles external to the distal urethra, which
provide additional support to the abdominopelvic organs and aid in maintaining continence
in both sexes (Abelson et al., 2018).
LUT Function and Layers
The LUT exhibits two functional phases: filling and elimination. The urinary
bladder acts as a reservoir, passively storing kidney byproducts (i.e., urine) during filling.
The urethra, bladder neck and urethral sphincter, act as an outlet through which urine is
voided during the elimination phase (de Groat et al., 2015). The LUT consists of 3 main
tissue layers: the mucosa (closest to the lumen), the muscularis propria, and the surrounding
adventitia and serosa (Birder and Andersson, 2013) (Figure 1, Figure 2).
2

Mucosa: Urothelium and Lamina Propria
The mucosa is composed of the urothelium, basement membrane, lamina propria
and some smooth muscle cells (SMCs) (i.e., muscularis mucosae) (Birder and Andersson,
2013).
The urothelium is the innermost layer of the mucosa, lining the lumen of the
bladder. The urothelium consists of transitional epithelial cells organized in 3 layers
including a basal, intermediate, and superficial cell layer. The basal cell layer adheres to
the basement membrane. The intermediate and basal urothelial cell layers play important
roles in proliferation and differentiation during injury. A special type of epithelial cell
known as the umbrella cell forms the superficial urothelial layer. The bladder must be
inherently pliable to properly store accumulating urine. It must expand and contract during
the elimination and storage phases, while maintaining bladder function. Large (25-250
μm), hexagonally shaped, umbrella cells greatly contribute to this ability as they can
change shape in response to bladder filling, due to their unique protein expression profile
and vesicular trafficking mechanisms. Umbrella cells express uroplakin, specialized lipid,
and tight junction (e.g., occludins, claudins) proteins which aid in maintaining the
urothelial barrier (Birder and Andersson, 2013). A polysaccharide glycosaminoglycan
(Lavoie et al.) layer lines the luminal surface of the umbrella cells and provides additional
barrier support by preventing passage of microorganisms and toxic substances. The
urothelial layers and properties remain relatively consistent throughout the bladder (i.e.,
detrusor, trigone regions); however, the urothelial layer of the bladder neck/proximal
urethra and renal pelvis are notably different. The urethral urothelium exhibits stratified,
3

columnar epithelium and lacks urothelial specific protein expression (i.e., uroplakin,
occludins, claudins) (Birder and Andersson, 2013).
The urothelium was once thought to be a relatively inactive component of the LUT,
acting solely as a barrier, preventing toxins, urinary metabolites, and microorganisms from
penetrating the bladder wall. However, it is now well known that the urothelium is a
biologically active layer. Numerous studies demonstrate that the urothelium plays critical
modulatory roles in LUT sensory signaling (Birder and Andersson, 2013). Mechanical (i.e.,
stretch, pressure) or chemical (i.e., composition of urine, heat, transmitters released from
nerves and surrounding cells) stimuli may induce the release of neuroactive chemicals such
as ATP, acetylcholine (ACh), nitric oxide (NO), growth factors, etc., from urothelial cells.
Additionally, urothelial cells express channels and receptors responsive to a wide array of
stimuli such as noradrenaline, ACh, ATP, UTP, ADP, adenosine, corticotrophin releasing
hormone (CRH), neurotrophins, endothelins, estrogen, bradykinin, tachykinin, amilorideand mechanosensitive epithelial sodium channels, and TRP channels. Many of these
channels and receptors are also expressed on afferent nerves. Compounds released from
the urothelium may act by autocrine or paracrine mechanisms. Furthermore, they may
modulate sensory information by inducing changes in urothelial cells, lamina propria cells,
detrusor SMCs, blood vessels, inflammatory cells, and afferent nerves (Birder and
Andersson, 2013).
The lamina propria (LP) lies between the most external layer of the bladder,
muscularis detrusor, and the urothelial basement membrane. This tissue may also be
referred to as the submucosa or suburothelium. The LP is an extracellular matrix consisting
4

of many fiber types (i.e., elastin, collagen), cell types (i.e., adipocytes, fibroblasts,
interstitial cells), blood vessels, lymphatic vessels, smooth muscle fascicles (i.e.,
muscularis mucosae) and nerve terminal endings (Figure 2). The LP is one continuous
tissue; however, many investigators distinguish between an upper lamina propria (U. LP)
and deeper lamina propria (D. LP) (Gabella, 2019; Gevaert et al., 2017; Gevaert et al.,
2014; Neuhaus et al., 2018). The U. LP is an organized, compact region just beneath the
urothelium that contains a dense layer of interstitial cells, an extensive plexus of afferent
nerve endings, and a network of capillaries, amongst thin collagen fibers. The D. LP is a
loosely organized region between the U. LP and detrusor muscle, containing few interstitial
cells and occasional muscularis mucosae, amongst thick, interwoven collagen fibers,
(Figure 2, Figure 3).
Afferent nerve fibers primarily terminate in the lower region of the bladder body
and neck, within the U. LP, with some endings extending into the urothelium (Birder and
Andersson, 2013; Fowler et al., 2008) where they express vasoactive intestinal polypeptide
(VIP), calcitonin gene-related peptide (CGRP), tachykinin, or acetylcholinesterase.
Efferent nerve terminals are present but sparse in the LP and primarily terminate within
smooth muscle (Andersson and Arner, 2004). Small, parasympathetic intramural ganglia
are present in the LP and within detrusor smooth muscle bundles in the human bladder, but
are not found in rats, cats, guinea pigs and rabbits (Birder and Andersson, 2013; Gosling
and Dixon, 1974). Like the urothelium, investigators have recently begun to re-examine
the LP’s involvement in afferent signaling as numerous studies suggest that urinary bladder
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LP interstitial cells may act as intermediaries or amplifiers of bladder sensations (Birder
and Andersson, 2013; Koh et al., 2018; Neuhaus et al., 2020).
Muscularis Propria: Bladder
The detrusor muscle is the muscularis propria component of the bladder with the
primary function to contract during voiding events to expel urine from the bladder through
urethra and out of the body. The detrusor is made of smooth muscle cells (SMC) organized
in 3 sheets. Two longitudinal smooth muscle sheets surround a middle, circular smooth
muscle sheet. SMC bundles of varying sizes are interspersed throughout these sheets and
suspended in collagen-rich connective tissue (Andersson and Arner, 2004). The urinary
smooth muscle is difficult to categorize concerning smooth muscle nomenclature.
Andersson and Arner (2004) describe the detrusor as a relatively fast smooth muscle which
holds phasic characteristics. A urinary interstitial cell sub-population exists in the detrusor
and the urethral muscularis that is separate and distinct from LP interstitial cells (Gevaert
et al., 2017; Gevaert et al., 2014; Koh et al., 2012). These cells lie alongside and in between
smooth muscle bundles and may regulate SMC excitability (Koh et al., 2018). The detrusor
muscle extends over much of the bladder body and base yet is notably different than the
smooth musculature of the ureteral orifices/distal ureters, trigone, and urethra.
Muscularis Propria: Ureteral and Trigone Smooth Muscle
Two sheets of helical, longitudinally oriented SMCs ensheath the distal ureters. The
trigone region contains a triangular muscle sheet which extends over the base of the dorsal
detrusor, tapers out at the ureteral orifices, and slightly extends along the inner, dorsal
aspect of the urethra (Elbadawi, 1996). The smooth musculature of the trigone and distal
6

ureters is responsible for maintaining resistance at the ureterovesical junctions to avoid
urine reflux.
Muscularis Propria: Urethral Smooth Muscle
Trigone and detrusor smooth muscle both extend into the proximal urethra.
Additional layers of urethral smooth muscle include a thick, inner longitudinal layer and a
thin, outer circular layer (Mistry et al., 2020). An internal urethral sphincter does not exist
in the true, anatomical sense in males or females; however, the bladder base, neck and
proximal urethral musculature all contribute to create sphincteric-like action (Elbadawi,
1996).
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Figure 1: Urinary Bladder Wall Anatomy
The urinary bladder consists of three general layers including the mucosa (i.e., urothelium, lamina propria),
detrusor smooth muscle, and surrounding adventitia and serosa. Various receptor types and ion channels
are expressed throughout the urinary bladder including in the urothelium, bladder nerves, urinary interstitial
cells of Cajal (ICCs; also referred to as interstitial cells), and detrusor smooth muscle. Modified from
Macmillan Publishers Ltd: Nature Reviews Urology, Merrill L., Gonzalez E.J., Girard B.M., Vizzard,
M.A.. Receptors, channels, and signaling in the urothelial sensory system in the bladder. 13(4): 193-204,
copyright (2016).
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Figure 2: Light Microscopy of Urinary Bladder Wall Anatomy
(A) A transverse section of a distended (0.85 mL) rat urinary bladder (scale bar = 50 μm). The lumen,
above the urothelium, is the most superior aspect and the detrusor muscle (dark grey) the most inferior
aspect of the image. Light, circular, or ovular shaped structures are perfused blood vessels. A large nerve
trunk courses between the serosa and detrusor (large, oval object). Capillaries with surrounding pericytes
are also demonstrated. (B) A separate, un-perfused preparation of a transverse section of rat urinary bladder
at high magnification (scale bar = 20 μm) clearly demonstrating urinary bladder layers. Blood vessels with
red blood cells are demonstrated throughout the lamina propria. Interstitial cells are organized as thin layers
in the upper lamina propria region. The translucent elements coursing through the lamina propria are
collagen fibers, which become thicker and more dispersed in the deeper lamina propria. A small fragment
of the detrusor smooth muscle is barely visible. Ur, urothelium; lam.c, cellular or upper component of the
lamina propria; lam.f, fibrous or deeper component of the lamina propria; det, detrusor muscle (dark grey).
Modified from Wiley Periodical, Inc.: Neurourology and Urodynamics, Gabella G.. Lamina propria: The
connective tissue of rat urinary bladder mucosa. 38(8):2093-2103, copyright (2019).
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Figure 3: Immunohistochemistry of Urinary Bladder Wall Anatomy
Vimentin (vim) DAB (3,3′-diaminobenzidine)-immunohistochemistry is demonstrated in (A) human, (B)
guinea pig, and (C) pig urinary bladder sections. Clear differences in upper and deeper lamina propria
regions are consistently observed across species. The upper lamina propria exhibits a dense, layered
organization of vim+ cells, just inferior to the urothelium. The deeper lamina propria exhibits dispersed,
less organized vim+ cells. The dashed line represents the demarcation between upper and deeper lamina
propria. U, urothelium; ULP, upper lamina propria; DLP, deeper lamina propria. Scale bar = 100 μm.
Modified from Springer Link: Histochemistry and Cell Biology, Steiner C., Gevaert T., Ganzer R., Ridder
D.D., Neuhaus J.. Comparative immunohistochemical characterization of interstitial cells in the urinary
bladder of human, guinea pig and pig. 149(5):491-501, copyright (2018).
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1.1.2. Neural Control of the LUT
Efferent Innervation
Three nerves provide bilateral, efferent innervation to the LUT. The hypogastric,
pelvic, and pudendal nerves innervate bladder and urethral smooth muscle, providing
sympathetic, parasympathetic, and somatic input to the LUT (Figure 4).
Parasympathetic
Preganglionic parasympathetic neurons arise from the sacral parasympathetic
nucleus of the intermediolateral cell column (laminae V-VII) in the lumbosacral (L6-S1
for rodents; S2-S4 for humans) spinal cord. These fibers exit the spinal cord as pelvic
nerves and innervate postganglionic parasympathetic neurons in the pelvic plexus or
bladder wall (de Groat et al., 2015). Parasympathetic innervation to the LUT acts to
excite the detrusor muscle and relax the urethral muscle, resulting in voiding.
Acetylcholine (ACh) is the primary excitatory neuroeffector involved in parasympathetic
transmission. Although M2 and M3 muscarinic receptor subtypes are expressed in the
detrusor, ACh acts primarily via the M3 receptor to excite and contract the bladder (de
Groat et al., 2015). Non-cholinergic, purinergic transmission, via the excitatory
transmitter ATP, also plays a major role in bladder contraction. ATP mediates bladder
contraction primarily through the purinergic receptor subtype, P2X1, as this receptor is
the most commonly expressed purinergic receptor in the detrusor (de Groat et al., 2015) .
The parasympathetic nerves cause detrusor muscle contraction while
simultaneously inhibiting urethral smooth muscle to induce relaxation. Nitric oxide (NO)
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is the primary inhibitory transmitter involved in urethral relaxation (de Groat et al.,
2015). Parasympathetic stimulation to the LUT ultimately results in voiding.
Sympathetic
The preganglionic sympathetic fibers originate from the intermediolateral
(laminae V-VII) and medial (laminae X) regions in spinal cord segments L1-L2 in
rodents and T11-L2 in humans (de Groat et al., 2015). These fibers either synapse within
or course through the paravertebral ganglia. Those fibers that course through the
paravertebral ganglia form thoracolumbar splanchnic nerves and synapse on the
prevertebral, inferior mesenteric ganglia in the superior hypogastric and pelvic plexus.
These postganglionic fibers join the hypogastric nerve. Postganglionic, sympathetic
fibers projecting from the paravertebral ganglia join the pelvic nerve. Postganglionic
sympathetic fibers release noradrenaline, providing inhibitory input via Beta (β)adrenergic receptors to the detrusor smooth muscle and excitatory input via alpha (α)adrenergic receptors to the smooth muscle of the bladder base and urethra (de Groat et
al., 2015).
Somatic
Preganglionic, somatic efferent fibers originate in a small portion of the anterior
horn of the spinal cord, sometimes referred to as Onuf’s nucleus, in segments S3-4 (de
Groat et al., 2015). These lower motor neurons join the pudendal nerve to provide
cholinergic, excitatory input to the external urethral sphincter.
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Afferent Innervation
LUT sensory information is transmitted through pseudounipolar, afferent neurons
of the pelvic, hypogastric, and pudendal nerves to second-order neurons in the spinal
cord. Generally, there are two types of LUT afferent fibers being thinly myelinated, A
delta (δ) fibers and small unmyelinated, C-fibers. Aδ mechanoreceptor afferents respond
to low-pressure thresholds of passive urinary distention as well as active contraction. Aδ
afferents exhibit a graded increase in action potential discharge frequency as the bladder
fills and are silent when the bladder is empty (de Groat et al., 2015). C-fiber afferents are
insensitive to typical bladder sensory stimuli, such as distention and contraction. Thus,
they are often termed “silent C-fibers”. However, C-fibers become mechanosensitive to
distention in response to noxious stimuli, including chemical irritants (e.g., capsaicin,
turpentine oil), cooling, high potassium, low pH, and high osmolality (de Groat et al.,
2015). Urinary afferents terminate their peripheral projections throughout the bladder
wall; they are present in the serosal/adventitial, muscular, mucosal, and sub-mucosal
components of the LUT (de Groat et al., 2015; Gabella and Davis, 1998). However, a
dense collection of afferent terminals that are particularly relevant to urinary sub-mucosal
and mucosal signaling terminate in the submucosa, with some fibers extending into the
urothelium (Fowler et al., 2008; Gabella and Davis, 1998). The dorsal root ganglia
(DRG) of spinal cord segments S2-S4 and T11-L2 in humans and L6-S1 and L1-L2 in
rodents contain LUT sensory neurons (Fowler et al., 2008). The central projections of
LUT afferents enter the dorsal horn of spinal cord white matter through Lissauer’s tract
and synapse with spinal cord neurons in lamina V-VII and X. Urinary afferents synapse
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with spinal cord interneurons involved in micturition reflexes or second-order neurons,
which project to higher brain centers regulating the LUT (de Groat and Wickens, 2013;
Fowler et al., 2008).
Spinal Cord Interneurons
Spinal cord interneurons involved in the control of micturition are in the dorsal
commissure, laminae I, V and VII of the sacral spinal cord. These are generally the same
regions in which central processes from LUT afferent fibers terminate in and
parasympathetic, preganglionic neurons exist. Spinal cord interneurons may participate in
local reflexes, providing excitatory and inhibitory input to preganglionic parasympathetic
neurons, or project to supraspinal brain regions involved in micturition, such as the PAG,
PMC, Raphe nuclei, RVM and nuclei of the hypothalamus and thalamus (de Groat et al.,
2015).
Reflexes
Sympathetic Storage Reflex
Sympathetic activity is not necessary for micturition. However, research clearly
suggests that sympathetic innervation contributes to the storage properties of the bladder
(de Groat et al., 2015).
As the bladder fills, pelvic nerve afferent fibers send signals to the sacral spinal cord.
Pelvic afferent fibers enter the dorsal horn of the spinal cord through Lissauer’s tract and
terminate in laminae V-VII and X. The sympathetic reflex involves intersegmental
circuitry in which interneurons project to the thoracolumbar (T11-L2) spinal cord to
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excite/stimulate sympathetic nuclei (i.e., lamina V-VII, X). Sympathetic fibers exit the
spinal cord to travel through the sympathetic chain ganglia and pelvic nerve, or transverse
the inferior mesenteric plexus and/or the superior hypogastric plexus to travel to the LUT
via the hypogastric nerve. Sympathetic fibers act to relax the bladder dome and body via
noradrenergic inhibition of 3-adrenergic receptors. Sympathetic fibers simultaneously
contract the urethra and bladder base via noradrenergic stimulation of 1-adrenergic
receptors (de Groat et al., 2015). Continence is then maintained until the micturition
threshold is reached (Figure 4).
Guarding Reflex and Other Urethral Storage Mechanisms
In addition to sympathetic innervation of the urethral smooth muscle, LMN
innervation of the striated, EUS aids in promoting continence.
Low-level filling of the bladder triggers pelvic and pudendal afferent activity
which stimulate lower motor neurons in the L5 and L6, dorsolateral motor nuclei (de
Groat et al., 2015; McKenna and Nadelhaft, 1986). These somatic efferent fibers travel
through the pudendal nerve to stimulate and contract the EUS. In turn, contraction of the
EUS leads to afferent stimulation and further reinforces EUS contraction. Afferents
activated by EUS contraction also act to suppress voiding activity via inhibitory
interneurons in the spinal cord which inhibit micturition nuclei and circuitry (de Groat et
al., 2015).
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Spinobulbospinal Reflex (Periaqueductal Grey & Pontine Micturition Center)
Once the micturition threshold is reached, voiding can occur. Multiple neural
circuits involving brainstem, forebrain, and subcortical pathways, contribute to
micturition. Brainstem pathways are pertinent to voiding, while forebrain and subcortical
pathways are more modulatory to micturition and regulate the social and emotional
aspects of voiding (de Groat et al., 2015). Intricate brainstem circuitry between the
periaqueductal grey (PAG) and pontine micuturition center (PMC), contributes to
suppressing the spinobulbospinal (SBS) voiding reflex as the bladder fills and exciting
the reflex once bladder volume has reached a set point. PAG and PMC circuitry is
complex; each region has multiple subpopulations of excitatory and inhibitory neurons,
exhibiting different firing patterns in relation to bladder activity (de Groat et al., 2015).
Despite this complexity, pharmacological and ablation studies suggest general roles for
these regions: the PAG is primarily responsible for setting the micturition threshold and
relaying LUT afferent information to higher brain regions, while the PMC is responsible
and essential for the switching circuitry from storage to voiding mode (de Groat et al.,
2015).
Mechanosensitive pelvic afferent nerves initiate the SBS reflex and increase their
firing during bladder filling (Figure 4). These afferents enter the dorsal horn of the spinal
cord to synapse on multiple types of second order neurons; some of these neurons project
to the PAG region of the midbrain and provide excitation to third order neurons. During
filling, the SBS reflex is suppressed due to tonically active inhibitory neurons in both the
PAG and PMC, and PAG excitation of inhibitory PMC interneurons, which inhibit
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descending excitatory signals. However, once afferent firing reaches a critical point, a
“switch” in PAG-PMC circuitry is triggered. The increased afferent signals provide the
PAG neurons enough excitation to overcome tonic inhibition and excite PMC neurons.
Excited PAG micturition neurons directly stimulate descending PMC neurons.
Descending PMC neurons excite the parasympathetic nuclei in the sacral spinal cord,
which excite and contract the bladder, while simultaneously inhibiting and relaxing the
urethra, culminating in voiding. Additionally, collateral axons of these descending
excitatory PMC neurons activate inhibitory feedback loops within the PMC to further
suppress inhibitory mechanisms. Once the bladder has emptied completely, afferent
signaling decreases and the storage phase resumes.
Brain Regions Involved in Micturition
Multiple forebrain, subcortical, and brainstem regions, in addition to the PAG and
PMC, contribute to storage and voiding.
Storage Contributions from Higher Brain Regions
Multiple higher brain regions contribute to maintaining continence including the
parahippocampal cortex, dorsal anterior cingulate cortex (dACC), supplementary motor
area (SMA), insula, lateral and medial prefrontal cortex (lPFC, mPFC). These regions are
not necessary for storage or voiding, but aid in monitoring bladder levels and maintaining
continence in compromising situations.
LUT afferent information is likely first relayed through the thalamus before
reaching higher brain regions. Insular activation increases as the bladder fills and is
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associated with a desire to void (de Groat et al., 2015). The insula has reciprocal
connections with certain regions of the prefrontal cortex (PFC), which have also been
suggested to modulate micturition mechanisms. A particular pattern of activation
amongst these regions has been noted specifically in patients with urge incontinence. As
the bladder fills and it becomes more difficult to hold urine, the insula activates the lPFC,
which sends inhibitory input to the mPFC. This reduces mPFC output to the PAG and
promotes continence. In addition to the insula and PFC, the urge to void in incontinent
patients also triggers dACC and SMA activation, which is associated with contraction of
the EUS and pelvic floor muscles (de Groat et al., 2015). These circuits show little to no
activation in normal individuals. In healthy controls, a parahippocampal-PAG circuit
appears to suppress voiding at low levels of bladder volume and afferent activity. The
parahippocampal cortex may also relay signals concerning safety to brainstem micturition
centers, as the parahippocampal cortex is directly adjacent to the amygdala (de Groat et
al., 2015).
Additional Brain Stem Regions Involved in Micturition
Brain stem regions, other than the PAG and PMC, and brain stem-related regions
may also alter micturition activity.
In cats and rats, rostral pontine reticular formation (RPRF) projections to the
nucleus reticularis gigantocellularis in the rostrodorsal medulla and to lumbosacral spinal
cord may contribute to the storage function of the bladder. Stimulation of this region
inhibits reflex bladder contractions. This inhibition may be mediated by RPRF
projections to the lumbosacral spinal cord that synapse on glycinergic inhibitory neurons.
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In cats, stimulation of the pontine urine storage center (PUSC), a region located
ventrolaterally to the PMC, inhibits micturition reflexes and induces EUS contractions.
Anterograde tracers suggest the PUSC projects to the sphincter motor nucleus in the
sacral spinal cord. The PUSC may mediate inhibition of micturition reflexes via its
projections to the medullary, nucleus raphe magnus (NRM) (de Groat et al., 2015;
Sugaya et al., 2005).
Dopaminergic neurons in the substantia nigra/ventral tegmental (SN/VTA) area
may also contribute to storage mechanisms, as destruction of these neurons promotes
voiding, while activation of these regions disrupts voiding (de Groat et al., 2015;
Yoshimura et al., 2003). D1 dopaminergic substantia nigra/ventral tegmental area
(SN/VTA) receptors regulate GABAergic, PAG neurons, further suggesting that the
SN/VTA can modulate micturition (Kitta et al., 2008).
Many animal models suggest that the cerebellum affects the micturition reflex via
tonic inhibition. However, cerebellar nuclei may serve dual functions, as excitatory roles
have also been reported. The cerebellum projects to numerous brainstem regions
including the nucleus subcoeruleus, local coeruleus, mesencephalic reticular formation,
and the PAG (de Groat et al., 2015). Similarly, the hypothalamus may exert both
excitatory and inhibitory influences over the micturition reflex. LUT afferent information
is partially relayed to the hypothalamus via the spinohypothalamic tract. The
hypothalamus projects to bladder related regions including the cerebellum, PMC, sacral
parasympathetic preganglionic efferent neurons, and sphincter lower motor neurons. The
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hypothalamus may play a role in communicating safety signals to the PMC for voiding
(de Groat et al., 2015).

Figure 4: Neural Control of Urinary Bladder Storage and Elimination
(A) Storage Reflexes. As the bladder fills, mechanoreceptors, R, gradually stimulate afferent fibers which
triggers sympathetic and somatic activity via excitatory spinal cord interneurons. Sympathetic fibers in the
hypogastric nerve release noradrenaline onto inhibitory β3 adrenergic receptors in the detrusor smooth
muscle and excitatory α1 adrenergic receptors in the urethral smooth muscle, to relax the detrusor and
contract the urethra. Somatic fibers from the pudendal nerve release acetylcholine onto excitatory nicotinic
receptors in urethral striated muscle (i.e., external urethral sphincter) inducing contraction. Stimulation of
brain stem regions involved in micturition, such as the pontine storage center, may also contribute to
external urethral sphincter contraction. (B) Elimination Reflexes. Once a critical threshold of bladder
volume and afferent firing is reached, the spinobulbospinal reflex (blue) is activated. Increased afferent
activity excites periaqueductal grey neurons, which stimulate pontine micturition center (PMC) neurons.
Descending PMC neurons excite parasympathetic outflow via pelvic nerve fibers (green), which release
acetylcholine onto excitatory M3 cholinergic receptors and contracts the detrusor. Descending PMC
neurons also inhibit sympathetic and somatic outflow. This culminates in voiding. R, receptors on afferent
nerve terminals. Modified from American Physiological Society: Comprehensive Physiology, de Groat
W.C., Griffiths D., Yoshimura N.. Neural control of the lower urinary tract. 5(1):327-96, copyright (2015).
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1.2. Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
1.2.1. Symptoms and Diagnosis
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic pain condition in
which patients experience pain, pressure or discomfort perceived to be related to the
urinary bladder, in addition to lower urinary tract symptoms, particularly increased
urinary frequency and/or urgency. IC/BPS presents with a very diverse clinical
phenotypes (Akiyama et al., 2020; Hanno et al., 2015). Despite this diversity, IC/BPS’s
hallmark feature, distinguishing the syndrome from other related LUT conditions, such as
OAB, is pain with bladder filling. Interestingly, some previous studies have found that
pelvic pain applies to 100% of their patient population (Hanno et al., 2015; Warren et al.,
2008). Patients may additionally report pain in other pelvic regions such as the urethra,
genitals, or rectum. IC/BPS is diagnosable after symptoms have persisted for 6 weeks and
other identifiable causes, such as infection, or related conditions have been excluded
(Hanno et al., 2015).
The classification and nomenclature of IC/BPS due to the diversity of clinical
phenotypes, has been a long, ongoing conversation amongst neuro-urological experts.
IC/BPS was first described in the early 1900’s by Dr. Guy L Hunner in a cohort of 8
women presenting with LUT symptoms. Upon cystoscopy examination, Dr. Hunner
identified redden, mucosal bladder ulcerations with abnormal capillary structures, edema,
granulation tissue, and inflammatory cell infiltrates (Hunner, 1915). Thus, these ulcers
were later termed Hunner ulcers or lesions, and became the identifying histological
feature of IC/BPS. However, throughout the years, the definition of IC expanded to
21

include patients who experienced the functional symptomatology yet exhibited little to no
histological features.
Currently, IC/BPS is categorized into 2 subtypes: 1) IC/BPS with Hunner lesions,
and 2) IC/BPS with little to no cystoscopic findings (Akiyama and Hanno, 2019;
Akiyama et al., 2020). Type 2 may include IC/BPS patients with normal cystoscopic
findings, or those with only small, pinpoint blood vessel hemorrhages, known as
glomerulations, present (van de Merwe et al., 2008). Experts have argued for the
separation of IC/BPS definition because IC/BPS with Hunner lesions presents as a
distinct disease entity, with distinctly different functional and clinical features than type 2
patients. IC/BPS patients with Hunner lesions are typically diagnosed at an older age,
exhibit bladder-centric symptoms and reduced bladder capacities, have fewer comorbid
conditions, and present more favorable outcomes with endoscopic treatment or surgery
than non-Hunner lesion IC/BPS patients. IC/BPS patients with Hunner lesions also
exhibit additional histological features associated with chronic inflammation (Akiyama et
al., 2020).
Non-Hunner lesion IC/BPS patients tend to have more comorbid conditions than
those with Hunner lesions. These patients exhibit increased rates of psychosocial and
mood disorders (e.g., anxiety, depression) and somatoform disorders such as irritable
bowel syndrome (IBS), fibromyalgia, vulvodynia, chronic fatigue syndrome, Sjogren’s
syndrome, and chronic migraines (Akiyama et al., 2020; Hanno et al., 2015). Some have
proposed that IC/BPS without Hunner lesion is a type of functional somatic syndrome
itself, in which other visceral organs may be involved (Chen et al., 2017; Hanno et al.,
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2015; Warren, 2014). Although little is known about the pathophysiology for IC/BPS as a
functional somatic syndrome, this theory may have some clout as many abdominopelvic
organs share sensory pathways. A portion (15%) of colonic afferents also innervate the
bladder (Christianson et al., 2007; Yoshikawa et al., 2015) and an overlapping population
of dorsal horn neurons respond to both bladder and colonic distension (Grundy and
Brierley; Grundy et al.; Grundy et al., 2018b).
Related conditions can further complicate the classification, diagnosis, and
understanding of pathophysiology of IC/BPS. Overactive bladder (OAB) is a similar
condition in which patients experience LUT symptoms, yet do not exhibit pelvic pain or
Hunner lesions (Peyronnet et al., 2019). IC/BPS patients typically void to circumvent
pain, while OAB patients void to avoid incontinence (Hanno et al., 2015). In males, there
is a high degree of overlap between IC/BPS and chronic prostatitis, a condition
characterized by pain in the perineum, testicles, glans of the penis, and/or in suprapubic
regions. Chronic prostatitis patients may additionally exhibit LUT symptoms (Forrest and
Schmidt, 2004; Suskind et al., 2013). Clinicians and investigators should consider the
similarity in symptoms of these related conditions and their implications for IC/BPS
pathophysiology and treatment.
Additionally, this classification of IC/BPS patients may suggest multiple
etiologies. Treating IC/BPS as one condition and failing to acknowledge distinctions may
explain previous ineffective interventions for some patients. One treatment is unlikely to
work for all IC/BPS patients.
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1.2.2. Treatment Options
Currently, there are few treatment options for IC/BPS patients. Most treatments
that are available aim to manage symptoms, rather than targeting the underlying
mechanisms of IC/BPS and many are used off-label. Additionally, treatment outcomes
vary greatly amongst patients and even with short-term treatment success, long-term
success is not often guaranteed. Pentosan polysulfate sodium, or Elmiron, is currently the
only FDA-approved medication specifically for IC/BPS, yet with modest success (Hanno
et al., 2015; Marcu et al., 2018).
The American Urological Association’s guidelines for the diagnosis and treatment
of IC/BPS, treatments are divided into 6 categories (Hanno et al., 2015). First line
treatments include stress management, pain management, behavioral modifications, and
patient education. These treatments should be provided to all patients. Second line
treatments include: 1) oral medications, such as pentosan polysulfate sodium,
amitriptyline, cimetidine, and hydroxyzine; 2) intravesical treatment with DMSO,
heparin, and lidocaine; 3) physical therapy, granted the patient exhibits pelvic floor
tenderness and appropriate clinicians are available; and 4) pain management. If
symptoms persist, progression to third line treatments may be necessary. These options
are more invasive with recommended cystoscopy under anesthesia and low pressure
hydrodistension. The patient may receive fulguration and/or a submucosal injection of
triamcinolone, a corticosteroid used to treat inflammation, if they present with Hunner
ulcers. Intra-detrusor botulinum toxin A injections may be used if symptoms persist.
Botulinum toxin A treatment may be improved with retreatments and/or when combined
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with hydrodistension in some patients. Sacral and pudendal neurostimulation implants
may also be used at this point, although neurostimulation efficacy of treating urinary
storage symptoms is debatable as the studies conducted are short-term, with low sample
sizes. Additionally, these devices are typically ineffective for pain (Hanno et al., 2015).
Cyclosporine A may be prescribed as a fifth-line treatment however, cyclosporine A may
cause many adverse effects such as immunosuppression, high blood pressure, and
nephrotoxicity. If all previous treatment options have failed, major surgery may be
offered as a last resort for severe and unresponsive patients. Surgery options include
urinary diversion with or without cystectomy, and substitutional cystoplasty (Hanno et
al., 2015).
1.2.3. Epidemiology
Prevalence estimates for IC/BPS have increased over the past 50 years (Davis et
al., 2015; Jones and Nyberg, 1997). This may be due to increased awareness of IC/BPS
symptoms and recognition of IC/BPS as a condition amongst physicians, leading to fewer
misdiagnoses. In a recent, nation-wide study (Berry et al., 2011) conducted via telephone
surveys with statistically modeled predictors for screening from 2007-2009, an estimated
2.70-6.53% of US women met IC/BPS diagnosis criteria, depending on a more or a less
stringent definition of IC/BPS. These percentages translate to 3.3 to 7.9 million US
women.
Historically, it’s been thought that IC/BPS has a higher prevalence in women
compared to men, with a ratio of 5:1 (Clemens et al., 2005). However, this notion has
been challenged in more recent years with some studies suggesting the accepted
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prevalence amongst men is higher than originally estimated due to misdiagnoses and
underreporting (Forrest and Schmidt, 2004; Suskind et al., 2013). Using a similar
methodological approach to Berry et al. (2011), Suskind et al. (2013) estimated the
prevalence of IC/BPS in US men at 1.9-4.2% (i.e., 2,107,727- 4,610, 653).
It should be noted that it is difficult to compare and draw concrete conclusions
concerning IC/BPS epidemiological estimates, because these studies often vary greatly in
their diagnostic criteria, methods, and populations studied.
1.2.4. Pathophysiology
The etiology of IC/BPS is still not well understood. However, there are consistent
pathological features associated with IC/BPS that may contribute to IC/BPS development
and/or persistence.
Urothelial Alterations
The GAG layer, specialized lipids, uroplakin proteins, and tight junction proteins
create a high transepithelial resistance, allowing the urothelium to act as a fantastic
barrier against irritative substances (Birder and Andersson, 2013). However, the
urothelium exhibits drastic changes in patients with and without Hunner ulcers, such as
reduced and aberrant expression of urothelial barrier proteins and deficient urothelial
repair mechanisms, leading to increased urothelial permeability, urothelial thinning, and
denudation (Birder and Andersson, 2013; Hauser et al., 2008; Keay et al., 2004; Parsons
et al., 1991). Cationic substances (e.g., potassium), metabolites from diet, medication, or
supplements, hormonal changes, and bacterial infections can exert cytotoxic effects on
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urothelial cells and impair barrier function (Akiyama et al., 2020). Furthermore,
increased urothelial permeability allows irritative substances that would normally be
contained and expelled, to permeate the urothelium, depolarize bladder wall constituents
(e.g., interstitial cells, nerve terminal endings, SMCs) and trigger secondary
inflammatory processes, in response to released endogenous pathogens from damaged
tissue (Akiyama et al., 2020; Birder and Andersson, 2013). General inflammatory
changes are also observed in IC/BPS patients including immune cell infiltration, MC
degranulation, angiogenesis, edema, and stromal fibrosis (Akiyama et al., 2020; Akiyama
et al., 2016; Arms et al., 2013; Arms et al., 2010; Gonzalez et al., 2013; Guo et al., 2018;
Malley and Vizzard, 2002). B cell clonal expansion is specifically noted in IC/BPS
patients with Hunner’s ulcers (Moldwin et al., 2022)(Moldwin et al., 2022).
Neural Upregulation: Mast Cell Infiltration
Mast cell infiltration and degranulation has long been considered a hallmark
histological feature of IC/BPS (Akiyama et al., 2020; Sant et al., 2007). Mast cells are
found in the bladder and urine of patients with IC/BPS and counts typically correlate with
LUT symptoms and inflammation (Aldenborg et al., 1986; Christmas and Rode, 1991;
Kastrup et al., 1983; Lynes et al., 1987; Theoharides et al., 1995; Tomaszewski et al.,
2001). Growth factors (e.g., stem cell factor (SCF), nerve growth factor (NGF), CRH),
neuropeptides (e.g., substance P, ACh), cytokines and chemokines can induce mast cell
activation and migration, as well as modulate proliferation and survival (Mukai et al.,
2018). Activated mast cells release a slew of inflammatory mediators (e.g., histamine,
heparin, proteases, growth factors, cytokines, chemokines) which induce vascular
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permeability, angiogenesis, leukocyte regulation and extravasation, urothelial alterations,
and afferent nerve sensitization (Mukai et al., 2018; Sant et al., 2007). Consistent
depolarization of afferent nerves results in the release of inflammatory neuropeptides
(e.g., VIP, PACAP, substance P, tachykinins, CGRP) which further exacerbate immune
and urothelial secretion of inflammatory mediators, creating a vicious feedback cycle.
Constant afferent nerve activation additionally induces sensitization of secondary spinal
cord neurons and reorganization of CNS, micturition reflex components. Central
sensitization allows the perception of pain to persist, in the absence of pain inducing
stimuli (e.g., inflammation) (Nazif et al., 2007).
Mast cells may modulate neural changes in IC/BPS but are likely not the primary
driver as they are typically found in patients with urothelial denudation and Hunner’s
ulcers (Nazif et al., 2007). The significance of mast cells in IC/BPS has been questioned
more recently with claims that non-specific staining methods have been previously used
to identify mast cells (Akiyama et al., 2020; Gamper et al., 2015). For instance, the
degree of mast cell densities did not differ in ulcerative IC/BPS, non-ulcerative IC/BPS,
non-IC chronic cystitis, and normal patient bladders, suggesting mast cells may not be a
distinct feature of IC/BPS (Akiyama et al., 2018).
Neural Upregulation: Stress and Nervous System Considerations
Stress may also contribute to neural changes and upregulation in IC/BPS. Stress
can exacerbate, and even induce, symptoms in IC/BPS patients (Koziol, 1994; Nazif et
al., 2007; Rothrock et al., 2001; Whitmore, 1994) and animal models (Birder and
Andersson, 2018; Charrua et al., 2015; Girard et al., 2017; Matos et al., 2017; Merrill et
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al., 2013; Mingin et al.; Mingin et al., 2014). The hypothalamic-pituitary-adrenal (HPA)
axis is a neuroendocrine feedback loop that acts to maintain physiological homeostasis.
However, abnormal, or chronic HPA activation is associated with dysregulated responses
to stress and inflammation and may result in aberrant sympathetic activation (Godoy et
al., 2018; Nazif et al., 2007; Sheng et al., 2020). In one study, subcutaneous
phenylephrine induced somatic sensitivity, L6 c-fos expression and bladder hyperactivity
(Matos et al., 2017). These effects were reversed by silodosin, a selective alpha 1A
adrenoceptor antagonist, and absent in TrpV1-/- mice. Corticotrophin releasing factor
(CRF) plays a crucial role in HPA activation. Rats with intermediate and chronic CYPinduced cystitis express CRF and its receptors (LaBerge et al., 2006), and CRF
expression is found in CNS regions that control voiding (Klausner and Steers, 2004).
IC/BPS patients exhibit HPA dysfunction and increased levels of stress (Lai et al., 2015;
Nazif et al., 2007). Additionally, some studies have demonstrated stress-induced mast
cell expression in the bladder, mediated via CRF or neuropeptide activation (Cao et al.,
2006; Spanos et al., 1997).
Autoimmunity and Infection
Some theories suggest that IC/BPS features (i.e., urothelial denudation,
inflammatory changes, afferent sensitization) may result due to autoimmunity and/or
infection (Akiyama et al., 2020; Bjorling et al., 2011; Grundy et al., 2018a). Autoantibodies have been reported in the bladder, serum and urine of IC/BPS patients
(Jokinen et al., 1972; Keay et al., 1997; Neal et al., 1991; Ochs et al., 1994; Silk, 1970).
Patients with auto-immune disorders such as Sjogren’s syndrome, systemic lupus
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erythematosus, and autoimmune thyroiditis, often present with LUT storage symptoms
and histologically, with urinary immunoglobulin and complement deposits (Haarala et
al., 2000; Leppilahti et al., 2003). Although at the point of diagnosis patients should have
a negative urine culture, infections may be more likely in IC/BPS patients and may
induce urinary changes. For instance, female IC/BPS patients exhibit increased rates of
positive urine cultures and altered urinary microbiomes (Akiyama et al., 2020; Grundy et
al., 2018a). Previous UTIs may increase the likelihood of developing IC/BPS
(Balachandran et al., 2016; Chuang and Kuo, 2013; Hanno et al., 2015; Yang et al.,
2021). 18-36% of women with IC/BPS had a recent, previous UTI before their IC/BPS
diagnosis (Hanno et al., 2015). However, autoimmunity claims remain controversial, as
autoantibodies specific to the LUT in IC/BPS patients have not been reported (Akiyama
et al., 2020). An infection may alter urinary histology and processes in patients with
IC/BPS, however it is debatable that infection is the primary insult as a negative urine
culture is necessary for IC/BPS diagnosis (Hanno et al., 2015).
Additional Factors
The contribution of other conditions and organ systems should be considered, as
IC/BPS is commonly comorbid with psychological (e.g., depression, generalized
anxiety), GI-related (e.g., irritable bowel syndrome, inflammatory bowel disease), autoimmune (e.g., Sjogren’s syndrome, Lupus) or somatoform syndrome (e.g., fibromyalgia,
chronic fatigue syndrome, vulvodynia). Non-ulcerative IC/BPS patients have higher rates
of comorbidities than those with Hunner ulcers (Akiyama et al., 2020). Interestingly,
animal models of colitis exhibit sensitized bladder afferents and increased voiding
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frequency (Grundy et al., 2018a; Grundy et al., 2018b; Yoshikawa et al., 2015). Genetic
susceptibility may be a minor contributing factor to IC/BPS, as first-degree relatives of
patients with IC/BPS may have a higher risk of developing the condition (Patnaik et al.,
2017; Warren et al., 2001; Warren et al., 2004). However, most evidence suggests
IC/BPS is not hereditary and twin studies demonstrate genetic factors account for less
than a third of phenotypic variance (Altman et al., 2011). Patients report that certain
drugs (e.g., alcohol, nicotine) and foods (e.g., caffeine, high potassium, high acid)
aggravate IC/BPS symptoms, however a direct link between diet and symptomology has
not been established (Patnaik et al., 2017).
Combination
IC/BPS pathophysiology and etiology is likely a combination of factors
mentioned above (Birder, 2019). Immune cell infiltration, urothelial and GAG alterations,
angiogenesis, afferent sensitization, and central sensitization work in concert to promote
damaging positive feedback cycles. Stress may further exacerbate or induce IC/BPS
features. Genetic susceptibility, previous infections, diet and medication, cross-organ
sensitization, and comorbidities may also contribute to IC/BPS pathophysiology. The
combination of these factors and the feedback cycles they create influence IC/BPS
progression and further complicates understanding, diagnosing, and treating IC/BPS
pathophysiology.
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1.2.5. Animal Models
There are multiple animal models of IC/BPS and a variety of different methods
used to induce cystitis. Birder and Andersson (2018) broadly groups IC/BPS animal
models into three categories: 1) bladder-centric models, 2) models with complex
mechanisms (i.e., CNS, immune system), and 3) psychological and physical stressors,
and natural models.
Most IC/BPS animal models are bladder-centric. These models employ chemical
irritants, via injection or intravesical bladder instillation, which accumulate as toxic
substances in the bladder. Irritants include hydrochloric acid, acetic acid, acetone, xylene,
mustard oil, croton oil, turpentine, lipopolysaccharide, protamine sulfate, acrolein and
cyclophosphamide (CYP). These models are advantageous due to the controllability of
timing and duration of inflammation. However, the extent of inflammation, in the bladder
and elsewhere, and denudation of the bladder wall varies across irritants (Birder and
Andersson, 2018; Bjorling et al., 2011).
Rather than focusing on the LUT as the primary region of insult, models with
complex mechanisms view IC/BPS as a systemic, multi-organ condition in which CNS
activation or autoimmunity induce LUT changes (Birder and Andersson, 2018).
Neurogenic cystitis is often modeled in rodents via an injection of pseudorabies virus into
the tail muscle. Experimental autoimmune cystitis can be induced using genetic knockout
mice, transgenic mice, and immunizations of bladder homogenate or urothelial antigens
(Akiyama et al., 2020).
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Patients with IC/BPS or OAB report that stressful circumstances exacerbate
symptoms (Koziol, 1994; Rothrock et al., 2001; Whitmore, 1994). Stress-inducing
paradigms, such as water avoidant stress, repeated-variable stress or social stress, induce
and exacerbate many features of human IC/BPS in rodents including LUT storage
symptoms, allodynia, hyperalgesia, urothelial thinning and permeability, increased
afferent nerve activity, pro-inflammatory mediator expression, and inflammatory cell
infiltration in the urinary bladder (Birder and Andersson, 2018; Charrua et al., 2015;
Girard et al., 2017; Matos et al., 2017; Merrill et al., 2013; Mingin et al., 2015; Mingin et
al., 2014). These models do not induce severe inflammation or urinary bladder ulceration;
thus, stress paradigms may provide ideal models for non-ulcerative IC/BPS. A natural,
spontaneously occurring form of IC/BPS exists in cats known as feline interstitial cystitis
(Birder and Andersson, 2018). This model recapitulates many human IC/BPS features but
is majorly limited by animal availability and inability to control, due to its spontaneous
nature. The feline interstitial cystitis model is minimally used (Birder and Andersson,
2018).
One model cannot perfectly recapitulate all human IC/BPS symptoms, especially
considering the variety of IC/BPS patient subsets. Investigator resources, research
questions, model advantages/disadvantages, clinical translatability, and perspective of
IC/BPS pathophysiology should be considered when assessing models. The IC/BPS
models briefly introduced above have been extensively reviewed previously (Birder and
Andersson, 2018; Bjorling et al., 2011; Westropp and Buffington, 2002). I will focus on
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the strengths, weaknesses, and clinical translatability of the bladder-centric, CYP-induced
cystitis model for the remainder of this section.
CYP was initially developed as a chemotherapeutic, inactive prodrug (Emadi et
al., 2009). CYP is hydroxylated by cytochrome p-450 to produce the unstable
intermediates, 4-hydroxycyclophosphamide and aldophosphamide. These intermediate
isomers can freely diffuse into cells yet are not cytotoxic. Depending on the cell type,
further decomposition of aldophosphamide produces cytotoxic phosphoramide mustard
and its byproduct, acrolein. The presence of acrolein in the bladder induces hemorrhagic
cystitis in the LUT (Cox, 1979). CYP-induced cystitis recapitulates many human IC/BPS
features including mucosal edema, immune cell infiltration, urothelial denudation,
bladder ulceration, bladder hypertrophy, pro-inflammatory mediators in bladder tissue
and urine, increased urinary frequency, enhanced somatic sensitivity, and central
sensitization (Batista et al., 2006; Eichel et al., 2001; Grundy et al., 2018a; Hurst et al.,
2015; Malley and Vizzard, 2002; Yoshimura and de Groat, 1999). CYP has been used to
model IC/BPS for over 50 years (Locher and Cooper, 1970) and is the predominant toxin
used to induce IC/BPS in bladder centric models (Birder and Andersson, 2018; Kuret et
al., 2021). Investigators can model multiple types of IC/BPS using CYP including acute,
intermediate, and chronic. Intraperitoneal injections of CYP over the course of multiple
days are necessary for the induction of chronic cystitis, whereas one injection is given for
acute or intermediate models, with examination 4-48 hours later (Birder and Andersson,
2018). This approach is easily feasible, repeatable, cost effective, and the extent of
inflammation can be relatively controlled (Birder and Andersson, 2018; Bjorling et al.,
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2011). CYP reportedly does not induce inflammation in other organs (Okamura et al.,
1992). Although CYP-induced cystitis models recapitulate many human IC/BPS features,
the inflammatory response to CYP can be severe, inducing pathology more specific to
hemorrhagic cystitis. This severe inflammation may mask subtle responses to therapeutic
interventions. Thus, CYP-induced cystitis may be better understood as hemorrhagic
cystitis models, rather than true IC/BPS models (Bjorling et al., 2011). Additionally,
responses to CYP may be species specific, as mice appear more tolerable of CYP effects
than rats (Birder and Andersson, 2018). Metabolic rates of CYP and response severity
may also differ across strain (Bjorling et al., 2007; Fraiser and Kehrer, 1992). Multiple
studies have replicated functional IC/BPS effects (e.g., increased urinary frequency and
sensitivity, detrusor overactivity) without urothelial denudation or inflammatory
infiltrate, using a chronic CYP protocol in which low repeated doses of CYP are
administered over a period of days, suggesting this design may be an effective model of
non-ulcerative IC/BPS (Boudes et al., 2011; Golubeva et al., 2014). However, others
suggest chronic CYP administration is just repetitive instances of acute cystitis (Birder
and Andersson, 2018). Thus, the translational value of the chronic CYP protocol for
human IC/BPS is unclear.
1.3. Platelet-Derived Growth Factors (PDGFs), PDGF Receptors (Rs), and Urinary
Bladder Interstitial Cells
1.3.1. PDGF/R Function and Expression
Platelet-derived growth factors (PDGFs) and their receptors are conserved
throughout the animal kingdom with expression in rodents, Xenopus laevis (frog), zebra
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fish, Lytechinus pictus (sea urchins), and PDGF and receptor I like proteins in Drosophila
melanogaster (fruit fly) and Caenorhabditis elegans (nematode) (Andrae et al., 2008;
Hoch and Soriano, 2003). In mammals, PDGF and associated receptors (PDGFR) are
widely expressed in numerous cells, tissues, and systems, including the lungs, gonads,
kidneys, GI system, skin, hematopoietic and vascular cells, and nervous system (Heldin
and Westermark, 1999; Hoch and Soriano, 2003).
PDGFs are secreted as disulfide bonded dimers, including types -AA, -BB, -CC, DD, and -AB. PDGFs are synthesized by many different cell types including platelets,
fibroblasts, macrophages, vascular smooth muscle cells, vascular endothelial cells,
mammary epithelial cells, retinal pigment epithelial cells, and uterus endometrial and
myometrial cells and act via paracrine signaling in normal physiological conditions.
PDGF expression may be induced by hypoxia, thrombin, cytokine, and growth factors
(Heldin and Westermark, 1999; Hoch and Soriano, 2003).
The PDGFRs are structurally similar to their fellow class 3 tyrosine kinase
receptors including c-KIT, CSFR1, and FLT 3 (Ségaliny et al., 2015). PDGFRs exhibit 5
extracellular immunoglobulin loops and a split intracellular tyrosine kinase domain
(Andrae et al., 2008). There are two PDGFR isoforms which immediately dimerize upon
PDGF binding to form 3 PDGFR types including PDGFR-αα, PDGFR-ββ, or PDGFRαβ. Numerous PDGF-PDGFR interactions have been demonstrated in vitro, but few in
vivo. PDGFRα binding has been shown for PDGF-CC and -AA, and PDGFRβ binding
for PDGF-BB in vivo (Andrae et al., 2008). Differential effects of PDGFR expression
have been reported depending on model systems, chemical messengers (e.g., growth
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factors, hormones, cytokines), as well as in vitro vs in vivo conditions. PDGFRs are
expressed on a wide variety of mesenchymal cells including fibroblasts and smooth
muscle cells that express both PDGFRα and -β, whereas other cell types, such as platelets
(-α) or pericytes (-β), express only one PDGFR type (Andrae et al., 2008; Heldin and
Westermark, 1999; Hoch and Soriano, 2003).
PDGF/Rs are generally involved in embryonic development, wound healing, and
disease. Homozygous inactivation of PDGF-A, -B, -C, and receptor -α and -β genes each
results in embryonic or perinatal lethality (Boström et al., 1996; Ding et al., 2004; Levéen
et al., 1994; Soriano, 1994; Soriano, 1997) except for PDGF-D deficient mice, which are
viable (Gladh et al., 2016). Genetic and pharmacological studies demonstrate PDGF-A
and PDGFRα as an essential epithelial mesenchymal signaling pair, in which PDGF-A
drives migration and differentiation of PDGFRα+ progenitors (e.g., oligodendrocyteastroglial, neural crest cells, mesenchymal). PDGF-A, -C and PDGFRα signaling is
necessary for proper development of the vertebral neural arch, palate and dental cusp
formation, alveolar walls of the lungs, epithelial villi in the GI tract, hair follicles in the
dermis, Leydig cells of the testes, interstitial mesenchyme of the kidney, epithelia of the
lens, and oligodendrocytes of the central nervous system (Andrae et al., 2008; Heldin and
Westermark, 1999). PDGF-B and PDGFRβ signaling is primarily involved with
cardiovascular development, as knockouts for both exhibit severe, but not complete,
widespread loss of pericytes and partial loss of vascular smooth muscle cells, due to an
inability to induce precursor migration and proliferation (Andrae et al., 2008; Hellström
et al., 1999). This results in numerous secondary insults including endothelial
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hyperplasia, excessive membrane folding, capillary microaneurysms, alterations in blood
vessel shape and diameter that can compound into serious effects such as hemorrhage,
edema, hypoxia, abnormal organ development, placental defects, and lethality (Andrae et
al., 2008; Heldin and Westermark, 1999). Additionally, neuroprotective roles for
PDGF/Rs have been suggested (Andrae et al., 2008; Heldin and Westermark, 1999).
PDGF/Rs are implicated in a broad range of diseases which can be generally
categorized into three groups: cancers and tumors, vascular diseases, and fibroses
(Andrae et al., 2008; Heldin and Westermark, 1999). Increased PDGF/R expression has
been demonstrated in sarcoma, carcinoma, blastoma, leukemia, and glioma tumor cells in
dermal, mammary, colorectal, pulmonary, pancreatic, ovarian, prostate, and neurological
tissues. Abnormal chromosomal processes (e.g., translocation, fusion, deletion,
amplification, mutation) may drive aberrant autocrine and paracrine PDGF/R signaling,
which promotes cancer cell properties (e.g., self-sufficient growth, angiogenesis,
metastasis, therapeutic resistance). Vascular diseases that exhibit increased PDGF/R
expression include atherosclerosis, restenosis, pulmonary arterial hypertension, and
ischemic retinopathies (i.e., proliferative diabetic retinopathy, proliferative
vitreoretinopathy, choroidal neovascularization). Increased PDGF/R expression and
signaling in organ epithelia and mesenchyme can induce mesenchymal proliferation and
matrix deposition, leading to multiple fibroses include pulmonary, liver, dermal, renal,
and cardiac. In accordance with their developmental roles, PDGFRα signaling is
generally involved in mesenchymal pathologies, whereas PDGFRβ signaling with
vascular pathologies (Andrae et al., 2008; Heldin and Westermark, 1999).
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1.3.2. PDGF/R Signaling Pathways: ERK and AKT
PDGFR dimerization stimulates autophosphorylation of tyrosine residues inside
and outside the tyrosine kinase domain, which respectively serves to increase kinase
catalytic efficiency and create docking sites for SH2 domain-containing signal
transduction molecules (Heldin and Westermark, 1999). Many SH2 domain-containing
signaling molecules bind to PDGFRs including, 1) enzymes: PI3K, PLC-γ, Src, SHP-2,
GTPase activating protein; 2) adaptor proteins: Grb2, Grb7, Crk, Nck, Shc; and 3)
transcription factors (5 members of Stat family molecules) (Figure 5). Some molecules
demonstrate stronger affinities for one PDGFR over the other and not all signaling
pathways have been demonstrated in both receptors. For instance, Crk binds
preferentially to PDGFRα, Stat transcription factors and Nck to PDGFRβ, and Grb2/7
and GAP binding has only been demonstrated for PDGFRβ (Andrae et al., 2008; Heldin
and Westermark, 1999). PDGFRs may also bind with integrins, as PDGFRβ-integrin
complexes have been reported (Andrae et al., 2008; Heldin and Westermark, 1999;
Ishigaki et al., 2011).
SH2 domain-containing molecules can initiate numerous downstream signaling
pathways such as PI3K/AKT, Ras/MAPK, JNK/SAPK, and PLC-γ/PKC (Figure 5).
Generally, PDGFR activation promotes cell growth, actin reorganization, chemotaxis,
calcium mobilization, and inhibits apoptosis. Under normal circumstances, PDGFR
signaling is also modulated by multiple negative feedback mechanisms which may occur
simultaneously with stimulatory signals and alter PDGFR signaling effects (Andrae et al.,
2008; Heldin and Westermark, 1999). PDGF binding also induces PDGFR internalization
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that is primarily clathrin-mediated and may be dependent on phosphorylation of the PI3K
binding sites (Joly et al., 1994; Rogers and Fantauzzo, 2020). Intracellular endosomal
signaling has been demonstrated for PDGFRβ (Jastrzębski et al., 2017; Wang et al.,
2004). Internalized PDGFRs eventually undergo lysosomal and proteasomal degradation,
leading to signal attenuation, with few reports of recycling (Rogers and Fantauzzo, 2020).

Figure 5: PDGFRα Signaling Cascades
Interactors, such as PI3K or Shc, recognize and bind to phosphorylated amino acid residues on dimerized
PDGFRs. Black arrows (small or large) indicate downstream effectors. Red text indicates negative
feedback pathways. PDGFR, platelet-derived growth factor receptor. Modified from Cold Spring Harbor
Laboratory Press: Genes and Development, Andrae J., Gallini R., Betsholtz C.. Role of platelet-derived
growth factors in physiology and medicine. 22(10):1276-312, copyright (2008).
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1.3.3. Interstitial Cells
The term “interstitial cell” most literally denotes cells occupying the interstitium,
between the defining tissues of an organ. This encompasses a broad range of cell types
including fibroblasts, myofibroblasts, telocytes, immune cells (e.g., mast cells,
macrophages), and interstitial cells of Cajal (Sanders et al., 2014). These cells often
regulate smooth muscle electrical activity and may transduce efferent and afferent neural
signals. Interstitial cells are wildly diverse morphologically, chemically, and functionally,
but are often broadly categorized as myoid (muscle)-like or fibroblast-like. Most research
concerning interstitial cells has been conducted in the gut, thus our understanding of these
cells is most advanced in this region. For this reason, interstitial cell classification and
function in other systems (e.g., urinary, reproductive) is often based on our initial
knowledge of gastrointestinal (GI) interstitial cells, especially the interstitial cells of
Cajal.
Urinary interstitial cells have also been reported in the renal pelvis and ureter,
bladder, and urethra (Sanders et al., 2014). This dissertation primarily concerns an
interstitial cell subpopulation within the urinary bladder. Bladder interstitial cells are a
more recently discovered cell type which have been identified in multiple species
including human, rat, mouse, guinea pigs, and pigs (Gevaert et al., 2017a; Steiner et al.,
2018). Early studies reported immunoreactivity (IR) for the GI interstitial cell of Cajal
marker, tyrosine kinase stem cell factor receptor, c-KIT, within the bladder (Biers et al.,
2006; McCloskey and Gurney, 2002). Thus, investigators initially assumed c-KIT
expression was due to a LUT type of interstitial cell, similar in structure and function to
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the interstitial cells of Cajal. However, numerous reports confirm c-KIT expression is
primarily due to mast cells, which are rarely found in the normal bladder (Gevaert et al.,
2011; Gevaert et al.; Gevaert et al.; Gillespie et al., 2004; Koh et al., 2018; Pezzone et al.,
2003; Steiner et al., 2018). The current commonly accepted markers for interstitial cells
in the bladder are PDGFRα and the non-specific, intermediate filament protein, vimentin
(vim) (Gevaert et al., 2011; Gevaert et al.; Gevaert et al.; Koh et al., 2012; Koh et al.;
Monaghan et al., 2012; Steiner et al., 2018). Many but not all, LUT interstitial cells
express PDGFRα and all express vimentin, as interstitial cells are of mesenchymal origin
(Steiner et al., 2018). In the bladder, interstitial cells are dispersed throughout the upper
LP (U. LP) and deeper LP (D. LP), and adjacent and within smooth muscle bundles in the
detrusor, with differing phenotypes (Table 1). Our understanding and identification of
urinary bladder interstitial cells has been a process, maturing over the past few decades
but made difficult by phenotypic diversity and nuance, leading to a confusing,
inconsistent nomenclature that is still not universally accepted. This is further
compounded by the variety of methodological approaches and materials used, and species
differences. In recent reports, investigators compare ultrastructural and
immunohistochemical interstitial properties in human, mouse, rat, guinea pig, and pig
bladder tissue (Gevaert et al., 2017a; Steiner et al., 2018) (Figure 6).
U. LP interstitial cells are described as spindle or stellate shaped cells, which form
and interconnecting networks and are organized in densely pack layers just beneath the
urothelium (Gevaert et al., 2017a; Koh et al., 2012; Neuhaus et al., 2018; Steiner et al.,
2018). U. LP interstitial cell-urothelial contacts are not observed; however, one
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interesting case using high resolution scanning microscopy techniques identified an U.
LP interstitial cell, with multiple branches penetrating the basal lamina, contacting
urothelial cells (Neuhaus et al., 2018). The implications of this finding are intriguing, yet
not readily interpreted, due to very low subject and cell sample sizes. U. LP interstitial
cells demonstrate vim+, caveolar 1+, mostly PDGFRα+, TrpA1+, CD34-, desmin- and
ANO-1- IR in agreement with other studies (Gevaert et al.; Gevaert et al., 2014; Koh et
al., 2012; Steiner et al., 2018) (Figure 6). U. LP interstitial cells are predominantly
vim+/PDGFRα+, with 90% of human, 75% of guinea pig, and 81% of pig U. LP cells
exhibiting this phenotype, based on IR quantification (Steiner et al., 2018). LP interstitial
cells exhibit myogenic features including strong alpha-smooth muscle actin (α-SMA)
expression and contractile microfilaments. These features were exhibited to a much lesser
extent in rats and guinea pigs, and nearly absent in mice, indicating potential functional
differences between U. LP interstitial cells across species.
D. LP interstitial cells are more loosely organized, spindle-shaped and exhibit
long cytoplasmic processes with tortuous dilations, containing distal mitochondria and
rough endoplasmic reticulum (RER). They demonstrate vim+, PDGFRα+, TrpA1+ and
CD34+ IR, α-SMA-, desmin- and ANO-1- (Figure 6). Shape and expression profile is
consistent across species (Gevaert et al.; Gevaert et al., 2014; Koh et al., 2012; Steiner et
al., 2018).
Detrusor interstitial cells are very similar in shape, ultrastructure, and expression
profile to D. LP interstitial cells. Clathrin-coated pits were observed in mouse and rat
detrusor interstitial cells, but not in the D. LP interstitial cells, and not in humans
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(Gevaert et al., 2017a). D. LP and detrusor interstitial cells present as interstitial cell of
Cajal-like cells with similar features, but absence of c-KIT and ANO-1 IR (Gevaert et al.;
Gevaert et al., 2014; Koh et al., 2012; Steiner et al., 2018). D. LP and detrusor interstitial
cells have also been identified as telocytes, due to their long, thin, convoluting processes
from the cell body and CD34+ expression (Gevaert et al.; Gevaert et al.; Vannucchi et al.,
2014).
Some investigators define U. LP interstitial cells as myofibroblasts (Sui et al.,
2002; Wiseman et al., 2003) yet a defining myofibroblast feature, the fibronexus, is rarely
identified in U. LP cells (Eyden, 2009; Gevaert et al.; Gevaert et al., 2014). This
disagreement may be due to species differences, as U. LP interstitial cells subpopulations
with a fibronexus have been reported in the human bladder, albeit rarely (Gevaert et al.;
Gevaert et al.; Neuhaus et al., 2018; Vannucchi et al., 2014). However, transformation of
LP interstitial cells into a myofibroblast phenotype under pathological conditions is a
possibility (Gevaert et al., 2011; Koh et al., 2018; Sunagawa et al., 2015).
Phenotypic differences in urinary bladder interstitial cells suggests functional
specializations. Current theories suggest that LP interstitial cells may act as sensory
intermediaries, communicating signals from the urothelium and/or nerves to the detrusor,
and detrusor interstitial cells may regulate SMC activity (Koh et al., 2018).
L-type (McCloskey, 2006) and T-type (Deng et al., 2012) calcium channels,
mechanosensitive cationic channels (e.g., TrpA1, TrpV4) (Lee et al., 2017; Steiner et al.,
2018) and release from intracellular calcium stores (Johnston et al., 2008) may contribute
to spontaneous, asynchronous calcium transients and inward currents observed in
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detrusor interstitial cells (Gray et al., 2013; Ikeda et al., 2007). Detrusor interstitial cells
also exhibit outward currents. Pharmacological studies suggest KCNQ (voltage-gated
K+) channels (Anderson et al.; Anderson et al., 2009) and SK3 (small conductance
calcium-activated K+) channels contribute to detrusor interstitial cells outward currents.
SK3 channel activation has been shown via ATP and UTP receptors (i.e., P2Y1, P2Y2,
P2Y4) and TrpV4 channels in detrusor interstitial cells (Lee et al.; Lee et al., 2014; Lee et
al.). Generally, agonists of these receptors reduce or abolish detrusor contractile activity
and promote hyperpolarization, whereas antagonists increase contractile activity and
promote depolarization, suggesting that detrusor interstitial cells may provide inhibitory
regulation of SMCs (Koh et al., 2018).
LP interstitial cells are well positioned to receive and communicate sensory
signals as they are located just beneath the urothelium and near afferent and efferent
nerve terminals (Gevaert et al., 2011; Gevaert et al.; Gevaert et al.; Koh et al., 2012;
Steiner et al., 2018; Wiseman et al., 2003). LP interstitial cells may be involved in
cholinergic, purinergic, and nitrergic signaling. Two reports suggest muscarinic receptor
expression (i.e., M2, M3) in human and guinea pig bladder LP interstitial cells, however
electrophysiological or functional significance of ACh receptor expression in LP
interstitial cells has not been assessed (Grol et al., 2009; Mukerji et al., 2006). Strong
P2Y6 receptor IR has been demonstrated in the LP interstitial cells of rats and guinea
pigs (Fry et al., 2012; Sui et al., 2006) with weaker expression for P2Y2, P2Y4 (Sui et al.,
2006), P2X3 (Li et al., 2013; Sui et al.), P2X2 and P2X5 (Meng et al., 2015). LP
interstitial cells exhibit spontaneous calcium transients and inward currents which have
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been shown to be evoked by ATP, UTP and electrical field stimulation, and may be
partially due to a calcium-activated chloride current (Fry et al., 2012; Gray et al., 2013;
Sui et al., 2008; Wu et al., 2004). P2X or ACh receptors are unlikely to mediate this
response, as agonists do not replicate ATP-evoked calcium transients or inward currents
in LP interstitial cells in patch-clamp experiments (Wu et al., 2004). Reports also suggest
nitrergic signaling in LP interstitial cells. LP interstitial cells in guinea pig (de Jongh et
al., 2007; Gillespie et al., 2004; Gillespie et al.; Smet et al., 1996), rat (Sancho et al.,
2017) and human bladders (Smet et al., 1996) demonstrate increased immunoreactivity
for the β1 subunit of soluble guanylyl cyclase (NO receptor) and NO downstream
effectors (cGMP-dependent protein kinase 1 and cGMP), after stimulation with a NO
donor. In patch-clamp experiments, NO donor application on LP interstitial cells
reversibly attenuated ATP evoked inward currents (Sui et al., 2008). Interstitial cells also
demonstrate responsiveness to other mediators involved in bladder excitability and
afferent signaling. Hyperpolarization-activated cationic channels (HCN) (Deng et al.,
2015; Liu et al., 2017; Wu et al., 2017), prostaglandin receptors EP1 and EP2 (Rahnama’i
et al., 2010; 2011; 2012) and prostaglandin synthase (COX1 and 2) (Collins et al., 2009;
de Jongh et al., 2009; Rahnama'i et al., 2011) expression is present in detrusor and LP
interstitial cells, and EP2 receptors may interact with HCN channels to mediate bladder
excitability (Wu et al., 2017). Mechanosensitive (i.e., Piezo 1, Trpv4, TrpA1) channel
activity and expression in interstitial cells suggests they may be stretch responsive
(Heppner et al., 2017; Liu et al., 2018; Steiner et al., 2018; Zhao et al., 2021).
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Network like interconnections between interstitial cells have been observed in
human, mice and rats in the LP and detrusor (Gevaert et al.; Gevaert et al., 2014; Koh et
al., 2012; Neuhaus et al., 2018). Connexin 43 (Cx43) is a ubiquitous gap junction protein,
reportedly expressed in U. LP, D. LP, and detrusor interstitial cells (Gevaert et al., 2014;
Ikeda et al., 2007; Neuhaus et al., 2005; Neuhaus et al.; Rasmussen et al., 2009; Sui et al.,
2002). Some suggest that bladder interstitial cells may transmit electrical signals via gap
junctions (Hashitani et al., 2004; Ikeda et al., 2007; Sui et al., 2002). This is unlikely in
LP interstitial cells, as others present ultrastructural (Gevaert et al.; Gevaert et al., 2014)
and electrophysiological (Sui et al., 2008) evidence that suggests LP interstitial cells
intercellular contacts are adherence, not gap, junctions, despite Cx43+ staining.
Cadherins, proteins crucial for adherence junctions, have been identified in vim+ LP
interstitial cells (Kuijpers et al.; Kuijpers et al., 2007). Ultrastructural and
electrophysiological evidence suggests communication via gap junctions in detrusor
interstitial cells is more likely (Gevaert et al., 2017a; Hashitani et al., 2004).
Coordinated calcium events that propagate throughout the LP interstitial cell
network have been observed in: 1) cultured LP vim+/α-SMA+ interstitial cells (Neuhaus
et al., 2020) in response to mechanical stress, 2) vim+ interstitial cells in mucosal preps
without urothelium, in response to electrical field stimulation, and 3) TrpV4+/PDGFRα+
U. LP interstitial cells in mucosal preparations without detrusor (Heppner et al., 2017).
ATP increased the number of cells exhibiting calcium transients and facilitated
coordinated calcium events. TrpV4 modulates calcium activity, as agonists promoted
calcium events, yet absence of effect of TrpV4 antagonists suggests calcium influx via
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TrpV4 does not drive these events. Calcium events likely originate from internal stores,
as inhibitors dramatically reduced calcium propagation (Heppner et al., 2017).
Additionally, in patch-clamp studies U. LP interstitial cell pairs demonstrated enhanced
responding to ATP and reduced response thresholds. A non-specific PDGFRα inhibitor
reduced the enhanced sensitivity to ATP in cell pairs (Sui et al., 2008). These studies
suggest that LP interstitial cells are mechanosensitive, form a functional syncytium, and
primarily mediate signals via calcium events.

Figure 6: Urinary Bladder Interstitial Cells
Confocal microscopy images demonstrating PDGFRα (red) and vimentin (VIM, green) immunoreactivity
in the lamina propria (LP) of the urinary bladder in (A) human, (B) rat, (C) mouse, (D) guinea pig, and (E)
pig. Yellow arrows denote PDGFRα+/VIM+ interstitial cells. White arrows denote PDGFRα-/VIM+
interstitial cells. Scale bar = 25 um. (D, E) Scale bar = 30 um. H, human. R, rat. M, mouse. U, urothelium.
LP, lamina propria. V, blood vessel. (A-C) Modified from SpringerLink: Histochemistry and Cell Biology,
Gevaert T., Neuhaus J., Vanstreels E., Daelemans D., Everaerts W., Der Aa F.V., Timmermans J.P.,
Roskams T., Steiner C., Pintelon I., Ridder D.D.. Comparative study of the organization and phenotypes of
bladder interstitial cells in human, mouse and rat. 370(3):403-416., copyright (2017). (D, E) Modified from
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SpringerLink: Histochemistry and Cell Biology, Steiner C., Gevaert T., Ganzer R., Ridder D.D., Neuhaus
J.. Comparative immunohistochemical characterization of interstitial cells in the urinary bladder of human,
guinea pig and pig. 149(5):491-501., copyright (2018).
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Table 1: Ultrastructural and Expression Differences in Urinary Bladder Interstitial Cells
Urinary bladder interstitial cells exhibit differences in morphology, ultrastructure, receptor and ion channel
expression, and function according to location (i.e., upper lamina propria (U. LP), deeper lamina propria
(D. LP), or detrusor). * denotes species differences which are further discussed in the text. ° denotes
conflicting reports. This table describes general, rather than fully exhaustive, urinary bladder interstitial cell
differences and represents findings from multiple reports using varied techniques and methodologies.
Additionally, not all studies distinguish the U. LP from the D. LP. Receptors and/or ion channels reported
from these studies are listed in both the U. LP and D. LP sections. Vim, vimentin (intermediate filament
protein). PDGFRα, platelet-derived growth factor receptor-α (interstitial cell receptor). α-SMA, α-smooth
muscle actin (myofibroblast filament). c-KIT, stem cell factor receptor. ANO-1, anoctamin-1 (calciumactivated chloride channel). Desmin (muscle-specific intermediate filament). TrpV4, transient receptor
potential vanilloid-type 4. TrpA1, transient receptor potential ankyrin-type 1. sGC, soluble guanylate
cyclase. cGMP, cyclic guanosine monophosphate. M, muscarinic. EP1, EP2, prostaglandin receptors.
COX1, COX2, cyclooxygenase-1, -2 (prostaglandin synthesizing enzymes). Cx, connexin. R, receptor.
Interstitial
Cell
Location
Upper
Lamina
Propria

Deeper
Lamina
Propria

Detrusor

Ultrastructure

Shape

Immunohistochemical
Markers

Receptor (R) and Ion
Channel Expression

Moderate rough
endoplasmic
reticulum (RER),
many caveolae
and mitochondria,
no fibronexus,
discontinuous
basal lamina,
contractile
microfilaments*,
clathrin-coated
pits*, adheren
junctions
Thin layer of
cytoplasm around
nucleus, many
RER and
mitochondria
distal to
perinuclear area,
no contractile
microfilaments,
sparse caveolae,
no clathrin-coated
pits, adheren
junctions
Thin layer of
cytoplasm around
nucleus, many
RER and
mitochondria
distal to
perinuclear area,
no contractile
microfilaments,

Spindle or
stellateshaped, with
cytoplasmic
processes

Positive:
vim, PDGFRα, α-SMA*

Spindleshaped with
long,
tortuous
cytoplasmic
processes
that vary in
thickness
throughout
processes

Positive:
vim, PDGFRα, CD34

Mechanosensitive: TrpA1,
TrpV4, Piezo1
Purinergic/Pyrimidinergic:
P2Y6, P2Y2, P2Y4,
P2X2, P2X5
Nitrergic: sGC R, cGMP
Cholinergic: M2, M3
Prostaglandin: EP1, EP2,
COX1, COX2
Gap Junctions: Cx43
Hyperpolarization
Activated Channels:
HCN1-4
Mechanosensitive: TrpA1,
TrpV4, Piezo1
Purinergic/Pyrimidinergic:
P2Y6, P2Y2, P2Y4,
P2X2, P2X5
Nitrergic: sGC R, cGMP
Cholinergic: M2, M3
Prostaglandin: EP1, EP2,
COX1, COX2
Gap Junctions: Cx43
Hyperpolarization
Activated Channels:
HCN1-4
Mechanosensitive: TrpA1,
TrpV4, Piezo 1
Purinergic/Pyrimidinergic:
P2Y1, P2RY2, P2RY4,
P2RY14
Nitrergic: sGC R, cGMP
Cholinergic: M2, M3

Spindleshaped with
long,
tortuous
cytoplasmic
processes
that vary in
thickness

Negative:
desmin, c-KIT, ANO-1°

Negative:
desmin, α-SMA, c-KIT,
ANO-1°

Positive:
vim, PDGFRα, CD34,
ANO-1
Negative:
desmin, α-SMA, c-KIT
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sparse caveolae,
sparse clathrincoated pits*, gap
junctions

throughout
processes

Prostaglandin: EP1, EP2,
COX1, COX2
Gap Junctions: Cx43
Potassium Channels:
KCNQ, SK3
Calcium Channels: Ltype, T-type, ER stores
Hyperpolarization
Activated Channels:
HCN1-4
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1.3.4. Interstitial Cells in LUT Dysfunction
The prescribed functions for interstitial cells as sensory intermediaries and
modulators of SMC electrophysiological activity may also implicate a role for these cells
in bladder dysfunction conditions.
Detrusor and LP interstitial cell-related changes including the following: 1)
alterations in interstitial cells ultrastructure, distribution, and morphology (de Jongh et al.,
2007; Gevaert et al., 2011; Gevaert et al.; Ikeda et al., 2007; Johnston et al., 2012;
Neuhaus et al., 2005), increases in expression of receptors and channels associated with
interstitial cells (de Jongh et al., 2007; Deng et al., 2015; Jin et al., 2017; Kim et al.,
2011; Meng et al., 2015; Sancho et al., 2017), and alterations in spontaneous calcium
transients (Deng et al., 2013) and increased Ih (HCN channel) current densities (Deng et
al., 2015), have been reported in rodent models of OAB (de Jongh et al., 2007; Deng et
al., 2013; Deng et al., 2015; Ikeda et al., 2007; Jin et al., 2017; Johnston et al., 2012; Kim
et al., 2011), and IC/BPS (Giglio et al., 2018; Sancho et al., 2017), as well as in human
patients with IC/BPS or OAB (Gevaert et al., 2011; Meng et al., 2015; Neuhaus et al.,
2005).
1.3.5. Inhibition of PDGFRα+ Interstitial Cells with Imatinib Mesylate
Over the past few decades, investigators have used genetic and pharmacological
means to examine the role of LUT interstitial cells in normal and pathological bladders.
Pharmacological inhibition of interstitial cells with the tyrosine kinase inhibitor, imatinib
mesylate, is perhaps the most widely used and commonly accepted technique, with
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prevalent use in preclinical OAB and IC/BPS rodent models. Imatinib mesylate, also
referred to as STI-571, Gleevec or Glivec, is currently used as a therapeutic treatment for
chronic myeloid leukemia and GI-stromal tumors, due to its ability to potently inhibit Abl
kinase activity of the abnormally expressed BCR-ABL fusion gene (IC50 = 0.25 μM) and
c-KIT (IC50 = 0.1 μM), respectively (Buchdunger et al.; Buchdunger et al., 1996;
Capdeville et al., 2002). Imatinib also inhibits PDGFRα (IC50 = 0.1 μM), making it a
prime candidate to study interstitial cells. Imatinib may also inhibit similarly related
tyrosine kinase receptors, such as c-FMS (IC50 > 100 μM) and FLT3 (IC50 > 10 μM), yet
at much higher concentrations (Capdeville et al., 2002).
Imatinib administration generally improves LUT functional outcomes (e.g.,
increased void and residual volumes, increased infused volume and capacitance), reduces
detrusor contractile properties (e.g., amplitude and/or frequency), and reduces interstitial
cells markers in preclinical OAB (Abrams et al., 2012; Deng et al., 2013; Kjell et al.,
2015; Sui et al., 2008) or IC/BPS (Giglio et al., 2018; Sancho et al., 2017) rodent models,
or in detrusor tissue from OAB patients (Biers et al., 2006). In controls, sham-operated
rodents, or normal human detrusor tissue (Biers et al., 2006) imatinib administration
increased bladder function (Biers et al., 2006; Deng et al., 2013), decreased calcium
waves in detrusor interstitial cells (Deng et al., 2013), decreased spontaneous contractile
properties (Biers et al., 2006; Deng et al., 2013; Gevaert et al., 2011; Kubota et al.;
Kubota et al., 2004; Min et al., 2011), decreased pelvic nerve electrical field stimulation-,
stretch-, carbachol- and methacholine-evoked detrusor contractions (Gevaert et al., 2011;
Giglio et al., 2018; Kubota et al.; Kubota et al., 2004; Min et al., 2011).
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Together, these studies suggest 1) a role for PDGFRα+ interstitial cells in normal
and pathological LUT function, and 2) imatinib mesylate may improve LUT functional
outcomes in animal models of bladder dysfunction, which further implicates potential
therapeutic significance of this drug in patients with OAB or IC/BPS. However, few
studies address the mechanism(s) by which imatinib may improve LUT function.
Functional improvements observed with imatinib administration in OAB or IC/BPS
rodent models may be mediated by multiple mechanisms, including changes in the
urinary inflammatory milieu. Two studies with similar contusion SCI models investigate
the effect of imatinib treatment on the inflammatory milieu at various time points, both of
which report imatinib treatment improves hindlimb locomotion and bladder function in
SCI rats (Abrams et al., 2012; Kjell et al., 2015). Imatinib treatment increased serum
concentrations of inflammatory mediators (monocyte chemoattractant protein-1,
macrophage inflammatory protein-3α, interleukin (IL)-8), and increased CD68, a
monocyte/macrophage marker, immunoreactivity (IR) in the spleen, bone marrow and
thymus, but decreased CD68 and other macrophage and microglia marker IR at site of
injury in rats with SCI (Kjell et al., 2015). By a similar design, plasma cytokine (IL-1β,
IL-6, IL-8, tumor necrosis factor-α) concentrations were largely unaffected but astrocytic
reactivity markers and CD68 IR decreased at the site of injury with imatinib treatment in
rats with SCI (Abrams et al., 2012).
The effect of imatinib on the inflammatory response has been more widely
examined outside of the LUT (e.g., lung, kidney, brain, spinal cord, bone marrow) in a
variety of animal models and clinical studies. Imatinib has improved clinical outcomes of
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multiple auto-immune and inflammatory disorders (Adzemovic et al., 2013; Boucher et
al., 2003; Daniels et al., 2004; Ma et al., 2011; Paniagua et al., 2006; Roskoski, 2018;
Tanaka et al., 2016; Wang et al., 2005), directly modulates immune cell signaling and
affects cytokine and chemokine expression (Hayashi et al., 2012; Leder et al., 2007;
Mokhtari et al., 2011; Pardanani et al., 2003; Seggewiss et al., 2005).
Additionally, numerous studies suggest imatinib administration improves
endothelial barrier properties, possibly due to altered expression of tight junction proteins
(Abrams et al., 2012; Adzemovic et al., 2013; Aman et al., 2012; Chislock and
Pendergast, 2013; Ma et al., 2011; Zhan et al., 2015). Imatinib may mediate vascular
protective effects through inhibition of the PDGFR, c-Kit, or ABL tyrosine kinases.
These kinases can be activated by growth factors, chemokines, and cytokines, which may
further promote inflammation and vascular permeability changes (Andrae et al., 2008;
Colicelli, 2010; Lennartsson and Rönnstrand, 2012). For instance, VEGF has been
suggested to induce endothelial permeability by ABL activation (Aman et al., 2012;
Chislock and Pendergast, 2013).
1.4. Project Goals and Hypotheses
Bladder dysfunction conditions such as IC/BPS and OAB can be burdensome,
painful conditions that reduce quality of life and place significant strain on patients’ work
life, finances, relationships, psychological and general health (Clemens et al., 2005;
Hanno et al., 2015). Few treatment options are available, with only one pharmaceutical
approved by the FDA. However, treatments are not effective for all patients, as bladder
dysfunction conditions, especially IC/BPS, present clinically with varying histological
55

and functional symptomology, as well as comorbidities, which may affect treatment
efficacy. Additionally, long term therapeutic use or effectiveness may not be feasible, and
treatments may be undesirably invasive (e.g., hydrodistension, surgery). Overall
treatment costs estimate $230 million/year (Patnaik et al., 2017). IC/BPS and OAB are
often diagnosed in middle age and the US population is aging, along with many other
countries, according to the US Census Bureau. Thus, novel treatment targets and
therapeutic options are desperately needed for IC/BPS and OAB. Additionally, basic
science research questions concerning the mechanism(s) of action for afferent signaling
and detrusor contraction in the urinary bladder, remain unanswered. The main objectives
of this dissertation are to characterize the effects of a potential therapeutic treatment,
imatinib mesylate, on urinary bladder function and examine the contribution of
PDGFRα+ interstitial cells in the normal and pathological urinary bladder in a murine
model of IC/BPS. Our central hypothesis is that PDGFRα+ interstitial cells contribute to
bladder dysfunction (e.g., decreased voiding frequency, infused volumes, increased
somatic sensitivity) by altering the inflammatory milieu of the micturition reflex
components (e.g., urinary bladder) in a preclinical CYP-induced cystitis murine model.
In chapter 2, we examine the functional effects of imatinib using a prevention or
treatment design, in which imatinib is delivered via oral gavage or intravesical bladder
infusion, respectively, in the presence or absence of LUT inflammation in female and
male mice. We hypothesize that the PDGFRα+ subpopulation of interstitial cells
contributes to increased urinary frequency and pelvic somatic sensitivity in an overactive
(CYP-induced cystitis) mouse model. In chapter 3, we explored potential underlying
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mechanisms (e.g., inflammatory mediators, cell signaling pathways) mediating the
functional effects of imatinib in the normal and inflamed urinary bladder and lamina
propria in female mice, using a prevention and treatment design. We hypothesize that
disruption of PDGFRα+ subpopulation with imatinib alters the inflammatory milieu of the
urinary bladder in an overactive (CYP-induced cystitis) mouse model. Upon completion
of these experiments, we will have 1) characterized the LUT functional effects and
potential mechanisms of imatinib in CYP-induced cystitis, 2) provided preclinical
evidence for the potential use of a new therapeutic, imatinib, for IC/BPS and/or OAB,
although this warrants more research, and 3) contributed to the growing body of literature
suggesting interstitial cells play crucial roles in normal and pathological urinary bladder
afferent signaling.
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Abstract
Lamina propria interstitial cells that express the tyrosine kinase receptor, platelet-derived
growth factor receptor alpha (PDGFRα) may play a role in urinary sensory signaling.
Imatinib mesylate, also referred to as imatinib, is a tyrosine kinase inhibitor that can
inhibit PDGFRα and has been widely used in urological research. We evaluated the
functional effects of imatinib administration (via oral gavage or intravesical infusion)
with two different experimental designs (prevention and treatment), in a
cyclophosphamide (CYP)-induced cystitis (acute, intermediate, chronic), male and
female rodent model using conscious cystometry and somatic sensitivity testing. Imatinib
significantly (0.0001 ≤ p ≤ 0.05) decreased voiding frequency and increased bladder
capacity in acute CYP-induced cystitis, by the prevention (females) and treatment
(females and males) designs. Imatinib was not effective in preventing or treating
intermediate or chronic CYP-induced cystitis in either sex. Interestingly, in the
prevention experiments, imatinib administration increased (0.0001 ≤ p ≤ 0.01) voiding
frequency and decreased bladder capacity in control mice. However, in the treatment
experiments, imatinib administration decreased (0.01 ≤ p ≤ 0.05) voiding frequency and
increased bladder capacity in control mice. Bladder function improvements observed
with imatinib treatment in acute CYP-induced cystitis mice remained and additionally
improved with a second dose of imatinib 24 hours after CYP treatment. Imatinib
administration did not affect pelvic somatic sensitivity in female mice with acute CYPinduced cystitis. Our studies suggest that (1) imatinib improves bladder function in mice
with acute CYP-induced cystitis with a prevention and treatment design and (2)
86

interstitial cells may be a useful target to improve bladder function in cystitis.
Keywords: Interstitial cystitis, interstitial cells, platelet-derived growth factor receptor
(PDGFR), imatinib mesylate, conscious cystometry, somatic sensitivity
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Introduction
The storage and release functions of the urinary bladder are highly organized
and coordinated by peripheral and central neural pathways involving the spinal cord,
brain, afferent and efferent nerves, dorsal root ganglia (DRG), autonomic ganglia and the
urinary bladder (de Groat et al., 2015; Andersson, 2002). The urinary bladder is
organized into layers: the mucosa, muscularis propria, and the adventitia/serosa. The
mucosal layer consists of transitional epithelial (urothelial) cells that line the lumen of the
bladder and a lamina propria (LP) (also referred to as the submucosa) beneath the
basement membrane of the epithelial cells (Merrill et al., 2016; Andersson, 2002; 2004).
The urothelium responds to stimuli and releases various factors including ATP, ACh and
nitric oxide (Merrill et al., 2016; Birder and Andersson, 2013). The urothelium can be
compromised with injury or inflammation, allowing toxic substances to reach the
suburothelial nerve plexus and muscular layers, contributing to urinary urgency,
frequency, and pain during voiding (Birder and Andersson, 2013; Birder, 2005). The LP
is composed of loose connective tissue, interstitial cells (ICs), vasculature, adipocytes,
lymphatic vessels, fibroblasts, nerve fibers and endings and may integrate urothelial and
smooth muscle input (Andersson, 2002; 2004; Birder and Andersson, 2013).
Neuro-urological research continues to advance our understanding of the
mechanisms underlying bladder function and dysfunction. However, many questions
remain concerning the identity of potential treatment targets as well as treatment options
for urinary bladder dysfunction. For example, current theories suggest a sensory
intermediary function for the LP ICs to mediate signals from the urothelium to afferent
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nerves and/or the detrusor muscle, to regulate bladder sensation and contractility (Koh et
al., 2018; Gray et al., 2013; Heppner et al., 2017). LP ICs in the urinary bladder are
positioned near afferent nerve terminals in the suburothelial plexus (Koh et al., 2012;
Gabella, 2019) and exhibit cholinergic (Grol et al., 2009; Mukerji et al., 2006), purinergic
(Fry et al., 2012; Sui et al., 2006; Heppner et al., 2017; Lee et al., 2014) and nitrergic
(Gillespie et al., 2006; de Jongh et al., 2007; Smet et al., 1996) properties (Koh et al.,
2018). Other potential roles for LP ICs include: transduction of bladder
mechanosensation (Heppner et al., 2017; Isogai et al., 2016; Steiner et al., 2018; Dalghi et
al., 2019; Liu et al., 2018), propagation of calcium transients (Heppner et al., 2017) and
signal transmission via gap junctions (Ikeda et al., 2007). A subset of LP ICs express the
tyrosine kinase receptor platelet-derived growth factor receptor alpha (PDGFRα) (Koh et
al., 2012; Monaghan et al., 2012; Sancho et al., 2017) and this subpopulation may be
important for bladder voiding during early postnatal development before coordinated
urinary function (Heppner et al., 2017; Kanai et al., 2007). Studies suggest that
PDGFRα+ LP ICs may also contribute to bladder dysfunction (e.g., interstitial
cystitis/bladder pain syndrome, IC/BPS) because preclinical rodent models show
increased expression of ICs markers (Sancho et al., 2017; Gevaert et al., 2011; Liu et al.,
2017; Liu et al., 2018; Meng et al., 2015; Roosen et al., 2009; Neuhaus et al., 2005;
Kubota et al., 2008; Kim et al., 2011; de Jongh et al., 2007; Deng et al., 2015; Abrams et
al., 2012; Johnston et al., 2012; Kjell et al., 2015). Additionally, ICs display abnormal
electrophysiological properties in IC/BPS and may contribute to the increased and
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spontaneous contractions observed in the detrusor (Rosenberg et al., 2016; Liu et al.,
2017; Liu et al., 2018).
Imatinib mesylate, also referred to as imatinib, is a competitive inhibitor of the
ATP-binding site of certain receptor tyrosine kinases including PDGFRα (Buchdunger et
al., 2000; Buchdunger et al., 1996; Kilic et al., 2000) and has been commonly used in
lower urinary tract (LUT) studies to target PDGFRα+ LP ICs (Kjell et al., 2015; Kubota
et al., 2006; Abrams et al., 2012; Biers et al., 2006; Gevaert et al, 2014; Min et al., 2011;
Sancho et al., 2017; Giglio et al., 2018; Deng et al., 2013). Recent reports indicate that
imatinib administration reduces PDGFRα expression and voiding frequency in rodents
with IC/BPS (Sancho et al., 2017; Giglio et al., 2018). In this study, we expand upon
previous studies (Sancho et al., 2017; Giglio et al., 2018) to determine the functional
effects of imatinib mesylate administration (e.g., gavage, intravesical) in a
cyclophosphamide (CYP)-induced cystitis (acute, intermediate, chronic) mouse model
(male and female) using conscious, unrestrained, open-outlet cystometry. We also assess
the mechanical sensitivity of the pelvic region in a CYP-induced cystitis mouse model
with and without imatinib treatment (e.g., gavage, intravesical).
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Materials and Methods
Experimental Animals
Male and female wildtype (WT), C57BL/6 mice (3-5 months) (Jackson Labs,
Bar Harbor, ME, USA) were used in these studies. Mice were bred locally at The Larner
College of Medicine, University of Vermont (UVM) animal facilities in standard
laboratory conditions, as previously described (Tooke et al., 2019). The UVM
Institutional Animal Care and Use Committee (IACUC) approved all experimental
procedures involving animal use (IACUC #X9-020). The UVM Office of Animal Care
and Management managed animal care in accordance with the American Association for
Accreditation of Laboratory Animal Care (AAALAC) and National Institutes of Health
(NIH) guidelines. All efforts were taken to minimize animal pain and distress. Mice
exhibiting signs of pain and distress that could not be managed with post-operative
analgesics were immediately euthanized. Separate cohorts of littermate WT mice were
used in these studies. Female mice were primarily used because of the increased IC/BPS
prevalence in human females (Hanno et al., 2015). The estrous cycle status of mice was
not determined.
CYP Dosing and Administration
CYP treatment groups received CYP injections (i.p.) to induce acute (200
mg/kg, 4 h), intermediate (200 mg/kg, 48 h) or chronic (75 mg/kg, every 72 h for 8 days)
urinary bladder inflammation as previously described (Guo et al., 2018; Malley and
Vizzard, 2002; Bjorling et al., 2011). Control groups did not receive CYP. After
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completion of CYP treatment, mice were used for bladder function testing (i.e.,
cystometry) or tissues (e.g., urinary bladder) were harvested from anesthetized (5%
isoflurane in oxygen) mice subsequently euthanized by thoracotomy. Urinary bladders
were collected and stored for future experiments.
Imatinib Mesylate Dosing and Administration
The dose and route of imatinib were determined in pilot studies (data not shown)
and by using previous reports (Abrams et al., 2012; Kjell et al., 2015; Sancho et al., 2017)
as guidance. Imatinib or vehicle (i.e., water or saline) was delivered by two different
routes in separate cohorts of mice: (1) systemically by oral gavage (250 mg/kg; 22
gauge/25mm, stainless steel); or (2) directly by intravesical infusion (50 μM) via an
externalized bladder catheter, or by transurethral intravesical infusion (50 μM). Upon
cessation of gavage and infusion, mice were used for testing and/or euthanized for tissue
collection.
Oral Gavage (Prevention Schedule)
Mice were placed headfirst in a cone shaped, plastic bag with the far corner cut.
Alternative handling techniques (i.e., scruff) could not be used because of the intravesical
implant surgery with exteriorization at the base of the neck. Mice were monitored
constantly to ensure correct gavage needle placement and animal well-being. The same
individual performed all gavage procedures at the same time of day (8 am-12 pm) to
reduce potential variability.
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Mice were pre-treated with imatinib (250 mg/kg) for 5 days prior to CYP (i.p.)
administration ranging from 5-12 days total, depending on the CYP dosing schedule. All
groups were gavaged daily throughout the entire experimental period with imatinib or
vehicle control, including on surgery, CYP administration and cystometry testing days.
On these days, mice were gavaged and left undisturbed in their home cages for at least 30
min prior to surgery, CYP administration or cystometry testing.
Catheter Implant for Intravesical Infusion (Prevention Schedule)
Mice were pre-treated with imatinib (50 uM, 30 min, 0.5 mL, 1X/day) via an
externalized bladder catheter for 5 days prior to CYP (4 h, 200 mg/kg, i.p.)
administration. Some cohorts additionally received protamine sulfate (PS; 10 mg/kg, 0.5
mL, 30 min) infusions, prior to imatinib. Bladder parameters were assessed using
conscious, open outlet cystometry after acute (4 h) CYP.
Catheter Implant for Intravesical Infusion (Treatment Schedule)
Acute (4 h, 200 mg/kg, i.p.) or chronic (every 72 h for 8 days, 75 mg/kg, i.p.)
cystitis was induced with CYP as previously described (Tooke et al., 2019; Guo et al.,
2018). Bladder parameters were assessed using conscious, open outlet cystometry before
and after the imatinib infusion (50 µM, 30 min, 0.5 mL).
Transurethral Intravesical Infusion (Treatment Schedule)
Mice were anesthetized with isoflurane in oxygen (3-4%), placed in the supine
position on a water mat heating pad and catheterized by inserting lubricated polyethylene
tubing (PE-10, Clay Adams, Parsippany, NJ) into the bladder through the urethra. The
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mice were manually voided before the urethral instillation procedure. Solution (i.e.,
imatinib or saline) was instilled into the bladder until a full bladder could be palpated
(25-400 µL). The catheter was then removed from the urethra while the mice remained
anesthetized (30 min).
Intravesical Catheter Implantation
Intravesical catheter implantation was performed as previously described
(Schnegelsberg et al., 2010; Gonzalez et al., 2013). Mice received analgesics (carprofen,
0.1 mg/kg, s.c.) before and after (every 24 h for 48 h total) surgery.
Conscious, Open-Outlet Cystometry with Continuous Infusion of Saline
Conscious, open-outlet cystometry with continuous saline infusion was
performed as previously described (Tooke et al., 2019; Guo et al., 2018). Three days after
surgery, mice were placed, unrestrained, in a wire bottom cage with the dorsal neck
tubing exteriorized and connected to the cystometry system (Med Associates, St. Albans,
VT, USA). Room temperature saline was infused into the bladder (25 µl/min) to elicit
repetitive bladder contractions. After an initial accommodation period (20-30 min), a
minimum of 6 consistent micturition cycles were recorded. Urodynamic measures
included: minimum pressure (pressure at the beginning of bladder filling), threshold
pressure (bladder pressure immediately before micturition), maximum pressure,
intermicturition interval (time between micturition events) and infused volume. Bladder
capacity is defined as the infused volume necessary to elicit a micturition event. Voided
volume was not analyzed as multiple groups (e.g., CYP groups) were unable to be
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assessed, due to very small volume voids. Nonvoiding contractions (NVCs) were also not
analyzed because multiple groups did not reliably produce NVCs.
Imatinib (50 µM) was intravesically infused into the bladder for some
experiments where mice served as their own controls and were evaluated before and after
imatinib treatment. Baseline bladder function testing was conducted with intravesical
saline, followed by intravesical imatinib treatment, then bladder function testing was
repeated. At least 6, reproducible micturition cycles were obtained before and after
imatinib treatment. After cystometry, mice were euthanized by thoracotomy. Urinary
bladders were harvested for future experiments.
Pelvic Mechanical Sensitivity Testing
Mechanical sensitivity was assessed in separate groups of mice that did not
undergo the intravesical catheter implantation surgery nor cystometry. The imatinib
prevention (gavage) and treatment schedules (intravesical infusion) were evaluated. All
mice were acclimated to the testing environment for 2 h/day for two days prior to
(Schnegelsberg et al., 2010) and on the test day.
Prevention. Cohorts received daily doses of imatinib or vehicle (water) via oral
gavage, 1X/day for 5 days. On the test day (i.e., last day), the cohorts received the final
dose of imatinib, followed 30 min later with acute CYP treatment. Mechanical sensitivity
was evaluated 4 h after CYP treatment.
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Treatment. Cohorts received acute CYP treatment followed 4 h later by an
intravesical infusion (transurethral catheter) of imatinib or vehicle (saline) followed (30
min) by mechanical sensitivity testing.
Control mice did not receive CYP treatment. Mice were tested in individual
plexiglass chambers with a stainless-steel wire grid floor, using calibrated von Frey
microfilaments (0.008-1 g, Semmes Weinstein, Stoelting Co, Wood Dale, IL).
Microfilaments were applied in a perpendicular manner, until the hair buckled to the
lower pelvic/abdominal region overlying the bladder for 1-3 s with an interstimulus
interval of at least 15 s. Positive behaviors included sharp retraction of the abdomen,
jumping or immediate licking or scratching of the affected area (Schnegelsberg et al.,
2010; May and Vizzard, 2010). Mechanical sensitivity testing was performed in a blinded
manner, with mixed treatment and control groups. The groups were decoded following
analyses.
Mechanical Sensitivity Analysis
The mechanical force needed to elicit a withdrawal response in 50% of the mice
was determined using the up-down method (Deuis et al., 2017). At least 4 responses were
obtained after the first change in von Frey filament direction. The withdrawal threshold
was defined as a positive response, followed by a negative response in either direction,
repeated at least twice. Two separate evaluators determined the withdrawal thresholds;
one evaluator was blinded to all conditions.
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Pain Behavioral Assessments
Secondary behavioral assessments that may be indicative of pain or distress
were also conducted. Behavior was only assessed in the control and treatment
(intravesical) groups also undergoing mechanical sensitivity testing. Mice were
acclimated to individual cages 30 min/day, for 2 days before behavioral assessments. On
the test day, after microfilament sensitivity testing, mice were immediately placed in
individual cages for acclimation (10 min). Mice were then recorded using a video camera
for 15 min. An evaluator, blinded to groups, examined the video and determined total
time moving and total licking behaviors of the abdominal pelvic area (Arras et al., 2007;
Boucher et al., 2000; Yoshikawa et al., 2012).
Exclusionary Criteria
Mice were withdrawn from study because of adverse postoperative events or
pain, lethargy, or if distress could not be alleviated by postoperative analgesics. Some
cystometry recordings were rendered unusable due excessive behavioral movements
(e.g., grooming, standing, walking, defecation, chewed tubing). Approximately 10% of
mice (n=32) were removed from the study.
Statistical Analyses
All values represent mean ± SEM. When the F ratio exceeded the critical value
at α = 0.05, post-hoc multiple comparisons tests were performed. Data were analyzed
using a two-way analysis of variance (ANOVA) with Bonferroni’s multiple comparisons
test, a repeated measures two-way ANOVA with Šídák’s multiple comparisons test, or
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Student’s paired t-test, as indicated by experimental design. All analyses were performed
using GraphPad Prism software (GraphPad Prism version 8.0.0 for Windows, GraphPad
Software, San Diego, California USA, www.graphpad.com).
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Results
Imatinib Decreases Voiding Frequency and Increases Bladder Capacity in the Acute
(4 h) CYP-Induced Cystitis Model: Prevention or Treatment Design
Administration of imatinib significantly (p ≤ 0.001) increased the
intermicturition interval (IMI) and the infused volume (IV) in mice with acute (200
mg/kg, i.p., 4 h) CYP-induced cystitis when evaluated in two different drug delivery
methods and experimental designs (Figs. 1, 3).
Prevention effects: Mice were pre-treated daily via oral gavage or direct
intravesical infusion with imatinib mesylate, followed by induction of CYP-induced
cystitis (Fig. 1A). Female and male mice with acute (4 h) CYP-induced cystitis exhibited
significantly (p ≤ 0.01) decreased IMI and IV compared to controls, as expected (Figs.
1B-E, 2A, B). In female mice with acute (4 h) CYP-induced cystitis, imatinib (250
mg/kg, 5 days) administration via oral gavage significantly (p ≤ 0.001) increased IMI and
IV compared to vehicle (water) treated mice (Figs. 1B, D, 2C, D). However, this imatinib
delivery method and treatment schedule did not affect IMI or IV in male mice with CYPinduced cystitis (Figs. 1C, E). Imatinib pre-treatment significantly (p ≤ 0.01) increased
bladder pressures (minimum, threshold, maximum) in male and female mice with acute
CYP-induced cystitis, compared to controls (Table 1).
The systemic administration of imatinib by gavage may have off-target effects
not specifically due to PDGFRα inhibition at the level of the urinary bladder. Thus, we
conducted a series of experiments to intravesically infuse imatinib to investigate bladder99

specific effects of PDGFRα inhibition. Mice were pre-treated with imatinib (50 μM, 0.5
mL, 30 min) for 5 days and acute cystitis was induced via CYP on day 5. This treatment
and dosing schedule resulted in mice exhibiting increased voiding frequency as
documented in mice with only CYP-induced cystitis (4 h) (data not shown). We
hypothesized that intravesical imatinib was unable to penetrate the intact urothelial
barrier to access the LP. Thus, we performed a follow-up study in a separate cohort of
mice that received intravesical protamine sulfate (PS) (10 mg/kg, 0.5 mL, 30 min) every
other day, prior to imatinib infusions, to disrupt the urothelial lining (Stein et al., 1996).
PS does not affect voiding frequency at this concentration (Klinger and Vizzard, 2008;
Fraser et al., 2003; Chaung et al., 2003). Urinary bladder function resembled that in CYPtreated mice (without imatinib) but imatinib treatment did not significantly affect IMI or
IV, despite PS treatment (data not shown).
Treatment effects: We then evaluated potential treatment effects of direct
intravesical infusion of imatinib in mice with acute CYP-induced cystitis. Mice were
treated with imatinib via intrabladder infusion (50 μM, 0.5 mL, 30 min) after induction of
acute (4 h) CYP cystitis (Fig. 3A). Bladder function was recorded before and after
imatinib infusion. Acute CYP treatment significantly (p ≤ 0.01) reduced IMI and IV in
female mice (Figs. 3B, D). Imatinib treatment significantly increased IMI and IV in
female (1.7-fold) (p ≤ 0.0001) (Figs. 3B, D, 4A-D) and male (1.6-fold) (p ≤ 0.05) (Figs.
3C, E) mice with acute CYP-induced cystitis. Imatinib treatment significantly (p ≤ 0.05)
reduced minimum bladder pressure in female mice with acute CYP-induced cystitis but
did not affect bladder pressures in male mice (Table 2). Bladder function changes in mice
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with imatinib infusion were observed within 30-50 min. Most mice (n = 16/19, 84%)
exhibited changes in bladder function following imatinib infusion that persisted until the
end of the recording session (i.e., 30-60 min).
Imatinib is Not Effective in Preventing or Treating Intermediate (48 h) or Chronic
(8 day) CYP-Induced Cystitis
We investigated the effects of PDGFRα blockade with imatinib in mice with
intermediate (48 h) and chronic (8 day) CYP-induced cystitis using prevention (i.e.,
imatinib via oral gavage before CYP treatment) and treatment (i.e., CYP treatment
followed by intrabladder infusion of imatinib) methods (Figs. 5A, 6A).
Prevention: Before CYP treatment, mice were pre-treated daily with imatinib for
5 days. CYP treatment began on the 5th day for intermediate and chronic schedules.
Intermediate CYP treatment consisted of a single CYP injection (200 mg/kg, i.p.)
followed by bladder function testing at 48 h (intermediate) after injection. For the chronic
cystitis model, mice received 3 CYP injections every 72 h (75 mg/kg, i.p.) followed by
bladder function testing on the last day. Daily imatinib administration continued
throughout the CYP treatment period for a total of 7 or 12 total days for the intermediate
or chronic CYP schedules, respectively. Mice with chronic (75 mg/kg, i.p. every 72 h, 8
days) CYP-induced cystitis exhibited significantly (p ≤ 0.05) decreased IMI and IV
compared to controls (Figs. 5B, C). Mice pre-treated with imatinib (250 mg/kg, 12 total
days) by gavage with chronic CYP treatment, did not exhibit significant differences in
IMI or IV compared to chronic CYP groups pre-treated with vehicle (Figs. 5B, C).
Imatinib pre-treatment significantly (p ≤ 0.01) increased minimum pressure in chronic
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CYP-induced cystitis female mice, compared to vehicle controls (Table 1). We
additionally assessed the effectiveness of imatinib at an intermediate CYP-induced
cystitis time point (200 mg/kg, i.p., 48 h) with imatinib pre-treatment (gavage, 250
mg/kg, 7 total days) and found no significant differences in IMI or IV compared to
vehicle treated groups or controls (data not shown).
Treatment: Mice were treated by intravesical infusion with imatinib (50 μM, 0.5
mL, 30 min) on the last day of the chronic CYP protocol (Fig. 6A;75 mg/kg, i.p. every 72
h, 8 days). Bladder function was recorded before and after the imatinib intravesical
infusion in the same mice. Mice with chronic CYP-induced cystitis treated with imatinib
via intrabladder infusion did not exhibit significant differences in bladder function
compared to pretreatment function (Figs. 6B, C; Table 2).
Use of imatinib mesylate as a prevention or treatment for bladder dysfunction
with CYP-induced cystitis was ineffective in intermediate (48 h) or chronic (8 day) CYP
treatment protocols. Due to the absence of effect(s) in female mice, studies were not
repeated with male cohorts.
Oral Gavage of Imatinib Increases Voiding Frequency and Decreases Bladder
Capacity in Control (No CYP) Mice
In prevention studies with imatinib pre-treatment, control (no CYP) groups were
necessary and allowed us to assess the effect of PDGFRα inhibition on bladder function
before CYP treatment. Control mice were treated with imatinib or vehicle throughout the
experimental period (Figs. 1A, 5A) and did not receive CYP injections. Female and male
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control (no CYP) mice treated with imatinib, via gavage, for the acute 5-day schedule,
exhibited increased voiding frequency (decreased IMI and IV) (p ≤ 0.01), compared to
vehicle treated control (no CYP) mice (Figs. 1B-E). In female mice, decreases in IMI and
IV were more dramatic in mice with acute CYP-induced cystitis treated with vehicle
compared to the imatinib treated control (5 day) group (Figs. 1B, D). However, in male
mice, the imatinib treated control group (5 day) and 4 h CYP treatment with vehicle
groups were not significantly different (Figs. 1C, E). Imatinib significantly (p ≤ 0.01)
increased bladder pressure for both female (threshold) and male (threshold and
minimum) control mice (Table 1). Imatinib treatment in control mice (no CYP) did not
significantly affect bladder function with the intermediate (8 day) (data not shown) or
chronic (12 day) schedules (Figs. 5B, C; Table 1).
Intrabladder Infusion of Imatinib Decreases Voiding Frequency and Increases
Bladder Capacity in Male and Female Control (No CYP) Mice
Imatinib treatment, via intrabladder infusion, significantly decreased voiding
frequency (increased IMI and IV) in female (p ≤ 0.01) (1.5-fold) and male (p ≤ 0.05)
(1.4-fold) control (no CYP) mice but did not affect bladder pressures in either sex (Figs.
3B-E; Table 2).
Multiple Treatments with Intrabladder Infusion of Imatinib may Further Improve
Bladder Function with Acute (4 h) CYP-Induced Cystitis in Female Mice
We evaluated if an additional treatment with imatinib mesylate would result in a
greater improvement in bladder function in the acute CYP-induced cystitis mouse model
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beyond what was observed with a single intrabladder infusion. In this experiment, mice
received imatinib treatment (50 μM, 0.5 mL, 30 min) via intrabladder infusion 4 h and 24
h after inducing acute (4 h) cystitis with CYP. Bladder function was recorded before and
after imatinib treatment, both 4 h and 24 h after CYP administration (Fig. 7A). IMI and
IV significantly increased (p ≤ 0.01) after the first dose of imatinib treatment with acute
(4 h) CYP treatment (Figs. 7B, C). Twenty-four hours later, before the second dose of
imatinib, significant (p ≤ 0.01) changes in bladder function (e.g., increased IMI and IV)
persisted. The second dose of imatinib, 24 h after CYP treatment significantly (p ≤ 0.05)
increased IMI and IV compared to acute (4 h) CYP-induced cystitis before (p ≤ 0.001)
and after the effects of a single dose of imatinib (p ≤ 0.01) (Figs. 7B, C). Imatinib
treatment did not affect bladder pressures at 4 h or 24 h (Table 2). These results suggest
that multiple doses of imatinib may improve bladder function outcomes with acute (4 h)
CYP-induced cystitis.
Oral Gavage or Transurethral Infusion of Imatinib does not Affect Pelvic Somatic
Sensitivity in Female Mice with Acute (4 h) CYP-Induced Cystitis
Acute CYP administration significantly (p ≤ 0.05) increased pelvic somatic
sensitivity compared to control (no CYP) (Appendix A, Figure 1). In controls (no CYP),
imatinib delivery via gavage (prevention protocol) increased pelvic sensitivity (p ≤ 0.05)
but no effect was observed with transurethral infusion of imatinib (treatment protocol)
(Appendix A, Figure 2). In mice with acute CYP-induced cystitis, imatinib treatment
(transurethral intrabladder infusion, 50 μM, 0.5 mL, 30 min) or prevention (oral gavage,
250 mg/kg, 5 days) did not affect pelvic somatic sensitivity (Appendix A, Figures 1, 2).
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We additionally scored behaviors in female mice with acute CYP-induced cystitis
following transurethral infusion (50 μM, 0.5 mL, 30 min) of imatinib or vehicle. Total
licking behaviors were significantly (p ≤ 0.05) increased in mice with 4 h CYP-induced
cystitis. However, imatinib treatment did not significantly affect either total time moving
or total licking behaviors in control mice or in mice with 4 h CYP-induced cystitis
(Appendix A, Figure 2).

105

Discussion
Our studies demonstrate different effects of imatinib treatment depending on its
use in control (no CYP), CYP-treated or mice with varying durations of CYP-treatment.
Our studies expand upon previous reports investigating the effects of imatinib in the
micturition system in a variety of bladder dysfunction models, including: CYP-induced
cystitis (Sancho et al., 2017; Liu et al., 2018), radiation-induced cystitis (Giglio et al.,
2018); spinal cord injury (SCI)-induced overactive bladder (Abrams et al., 2012; Kjell et
al., 2015; Deng et al., 2013), and bladder outlet obstruction (Kim et al., 2011; Preis et al.,
2015). Although various in vivo and ex vivo approaches have been used to determine
effects of imatinib on rat and guinea pig bladder function (Sancho et al., 2017; Abrams et
al., 2012; Kjell et al., 2015; Deng et al., 2013; Biers et al., 2006; Kim et al., 2011; Kubota
et al., 2004; 2006; Giglio et al., 2018; Liu et al., 2018; Gevaert et al., 2014), we believe
these studies are the first to use conscious, unrestrained cystometry to assess the effects
of imatinib mesylate on urinary bladder function in mice with CYP-induced cystitis. Our
studies suggest a role for imatinib mesylate given systemically (gavage) or intravesically
as a potential therapeutic in urinary bladder dysfunction in female mice with acute (4 h)
CYP-induced cystitis but not chronic CYP-induced cystitis. Interestingly, our prevention
(gavage) studies in control mice (no CYP) also demonstrate that imatinib treatment can
increase voiding frequency suggesting that imatinib and PDGFRα+ ICs may contribute to
the development and maintenance of bladder dysfunction (e.g., increased voiding
frequency). Although cystometry results demonstrate that intravesical imatinib can
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improve urinary bladder function in acute (4 h) CYP cystitis, intravesical imatinib does
not affect mechanical sensitivity of the pelvic region in these mice.
We demonstrate that imatinib administration to mice with acute (4 h) CYPinduced cystitis improved bladder capacity and reduced voiding frequency. Based on
previous reports and imatinib pharmacokinetics (Sancho et al., 2017; Abrams et al., 2012;
Peng et al., 2005), we initially evaluated a prevention protocol in which imatinib was
delivered (250 mg/kg) daily by oral gavage for 5 days prior to the onset of CYP-induced
cystitis. Imatinib pre-treatment increased IV and IMI in female mice with acute CYPinduced cystitis with this prevention protocol. However, the same prevention protocol
with imatinib was without effect in male mice with acute (4 h) CYP-induced cystitis.
Although imatinib does inhibit the tyrosine kinase receptor PDGFRα, like the majority of
other PDGFRα inhibitors, it is not a specific inhibitor (Roskoski, 2018). Imatinib was
initially designed to inhibit the abnormal tyrosine kinase activity of the BCR-ABL gene
which occurs in chronic myeloid leukemia (Capdeville et al., 2002). Imatinib additionally
inhibits PDGFRβ and the related tyrosine kinase receptor, c-KIT (Buchdunger et al.,
2000; Capdeville et al., 2002). Early studies of urinary ICs reported c-KIT expression in
the bladder (McCloskey et al., 2002; Davidson and McCloskey, 2005; Sui et al., 2002;
Koh et al., 2018). However, numerous recent studies demonstrate that urinary c-KIT
expression is minimal and primarily due to mast cells, and confirm that urinary PDGFRα
ICs do not express c-KIT (Koh et al., 2012; Rasmussen et al., 2007; Gevaert et al., 2017;
García-Pascual et al., 2008). With systemic administration of imatinib, we cannot exclude
the possibility that improvements in bladder outcomes were due to blockade of PDGFRα
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and other receptors throughout the body. Although we are unable to achieve specific
PDGFRα inhibition with imatinib given systemically or intravesically, we used
intravesical delivery to target the site of action of imatinib to the urinary bladder.
For the intravesical imatinib administration experiments, we initially conducted
a preventative design with daily imatinib bladder infusions prior to induction of acute (4
h) CYP-induced cystitis on the last experimental day. These mice exhibited increased
voiding frequency and decreased void volumes despite imatinib treatment. With this
experimental design, the urothelium was likely not disrupted until the last experimental
day when we induced cystitis. Thus, imatinib may not have penetrated the urothelial
barrier to act on LP ICs. Thus, we revised the preventative design and performed
intravesical PS to disrupt the urothelial barrier prior to intravesical imatinib infusions. PS
does not affect voiding frequency at this concentration (Klinger and Vizzard, 2008;
Fraser et al., 2003; Chaung et al., 2003). However, even with this modification,
intravesical imatinib infusion did not decrease voiding frequency in mice with CYPinduced cystitis. These results were not consistent with our prevention design studies
when imatinib was delivered by gavage in mice with acute (4 h) cystitis. Before
concluding that a prevention design with intravesical imatinib in mice with acute cystitis
is ineffective, one should consider the effect of a higher dose of imatinib. However, our
current data suggest that systemic use of imatinib is effective in reducing urinary
frequency prior to onset of acute cystitis but intravesical imatinib is not. In addition,
these data suggest that use of imatinib as a preventative treatment for increased voiding
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frequency associated with acute cystitis may involve blockade of PDGFR and other
receptors at non-bladder targets.
We next evaluated intravesical treatment studies to examine the effect of
imatinib on bladder function after inducing acute CYP cystitis. Intravesical imatinib
treatment significantly improved bladder capacity and reduced voiding frequency in
female and male mice with acute CYP-induced cystitis. Our results with both the
prevention and treatment experimental designs via oral gavage or intravesical infusion of
imatinib, respectively, demonstrate improvement in bladder function in mice with acute
(4 h) cystitis. The two routes of imatinib administration had similar magnitude of effect
in reducing urinary frequency and increasing capacity volumes in CYP-treated mice.
Despite improvements in voiding frequency and bladder capacity in CYP-treated mice,
systemic administration of imatinib was associated with increases in bladder pressures,
while intravesical infusion of imatinib reduced or had no effect on bladder pressures. If
these data can eventually be translated to humans with IC/BPS, the magnitude of effect
with route of administration, the ease and convenience of administration, as well as offtarget effects will need to be addressed.
Surprisingly, imatinib delivery via oral gavage (prevention) in control (no CYP)
female mice increased voiding frequency compared to vehicle treated controls but the
increased voiding frequency was less than that observed in female mice with acute CYPinduced cystitis. This surprising finding may be the combined result of the effects of
imatinib on PDGFRα+ IC cells located in the LP and in the detrusor. Increased voiding
frequency in control mice treated with systemic (gavage) imatinib treatment may be, in
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part, due to PDGFRα inhibition of detrusor ICs. Detrusor ICs exhibit inhibitory influence
over smooth muscle cells (SMCs) to regulate contractions during bladder filling (Koh et
al., 2018; Anderson et al., 2013; Lee et al., 2013; Parajuli et al., 2012; Lee et al., 2017).
The release of inhibitory control of excitable SMCs may in turn promote detrusor
overactivity with increased voiding frequency. Interestingly, similar results were not
observed when control mice were treated with intravesical imatinib administration.
Imatinib treatment (50 μM, 0.5 mL, 30 min) increased bladder capacity and reduced
voiding frequency in control (non-CYP) female and male mice. These results may, in
part, be due to imatinib blockade of PDGFRα and other receptors expressed by LP ICs.
Although we cannot entirely discount an effect of imatinib on detrusor ICs, intravesical
infusion of imatinib would likely first act on LP ICs based upon their proximity to the
bladder lumen infusion site. As suggested, LP ICs may act as communication
intermediaries to the detrusor and/or afferent nerves (Koh et al., 2018; Sancho et al.,
2017; Gray et al., 2013; Heppner et al., 2017; Wiseman et al., 2003). Blockade of LP ICs
may result in dysregulated bladder afferent nerve signaling that could result in changes in
micturition volume threshold and bladder capacity.
In a previous report, imatinib treatment in mice with incomplete SCI improved
bladder function and locomotion, while also increasing serum chemokine expression
(Kjell et al., 2015). Thus, an alternative explanation for increased voiding frequency in
control (no CYP) mice treated systemically (i.e., gavage) may be due to changes in the
inflammatory environment. Previous studies from our laboratory have demonstrated that
various chemokine and cytokine receptor antagonists are effective in improving bladder
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function by reducing voiding frequency in rodents with CYP-induced cystitis (Guo et al.,
2018; Arms et al., 2010; 2013; Gonzalez et al., 2013; 2014; 2016). In ongoing studies, we
are examining the expression of inflammatory mediators in the LUT before and after
imatinib treatment in control mice and those with cystitis. The intent of these ongoing
studies is to examine the effect of imatinib on LUT inflammatory mediator expression in
mice with and without acute CYP-induced cystitis. Altered inflammatory mediator
expression with imatinib administration may contribute to the bladder function changes
observed in mice with and without acute CYP-induced cystitis.
Imatinib was effective at improving bladder function in mice with acute (4 h)
CYP-induced cystitis for both the prevention (systemic gavage) and treatment
(intravesical) designs, yet imatinib did not affect bladder function in mice with
intermediate (48 h; gavage) or chronic (8 day; gavage and intravesical) CYP-induced
cystitis. Among the many significant changes occurring throughout the micturition
system, the expression of inflammatory mediators and signaling molecules in the bladder
layers, dorsal root ganglia, and spinal cord differ in acute, intermediate, and chronic
CYP-induced cystitis (Malley and Vizzard, 2002; Gonzalez et al., 2014; Guo et al., 2018;
Arms et al., 2013). For instance, CCL2 protein expression is significantly increased in the
detrusor and urothelium in the acute model of IC/BPS, compared to the intermediate and
chronic time points (Arms et al., 2013). Additionally, changes in the inflammatory milieu
as well as the involvement of peripheral and central sensitization mechanisms contribute
to symptom progression and exacerbation with acute, intermediate, and chronic CYPinduced cystitis (Gonzalez et al., 2014). These changes with duration of urinary bladder
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inflammation may increase the complexity of treating urinary bladder dysfunction and
may suggest that some treatments may only be effective at certain timepoints. In addition,
as acute urinary bladder inflammation progresses to chronic inflammation, a combination
of therapeutics and treatments may be beneficial. Future studies in mice with acute,
intermediate, and chronic CYP-induced cystitis that evaluate bladder function effects
when imatinib is combined with other treatments (e.g., neuropeptide, cytokine, and
chemokine receptor antagonists) should be considered (Guo et al., 2018; Arms et al.,
2010; 2013; Gonzalez et al., 2013; 2014; 2016; Girard et al., 2016; 2019; 2021; Tooke et
al., 2019; Merrill and Vizzard, 2014). In addition, repeated use of imatinib may offer
additional improvements in bladder function in acute CYP-induced cystitis and extend
symptom relief. In these studies, imatinib treatment at both 4 h and 24 h after CYP
treatment significantly improved bladder outcomes in female mice with acute CYPinduced cystitis. Additional studies should determine the duration of symptom relief
period and if bladder dysfunction with acute cystitis will return to control with multiple
imatinib treatments. Such studies may provide a better understanding of (1) when, how
often (i.e., frequency) and in what context (e.g., acute cystitis) imatinib treatment is
beneficial; (2) the combinational benefit of imatinib with other treatments and (3) the
treatment nuances between acute and chronic urinary bladder inflammation.
In addition to LUT symptoms, IC/BPS patients report unpleasant pelvic
sensations (e.g., pain, pressure, or discomfort) (Hanno et al., 2015). Thus, we also
examined mechanical sensitivity of the abdominal/pelvic region in cystitis with imatinib
treatment. However, imatinib had no effect on mechanical sensitivity in female mice with
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acute, CYP-induced cystitis by the prevention (i.e., gavage, 250 mg/kg, 5 days) or
treatment (i.e., transurethral infusion, 50 μM) design as determined with von Frey
microfilament testing. Our results suggest that imatinib treatment improves functional
bladder outcomes (i.e., IV, IMI), but may not affect pelvic sensation. This finding was
surprising to us because we have evaluated multiple pharmacological agents (Girard et
al., 2016; 2019; 2021; Arms et al., 2013; Guo et al., 2018) in rodents with CYP-induced
cystitis and have never demonstrated improvements in bladder function without
reductions in mechanical sensitivity (e.g., hindpaw or pelvic region). However, these
results may provide information about the role of LP ICs in the urinary bladder and their
potential communication with bladder nerve fibers. Bladder afferent nerves are composed
of Aδ and C-type fibers (de Groat et al., 2015): Aδ afferent fibers communicate normal
sensory information (e.g., bladder filling) and C-fibers communicate painful stimuli.
Although it is speculated that LP ICs communicate with bladder sensory nerves, the
nature of this communication is unknown. Similarly, it is not known if LP ICs
preferentially communicate with Aδ compared to C-fiber bladder afferents or if this
preferential communication underlies the absence of effect by imatinib on pelvic
sensitivity. Future studies using an ex vivo urothelium+LP nerve preparation can be used
to evaluate the effects of imatinib on pelvic nerve afferents (Aδ vs. C) with or without Cfiber blockade (Heppner et al., 2017; 2019; Gonzalez et al., 2016). Additionally, it is
important to consider methodological limitations with the Von Frey mechanical
sensitivity testing paradigm (Deuis et al., 2017). Animals repeatedly tested may develop
learned responses, and responses can be missed or mistaken, even by learned
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practitioners. Additional studies are planned to evaluate the effect of imatinib on pelvic
sensitivity in CYP-induced cystitis using visceromotor responses.
Further study is necessary to understand the role of PDGFRα, LP ICs in the
normal bladder and the mechanism of action by which these cells contribute to cystitis
conditions. PDGFs are synthesized in and secreted by a variety of cell types including
platelets, macrophages, fibroblasts, epithelial cells, and SMCs (Andrae et al., 2008;
Heldin and Westermark, 1999). PDGF ligand binding activates PDGFRs stimulating
receptor dimerization and autophosphorylation of the tyrosine kinase residues. The
PDGFRα is activated by ligands PDGF-AA, -BB, -AB, and -CC, although only -AA and
-CC have been shown in vivo (Andrae et al., 2008). However, PDGF-independent and
indirect PDGFR activation can also occur (Kazlauskas, 2017). Upon PDGFR activation,
multiple cell-signaling pathways can be initiated such as MAPK/ERK, PI3K/AKT, and
PLC-γ which ultimately promote cell proliferation, growth, and survival (Andrae et al.,
2008; Heldin and Westermark, 1999). Under normal conditions, the PDGF/R system is
primarily involved in the embryological development of organs with expression low in
the adult, except for wound healing. Overexpression and enhanced activity of the
PDGF/R system may also indicate pathological processes (e.g., cancerous, fibrotic,
inflammatory, and vascular conditions) (Andrae et al., 2008; Heldin and Westermark,
1999). In urinary bladder dysfunction, PDGF/Rs may contribute to underlying
mechanisms that induce or sustain inflammation. Although the PDGFRα LP ICs likely
serve important roles in the normal functioning bladder (e.g., communicating bladder
fullness to afferent nerves and regulating detrusor muscle contractions) (Heppner et al.,
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2017), they may also contribute to pathological states by altering the inflammatory milieu
of the urinary bladder. In mice with incomplete SCI treated with imatinib mesylate,
serum levels of monocyte chemoattractant protein-1, macrophage inflammatory protein
(MIP)-3α, and keratinocyte chemoattractant/growth-regulated oncogene (interleukin 8)
were significantly increased (Kjell et al., 2015) and yet mice exhibited improvements in
bladder function and hindlimb locomotion. Future studies that address mechanisms
underlying bladder functional recovery in the presence of, or possibly supported by, an
inflammatory activation by imatinib are needed. Our current studies are examining
inflammatory activation by imatinib in mice with and without CYP-induced cystitis.
In conclusion, our results suggest imatinib administration improves bladder
function (e.g., IMI and IV) in mice with acute CYP-induced cystitis by a prevention
(gavage; females) and treatment (intravesical infusion; females and males) experimental
design. Bladder function improvements in the acute CYP-induced cystitis model with
imatinib administration may be due, at least in part, to inhibition of the PDGFRα+ LP
ICs. Furthermore, these studies demonstrated changes in voiding frequency with imatinib
administration supporting the suggestion that these cells function as a sensory
intermediary role in control as well as the inflamed urinary bladder. The absence of effect
of imatinib administration by the prevention (gavage) and treatment (intravesical
infusion) on mechanical sensitivity in mice with acute CYP-induced cystitis may suggest
that imatinib mesylate may be more appropriate as a treatment for OAB where patients
present with urinary storage symptoms (e.g., increased urgency, frequency, nocturia)
without pelvic pain, pressure or discomfort reported by IC/BPS patients (Macdiarmid and
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Sand, 2007). These studies provide some insight into a novel cell population in the
urinary bladder that may be an effective target in managing cystitis-induced bladder
dysfunction.
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Abbreviations
IC/BPS, Interstitial Cystitis/Bladder Pain syndrome
OAB, Overactive Bladder
SCI, Spinal Cord Injury
LUT, Lower Urinary Tract
WT, Wild Type
PDGFRα, Platelet-Derived Growth Factor Receptor Alpha
PDGF, Platelet-Derived Growth Factors
c-KIT, tyrosine-protein kinase KIT
CML, Chronic Myeloid Leukemia
IC, Interstitial Cell
CYP, Cyclophosphamide
PS, Protamine Sulfate
i.p., intraperitoneal
s.c., subcutaneous
LP, Lamina Propria
DRG, Dorsal Root Ganglia
SMC, Smooth Muscle Cell
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ATP, Adenosine Triphosphate
ACh, Acetylcholine
CCL2, C-C Motif Chemokine Ligand 2
MAPK/ERK, Mitogen-Activated Protein Kinase/Extracellular Signal-Related Kinase
PI3K/AKT, Phosphatidylinositol 3-Kinase/Protein Kinase B
PLC-γ, Phospholipase C-gamma
IMI, Intermicturition Interval
IV, Infused Volume
BP, Bladder Pressure
NVC, Non-Voiding Contraction
h, hour(s)
min, minutes
s or sec, seconds
ANOVA, Analysis of Variance
CMG, Cystometrogram
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Table 1: Mean bladder pressures during conscious, open-outlet cystometry in control (no CYP),
acute CYP (4 h, 200 mg/kg, i.p.), or chronic CYP (75 mg/kg every 72 h for 8 days, i.p.) male and
female mice pre-treated with imatinib mesylate or vehicle via oral gavage
n = 5-9. Values are means ± SEM by two-way ANOVA with Bonferroni’s multiple comparisons test. *p ≤
0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 when compared to vehicle control, +p ≤ 0.05; ++p ≤ 0.01;
++++
p ≤ 0.0001 when compared to imatinib control, or #p ≤ 0.05; ##p ≤ 0.01; ####p ≤ 0.0001 when compared
to vehicle + acute CYP.
Threshold
Pressure
Female Mice

Minimum
Pressure

Maximum
Pressure

Vehicle (No CYP)

12.09 ± 0.7

10.23 ± 0.7

27.04 ± 2.1

Vehicle + Acute (4 h) CYP

28.84 ± 2.9**

24.12 ± 2.9**

34.25 ± 3.0

Imatinib (No CYP)

27.35 ± 2.1**

18.9 ± 1.4

38.82 ± 4.0

Group

+

Imatinib + Acute (4 h) CYP
Vehicle (No CYP)

++

39.34 ± 3.7 ****

32.41 ± 3.0 ****

21.71 ± 2.9

13.77 ± 1.1

+

Vehicle + Chronic (8 d) CYP

50.83 ± 4.8**
34.06 ± 3.5

+

44.87 ± 2.7

33.5 ± 2.7 *

27.88 ± 2.8 **

Imatinib (No CYP)

22.22 ± 1.5

16.45 ± 1.5

34.68 ± 2.0

Imatinib + Chronic (8 d) CYP

30.45 ± 2.7

26.04 ± 3.1**

42.77 ± 3.6

11.82 ± 0.2

28.71 ± 1.3

15.53 ± 0.8

34.22 ± 1.4

20.58 ± 2.0**

38.86 ± 2.9*

21.13 ± 1.6**

35.37 ± 2.1

Male Mice
Vehicle (No CYP)

12.65 ± 0.5
++

Vehicle + Acute (4 h) CYP
Imatinib (No CYP)

17.26 ± 0.4
26.23 ± 2.1****
#

Imatinib + Acute (4 h) CYP

24.22 ± 1.7 ***
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Table 2: Mean bladder pressures during conscious, open-outlet cystometry in control (no CYP),
acute CYP (4 h or 24 h, 200 mg/kg, i.p.), or chronic CYP (75 mg/kg every 72 h for 8 days, i.p.) male
and female mice treated with imatinib mesylate or vehicle (saline) via intravesical bladder infusion
n = 5-10. Values are means ± SEM by Student’s paired t-test (chronic CYP with imatinib infusion
experiment) or repeated measures, two-way ANOVA with Bonferroni’s (4 h/24 h CYP with imatinib
infusion experiment) or Šídák’s (female and male acute CYP with imatinib infusion experiment) multiple
comparisons test. *p ≤ 0.05 when compared to 4 h CYP, pre-imatinib infusion.

Threshold
Pressure
Female Mice

Group

Control (No CYP)

Minimum
Pressure

Maximum
Pressure

26.3 ± 1.5

17.9 ± 1.9

33.8 ± 2.4

Post-Imatinib

26.5 ± 1.8

15.8 ± 1.4

32.8 ± 1.5

Pre-Imatinib
Post-Imatinib

28.9 ± 2.4
27.0 ± 2.8

17.4 ± 1.7
13.7 ± 0.8*

39.4 ± 2.8
38.1 ± 2.8

28.0 ± 3.1
26.5 ± 3.4

18.1 ± 3.2
16.5 ± 4.1

38.1 ± 2.8
35.8 ± 3.4

29.1 ± 3.4
29.3 ± 2.7

15.3 ± 2.2
16.9 ± 2.1

29.1 ± 3.4
29.3 ± 2.7

26.6 ± 2.6

16.0 ± 1.4

37.7 ± 2.3

24.6 ± 2.2

15.6 ± 1.7

38.6 ± 2.4

27.1 ± 1.4

18.7 ± 1.9

39.7 ± 2.4

24.0 ± 1.6

16.4 ± 1.1

37.1 ± 1.7

28.9 ± 4.2
32.0 ± 6.6

24.2 ± 4.4
25.6 ± 6.8

42.6 ± 4.3
46.3 ± 6.8

Pre-Imatinib

Acute CYP (4 h)

Acute CYP (4 h)
Pre-Imatinib Infusion #1
Post-Imatinib Infusion #1
24 h CYP
Pre-Imatinib Infusion #2
Post-Imatinib Infusion #2
Chronic CYP (8 day)
Pre-Imatinib
Post-Imatinib

Male Mice
Control (No CYP)
Pre-Imatinib
Post-Imatinib
Acute CYP (4 h)
Pre-Imatinib
Post-Imatinib
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Figure 1: Imatinib mesylate pre-treatment via oral gavage significantly alters intermicturition
interval (IMI) and infused volume (IV) in an acute (4 h) cyclophosphamide (CYP)-induced cystitis
mouse model
(A) Acute CYP-induced cystitis (200 mg/kg, 4 h, i.p.) experimental schedule for imatinib mesylate pretreatment via oral gavage (250 mg/kg, 5 days, 1X/day). (B, D) Imatinib mesylate pre-treatment
significantly increased IMI and IV (p ≤ 0.001) in female mice with acute (4 h) CYP-induced cystitis. (C, E)
Imatinib mesylate pre-treatment did not significantly affect bladder measures in male mice with acute
CYP-induced cystitis. (B-E) Imatinib pre-treatment alone by gavage, without CYP, significantly (0.0001 ≤
p ≤ 0.01) decreased IMI and IV in both female and male mice, compared to vehicle treatment alone. n = 59. Values are mean ± SEM. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way ANOVA
with Bonferroni’s multiple comparisons test. CMG, cystometrogram.
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Figure 2: Representative bladder function cystometry recordings from female mice with acute
cyclophosphamide (CYP)-induced cystitis, pre-treated with imatinib mesylate or vehicle via oral
gavage
(A, B) Mice with 4 h CYP-induced cystitis (200 mg/kg, 4 h, i.p.) pre-treated with vehicle exhibited
significantly decreased intermicturition interval (IMI) (p ≤ 0.001) and infused volume (IV) (p ≤ 0.0001),
compared to control mice. (C, D) Mice with 4 h CYP-induced cystitis pre-treated with imatinib (250
mg/kg, 5 days, 1X/day) exhibited significantly (p ≤ 0.001) increased IMI and IV, compared to mice with 4
h CYP-induced cystitis pre-treated with vehicle. Recordings are from separate cohorts of mice. n = 5-9. *p
≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way ANOVA with Bonferroni’s multiple
comparisons test. CMG, cystometrogram. BP, bladder pressure.
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Figure 3: Imatinib mesylate treatment via intravesical infusion significantly increases
intermicturition interval (IMI) and infused volume (IV) in an acute (4 h) cyclophosphamide (CYP)induced cystitis mouse model
(A) Acute CYP-induced cystitis (200 mg/kg, 4 h, i.p.) experimental schedule for imatinib mesylate
treatment via intravesical infusion (50 μM, 30 min, 0.5 mL). (B-E) Imatinib treatment via intravesical
infusion significantly increases the IMI and IV in female (p ≤ 0.0001) and male (p ≤ 0.05) with acute (4 h)
CYP-induced cystitis. Imatinib treatment via intravesical infusion significantly increases the IMI and IV in
female (p ≤ 0.01) and male (p ≤ 0.05) control (no CYP) mice. Control (no CYP) and 4 h CYP treated mice
were separate groups of mice, each tested before and after imatinib infusion. n = 6-10. Values are mean ±
SEM. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way repeated measures ANOVA with
Šídák’s multiple comparisons test. CMG, cystometrogram.

144

Figure 4: Representative bladder function cystometry recordings from a female mouse with acute
cyclophosphamide (CYP)-induced cystitis, before and after imatinib mesylate treatment via
intravesical infusion
(A, B) Before imatinib treatment via intravesical infusion, mice with acute CYP-induced cystitis (200
mg/kg, 4 h, i.p.) exhibited decreased intermicturition interval (IMI) and infused volume (IV). (C, D) After
imatinib treatment via intravesical infusion (50 μM, 30 min, 0.5 ml), mice with 4 h CYP-induced cystitis
exhibited significantly (p ≤ 0.0001) increased IMI and IV. Recordings displayed are from the same mouse,
before and after imatinib treatment. Mice with 4 h CYP-induced cystitis in these experiments acted as their
own controls. n = 6-10. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way repeated
measures ANOVA with Šídák’s multiple comparisons test. CMG, cystometrogram. BP, bladder pressure.

145

Figure 5: Imatinib mesylate pre-treatment via gavage does not significantly affect bladder function in
mice with chronic (8 day) cyclophosphamide (CYP)-induced cystitis
(A) Chronic CYP-induced cystitis (75 mg/kg, every 72 h for 8 days) experimental schedule for imatinib
mesylate pre-treatment via oral gavage (250 mg/kg, 1X/day). (B, C) Imatinib pre-treatment via gavage did
not significantly affect intermicturition interval (IMI) or infused volume (IV) in female mice with chronic
CYP-induced cystitis. n = 7-9. Values are mean ± SEM by two-way ANOVA with Bonferroni’s multiple
comparisons test. CMG, cystometrogram.
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Figure 6: Imatinib mesylate treatment via intravesical infusion does not significantly affect bladder
function in mice with chronic (8 day) cyclophosphamide (CYP)-induced cystitis
(A) Chronic CYP-induced cystitis (75 mg/kg, every 72 h for 8 days) experimental schedule for imatinib
mesylate treatment via intravesical bladder infusion (50 μM, 30 min, 0.5 mL). (B, C) Imatinib treatment via
intravesical bladder infusion did not significantly affect intermicturition interval (IMI) or infused volume
(IV) in chronic CYP-induced cystitis, female mice. n = 7-9. Values are mean ± SEM by Student’s paired ttest. CMG, cystometrogram.
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Figure 7: Two intravesical infusions with imatinib mesylate significantly increases intermicturition
interval (IMI) and infused volume (IV) in female mice with acute (4 h) cyclophosphamide (CYP)induced cystitis
(A) Acute cyclophosphamide (CYP)-induced cystitis (200 mg/kg, 4 h, i.p.) experimental schedule for twodose imatinib mesylate treatment via intravesical bladder infusion (50 μM, 30 min, 0.5 mL). Acute cystitis
is induced on the third day. Bladder function with cystometrogram (CMG) is recorded 4 h after the CYP
injection, before and after an intravesical bladder infusion of imatinib mesylate, and again, 24 hours after
the CYP injection on day 4, before and after a second imatinib mesylate intravesical bladder infusion. (B,
C) Imatinib mesylate treatment significantly (p ≤ 0.01) increased the IMI and IV in female mice with acute
CYP-induced cystitis at 4 h and 24 h (p ≤ 0.001) following CYP. n = 4. Values are mean ± SEM. *p ≤ 0.05;
**p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way repeated measures ANOVA with Bonferroni’s
multiple comparisons test. CMG, cystometrogram.
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Abstract
Imatinib mesylate is a tyrosine kinase inhibitor that inhibits platelet-derived
growth factor receptor (PDGFR) -α, -β, stem cell factor receptor (c-KIT), and BCR-ABL.
PDGFRα is expressed in a subset of interstitial cells in the lamina propria (LP) and
detrusor muscle of the urinary bladder. PDGFRα+ interstitial cells may contribute to
bladder dysfunction conditions such as interstitial cystitis/bladder pain syndrome
(IC/BPS) or overactive bladder (OAB). We have previously demonstrated that imatinib
prevention via oral gavage or treatment via intravesical infusion improves urinary bladder
function in mice with acute (4 hour, h) cyclophosphamide (CYP)-induced cystitis. Here,
we investigate potential underlying mechanisms mediating the bladder functional
improvement by imatinib using a prevention or treatment experimental design. Using
qRT-PCR and ELISAs, we examined inflammatory mediators (NGF, VEGF, BDNF,
CCL2, IL-6) previously shown to affect bladder function in CYP-induced cystitis. We
also examined the distribution of phosphorylated (p) ERK and pAKT expression in the
LP with immunohistochemistry. Imatinib prevention significantly (0.0001 ≤ p ≤ 0.05)
reduced expression for all mediators examined except NGF, whereas imatinib treatment
was without effect. Imatinib prevention and treatment significantly (0.0001 ≤ p ≤ 0.05)
reduced pERK and pAKT expression in the upper LP (U. LP) and deeper LP (D. LP) in
female mice with 4 h CYP-induced cystitis. Although we have previously demonstrated
that imatinib prevention or treatment improves bladder function in mice with cystitis, the
current studies suggest that reductions in inflammatory mediators contribute to
prevention benefits of imatinib but not the treatment benefits of imatinib. Differential
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effects of imatinib prevention or treatment on inflammatory mediators may be influenced
by the route and frequency of imatinib administration and may also suggest other
mechanisms (e.g., changes in transepithelial resistance of the urothelium) through which
imatinib may affect urinary bladder function following CYP-induced cystitis. Keywords:
painful bladder syndrome, interstitial cells, platelet-derived growth factor receptor
(PDGFR), cytokines, cell signaling, lamina propria

151

Introduction
Efficient bladder function is essential for health and high quality of life.
Interstitial cystitis/bladder pain syndrome (IC/BPS) is characterized by pelvic pain and/or
discomfort, increased urinary urgency and frequency, low volume voids and
inflammation (Akiyama et al., 2020; Hanno et al., 2015; Marcu et al., 2018). These
functional and inflammatory changes are recapitulated in a cyclophosphamide (CYP)induced cystitis animal model. CYP treated rodents exhibit decreased intermicturition
intervals, infused volumes (IV), void volumes, and increased bladder pressure, afferent
nerve excitability and somatic sensitivity (Arms et al., 2013; Boucher et al., 2000;
Gonzalez et al., 2016; Guo et al., 2018; Yoshimura and de Groat, 1999) along with
altered inflammatory mediator (e.g., growth factors, chemokines, cytokines, and related
receptors) expression in the urinary bladder layers and associated dorsal root ganglia
(DRG) and spinal cord levels (Arms et al., 2013; Arms et al., 2010; Gonzalez et al., 2013;
Guo et al., 2018; Klinger et al., 2007; Klinger et al., 2008; Klinger and Vizzard, 2008;
Malley and Vizzard, 2002; Merrill et al., 2012).
Receptors associated with inflammation such as transient receptor potential
vanilloid-type 4 (Trpv4) and the tyrosine kinase receptor, platelet-derived growth factor
receptor alpha (PDGFRα), are expressed in a recently identified subset of urinary
interstitial cells (Gevaert et al., 2014b; Heppner et al., 2017; Koh et al., 2012; Monaghan
et al., 2012; Steiner et al., 2018; Zhao et al., 2021). Urinary interstitial cells are located in
the lamina propria (LP) of the urinary bladder and detrusor muscle and may be involved
in the transduction of urinary bladder mechanosensation (Gray et al., 2013; Heppner et
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al., 2017; Ikeda et al., 2007; Isogai et al., 2016; Koh et al., 2018; Liu et al., 2017; Liu et
al., 2018; Neuhaus et al., 2020; Wiseman et al., 2003). Reports indicate altered urinary
expression of PDGFRα, Trp channels and other interstitial cell markers in human patients
and animal models of bladder dysfunction including IC/BPS, overactive bladder (OAB),
spinal cord injury (SCI)-induced OAB, and bladder outlet obstruction (de Jongh et al.,
2007; Deng et al., 2015; Gevaert et al., 2011; Ikeda et al., 2007; Johnston et al., 2012;
Kim et al., 2011; Kubota et al., 2008; Liu et al., 2018; Meng et al., 2015; Mukerji et al.,
2006; Neuhaus et al., 2005; Preis et al., 2015; Roosen et al., 2009; Sancho et al., 2017).
Imatinib mesylate is a tyrosine kinase inhibitor that was originally designed to inhibit the
BCR-ABL tyrosine kinase in chronic myeloid leukemia, but was found to inhibit other
related receptors, such as PDGFRα (Buchdunger et al., 2000; Buchdunger et al., 1996;
Capdeville et al., 2002). Imatinib has been widely used in lower urinary tract (Rothrock
et al.) research (Abrams et al., 2012; Biers et al., 2006; Deng et al., 2013; Gevaert et al.,
2014a; Giglio et al., 2018; Kjell et al., 2015; Kubota et al., 2006; Kubota et al., 2004; Liu
et al., 2018; Min et al., 2011; Preis et al., 2015; Sancho et al., 2017; Sui et al., 2008;
Vahabi et al., 2011; Vahabi et al., 2013). We have recently characterized the urinary
bladder functional effects of imatinib administration involving two separate experimental
designs (i.e., prevention via oral gavage and treatment via intravesical infusion), in a
mouse (female and male) model of CYP-induced cystitis (Perkins M, 2022). Imatinib
administration via gavage or intravesical infusion improved functional (i.e., increased
IMI and IV) bladder outcomes in mice with acute (4 hour, h) CYP-induced cystitis,
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suggesting that urinary PDGFRα+ interstitial cells may contribute to the development
and/or maintenance of urinary bladder dysfunction.
Cytokines, chemokines, growth factors and their related receptors, including
PDGFRα, may activate cell signaling pathways such as the MAPK/ERK and PI3K/AKT
pathway, which can lead to transcriptional and translational changes promoting cell
survival, growth, inflammation, and proliferation (Andrae et al., 2008; Heldin and
Westermark, 1999). Increased expression of phosphorylated (p) ERK and pAKT have
been reported in the urinary bladder, and lumbosacral DRG and spinal cord of rodents
with CYP-induced cystitis, and blockade improves LUT functional outcomes (Arms and
Vizzard, 2011; Chung et al., 2010; Coelho et al., 2014; Corrow and Vizzard, 2007;
Corrow and Vizzard, 2009; Cruz et al., 2005; Liang et al., 2016; Liu et al., 2015; Qiao
and Gulick, 2007; Qiao et al., 2014; Yu et al., 2012).
Functional improvements observed with imatinib administration in acute (4 h)
CYP-induced cystitis may be mediated by multiple factors including changes in the
urinary inflammatory milieu and/or cell signaling pathways. The effect of imatinib on the
inflammatory milieu and signaling pathways in animal models of IC/BPS has not been
previously studied; however, the anti-inflammatory properties of imatinib have been
shown in other systems (Abrams et al., 2012; Adzemovic et al., 2013; Capdeville et al.,
2002; Hayashi et al., 2012; Kjell et al., 2015; Ma et al., 2011). In this study, we examine
the effect of imatinib administration using a prevention design, via oral gavage, or
treatment design, via intravesical bladder infusion, on urinary inflammatory mediators
and cell signaling kinases in an acute (4 h) CYP-induced, cystitis female mouse model,
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using real time quantitative reverse transcription-polymerase chain reaction (qRT-PCR),
enzyme-linked immunosorbent assays (ELISAs), and immunohistochemistry (IHC). We
examined the inflammatory mediators, BDNF, NGF, VEGF, IL-6, and CCL2, and
signaling kinases, pERK and pAKT, in the urinary bladder and LP, due to their
established involvement in CYP-induced cystitis (Arms et al., 2013; Arms and Vizzard,
2011; Corrow and Vizzard, 2007; Corrow and Vizzard, 2009; Girard et al., 2011a; Girard
et al., 2016; Malley and Vizzard, 2002; Murray et al., 2004; Vizzard, 2000).

155

Materials and Methods
Experimental Animals
Female wildtype (WT), C57BL/6 mice (3-5 months) (Jackson Labs, Bar Harbor,
ME, USA) were used in these experiments. The UVM Institutional Animal Care and Use
Committee (IACUC) approved all experimental procedures involving animal use
(IACUC #X9-020). Mice were bred and housed in standard laboratory conditions (Girard
et al., 2016; Guo et al., 2018; Tooke et al., 2019) at The Larner College of Medicine.
University of Vermont (UVM) animal facilities and the UVM Office of Animal Care and
Management supervised animal care according to the American Association for
Accreditation of Laboratory Animal Care (AAALAC) and NIH guidelines. Efforts were
taken to minimize animal pain and distress. Mice demonstrating signs of pain and distress
that could not be mitigated with post-operative analgesics were immediately euthanized.
Separate cohorts of littermate mice were used. Only female mice were used due to the
increased prevalence of IC/BPS in human females (Hanno et al., 2015). The estrous cycle
status of mice was not determined.
CYP Dosing and Administration
Acute cystitis was modeled using CYP injections (200 mg/kg, i.p.) (Bjorling et
al., 2011; Guo et al., 2018; Malley and Vizzard, 2002). Mice were anesthetized (5%
isoflurane in oxygen), euthanized by thoracotomy, and urinary bladders were collected
for qRT-PCR, ELISAs or IHC experiments (as detailed below) 4 hours (h) post-CYP
injection. Control cohorts did not receive CYP.
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Imatinib Mesylate Dosing and Administration
We determined the dose and route of imatinib administration in previous pilot
studies (data not shown) with the guidance of previous reports (Abrams et al., 2012; Kjell
et al., 2015; Sancho et al., 2017). Two different delivery routes and schedules were used
in these experiments: 1) systemically via oral gavage (250 mg/kg; 22 gauge/25mm,
stainless steel) (Fig. 1A); or 2) directly via intravesical (i.e., intrabladder) infusion (50
μM) with a transurethral catheter (Fig. 1B). Mice were euthanized (5% isoflurane in
oxygen; thoracotomy) for urinary bladder collection after completion of imatinib or
vehicle (i.e., saline or water) administration schedules.
Oral Gavage (Prevention Schedule)
Mice were placed into a small polyethylene, cone-shaped device with an
opening at the far end, allowing for proper mouse placement (180° upright, mouth
oriented upward) for oral gavage. Mice were constantly monitored to ensure correct
gavage placement and animal safety. To maintain consistency, administration was
performed in the morning (8 am-12 pm) by the same individual each day.
Before acute cystitis induction with CYP (4 h, 200 mg/kg, i.p.) mice were pre-treated
with imatinib (250 mg/kg, 1X/day) or vehicle (water) for 5 days. On the 5th (last)
experimental day, mice received imatinib via gavage and were left undisturbed in their
home cage for at least 30 min prior to CYP administration (Fig. 1A).
Transurethral Intravesical Infusion (Treatment Schedule)
Four (4) h post-CYP administration (200 mg/kg, i.p.), mice were anesthetized
and placed supine on a water mat heating pad. Breathing rate was monitored while mice
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were anesthetized to ensure mouse well-being. Bladders were manually expressed before
catheterization. Lubricated polyethylene tubing (PE-10, Clay Adams, Parsippany, NJ)
was inserted through the urethra to infuse imatinib (50 μM) or vehicle (saline) into the
bladder, until a full bladder could be palpated. The catheter was then removed, and mice
remained anesthetized for 30 min (Fig. 1B).
Immunohistochemistry (IHC)
Whole, urinary bladders were dissected from female, WT mice after 1) imatinib
prevention (oral gavage) or 2) treatment (transurethral intravesical infusion), with or
without 4 h CYP. IHC was performed as previously described (Arms et al., 2013; Girard
et al., 2016; Guo et al., 2018). Bladder sections were randomly selected from all regions
of the urinary bladder with the LP present. Primary and secondary antibodies are listed in
Table 1. Slides were mounted with 1 μL DAPI (Sigma-Aldrich, St. Louis, MO, USA)/1
mL CitiFluor AF2 (Electron Microscopy Sciences, Hatfield, PA, USA). Methodological
and procedural controls included: incubation of tissue with 1) primary antibody but
without secondary antibody, 2) secondary antibody but without primary antibody, and 3)
blocking solution without primary or secondary antibodies. All tissues (treatment and
controls) were processed simultaneously.
Visualization and Semi-Quantitative Analysis of LP Immunoreactivity (IR)
Bladder sections were imaged using a Yokogawa CSU-W1 confocal, spinning
disk system coupled to a Nikon Eclipse NI-E microscope (Microscopy Imaging Center,
UVM). Bladder sections were simultaneously imaged beginning with the brightest
condition (4 h CYP groups). FITC staining was visualized with a filter excitation range of
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488 nm and emission range of 525 nm. CY3 staining was visualized with a filter
excitation range of 560-596 nm and emission range of 610-655 nm. Images were saved
and exported as ND2 files. In the urinary bladder, upper LP (U. LP) and deeper LP (D.
LP) regions were isolated individually by thresholding until the entire region was selected
(FIJI Image Analysis Software) (Schindelin et al., 2012). The pPDGFRα antibody acted
as a tissue orientation reference, which distinctly defined the U. LP and D. LP. Binary
grey-scaled (8-bit) masks were then produced of either the U. LP (i.e., fibrous band of
tissue immediately deep to the urothelium) or D. LP (i.e., loosely distributed region of
tissue between the upper LP and detrusor). The mask and images for both channels (CY3,
FITC) were saved as TIFFs and imported into the image analysis software, Volumetry
(VolumetryG9a, Grant Hennig) (Cobine et al., 2010). A combination image was created
from the red and green channel images, with either the U. LP or D. LP mask overlayed.
FITC and CY3 fluorescence intensity were measured (VolumetryG9a, Grant Hennig)
(Cobine et al., 2010). Exported data included pixel intensity, number of pixels
fluorescing/each intensity level, and the total area measured. The number of pixels
fluorescing at a particular intensity level was divided by the total measured area. These
data were then displayed as a histogram with pixel intensity (intensity unit, IU8-bit) (xaxis) and pixel number or frequency/intensity measurement (y-axis), producing intensity
curves. Intensity curves were created for 2-6 sections/mouse and 5-8 mice/group. The
intensity curves from multiple sections from the same mouse were averaged/mouse. Once
intensity curves were determined for each mouse within a group, curves were
averaged/group. The median of each group’s fluorescence curve, which generally
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corresponded to the peak of the curve, was compared using a two-way ANOVA and
Bonferroni’s multiple comparisons test.
IHC Figure Preparation
Digital images were captured with two Andor Ixon EM CCD cameras coupled
to a Yokogawa CSU-W1 spinning disk confocal system and microscope. Imaging
settings were held constant for all image acquisition. Images were assembled and labeled
using Microsoft Paint (Windows 10, version 20H2, Microsoft Corporation©).
LP Preparation for qRT-PCR
Whole, urinary bladders were dissected from female, WT mice after 1) imatinib
prevention (oral gavage) or 2) treatment (transurethral intravesical infusion), with or
without 4 h CYP. Bladders were immediately transferred to a modified HEPES solution
(10 mM HEPES, 6 mM KCl, 134 mM NaCl, 7 mM glucose, pH = 7.4). The LP was
separated from the detrusor and urothelium using fine tip forceps under a dissecting
microscope as previously described (Girard et al., 2016; Guo et al., 2018). The LP was
stored at -80 °C and the excess tissue discarded.
Real Time Quantitative Reverse Transcription-Polymerase Chain Reaction (qRTPCR)
Real time qRT-PCR was used to determine mRNA transcript expression in the
LP of the urinary bladder for multiple inflammatory mediators (i.e., BDNF, NGF,
VEGFaa, VEGFab, IL-6, CCL2), as previously described (Girard et al., 2011a; Girard et
al., 2016; Girard et al., 2011b; Tooke et al., 2019). Total RNA was extracted using the
Stat-60 total RNA/mRNA isolation procedure (Tel-Test “B”, Friendswood, TX, USA).
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To reverse transcribe complementary DNA (cDNA), one μg of RNA/sample was mixed
with oligo dT primers, random hexamers, M-MLV buffer, M-MLV reverse transcriptase
(Promega Corp., Madison, WI, USA), dNTP, RNasin® ribonuclease inhibitor and
molecular grade water, producing a 25 μL final reaction volume. To establish quantitative
PCR standards for all transcripts, the amplified cDNA was ligated directly to the pCR2.1
TOPO vector, using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA).
Nucleotide sequences were verified by automated fluorescence dideoxy die terminator
sequencing (Vermont Cancer Center DNA Analysis Facility). Ten-fold serial dilutions
were prepared for each stock plasmid to establish quantitative standards and estimate the
relative expression of the receptor transcripts. cDNA templates were diluted 10-fold to
reduce inhibitory effects of the reverse transcription reaction components. cDNA
dilutions were assayed using Luna® Universal qPCR Master Mix (New England Biolabs,
Ipswich, MA, USA) and 300 nM from each primer, producing a total reaction volume of
20 μL. The Applied Biosystems 7500 Fast real-time PCR system (Applied Biosystems,
Foster City, CA, USA) was used for real-time PCR. The following standard conditions
were applied: 1) serial heating at 94 °C for 2 min and 2) amplification over 45 cycles at
94 °C for 15 s at 60-64 °C depending on primers set for 30 s. The amplified product
underwent SYBR Green I melting analysis. A single DNA melting profile was observed
under these dissociation assay conditions, demonstrating the amplification of a single
unique product free of primer dimers or other anomalous products. Oligonucleotide
primer sequences are listed in Table 2.
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Data Analysis for mRNA Quantification
Quantification of the mRNA transcripts was analyzed as previously described
(Girard et al., 2016; Gonzalez et al., 2013; Tooke et al., 2019). All data are expressed as
the relative quantity of the gene of interest, normalized to the relative quantity of the
housekeeping gene L32. All data are displayed as fold change with respect to the control
(vehicle, no CYP) group.
Enzyme Linked Immunosorbent Assays (ELISAs) for Protein Quantification
Whole, urinary bladders were dissected from the female, WT mice that received
either imatinib prevention (gavage) or treatment (intravesical), with or without acute (4 h)
CYP treatment. Bladders were weighed and placed in collection tubes with Tissue
Protein Extraction Reagent (1g tissue/20 mL) with complete protease inhibitor cocktail
tablets (Roche Applied Science, Mannheim, Germany) and stored at -20 °C. All protein
samples were assayed simultaneously. ELISA (i.e., NGF, BDNF, VEGF, IL-6, CCL2)
and Bradford assays were performed as previously described (Arms et al., 2013; Girard et
al., 2021; Girard et al., 2016; Gonzalez et al., 2013; Guo et al., 2018) and according to the
manufacturer’s instructions (DuoSet® ELISA Development Systems, R&D Systems,
Minneapolis, MN, USA).
Enzyme Linked Immunosorbent Assay (ELISA) Analysis for Protein Quantification
The standards provided with this protocol generated a linear standard curve for
each mediator measured. The background absorbance was subtracted from the samples
and standards absorbance values. Most ELISA samples were run without dilution
although some ELISA samples (CCL2) required further dilution. BDNF and CCL2
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ELISA samples for the imatinib pre-treated (gavage) samples exceeded the upper limits
of the standard curve. Unfortunately, we did not have adequate sample to repeat these
ELISAs. The curve fitting of the sample protein content values to standard values was
estimated using a least-squares fit analysis as previously described (Arms et al., 2013;
Girard et al., 2021; Girard et al., 2016; Gonzalez et al., 2013; Guo et al., 2018).
Statistical Analyses
All values represent fold change ± SEM with respect to vehicle control. Data
were analyzed using a two-way analysis of variance (ANOVA). When the F ratio
exceeded the critical value at α = 0.05, Tukey’s multiple comparisons test was performed.
Analyses were performed on raw data values before converting to fold change. All
analyses were performed using GraphPad Prism software (GraphPad Prism version 8.0.0
for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com).
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Results
Oral Gavage of Imatinib Reduces IL-6, CCL2, BDNF and VEGF, but not NGF
Lamina Propria (LP) mRNA and Reduces IL-6 and VEGF Protein (Whole Bladder)
Expression in Female Mice with 4 h CYP-Induced Cystitis
mRNA expression: Acute (4 h) CYP treatment (200 mg/kg, i.p.) significantly
(0.01 ≤ p ≤ 0.0001) increased IL-6 (3794.4-fold), CCL2 (142.1-fold), NGF (26.8-fold),
BDNF (13.9-fold) and VEGF isoforms, VEGFaa (4.4-fold) and VEGFab (3.7-fold) LP
mRNA expression, compared to control (no CYP) and imatinib (no CYP) groups (Figs.
2A-F). Imatinib prevention by oral gavage (250 mg/kg) significantly (0.0001 ≤ p ≤ 0.05)
decreased VEGFaa (1.6-fold), VEGFab (2.1-fold), IL-6 (3.1-fold), CCL2 (6.5-fold) and
BDNF (1.9-fold) LP mRNA but did not affect NGF LP mRNA in mice with 4 h CYPinduced cystitis (Figs. 2A-F). mRNA expression was not significantly different in mice
with 4 h CYP-induced cystitis pre-treated with imatinib, compared to control (no CYP)
groups, except for VEGFaa and BDNF. VEGFaa and BDNF mRNA expression was not
significantly different from imatinib (no CYP) levels but remained significantly (0.01 ≤ p
≤ 0.05) (2.7-7.4-fold) increased from vehicle control (no CYP) levels in acute (4 h) CYPinduced cystitis mice pre-treated with imatinib (Figs. 2E, C).
Protein expression: Acute (4 h) CYP treatment significantly (0.0001 ≤ p ≤
0.001) increased VEGF (2.4-fold) and IL-6 (10.2-fold) protein expression compared to
vehicle and imatinib controls (Fig. 3). Imatinib prevention by oral gavage (250 mg/kg)
significantly (0.001 ≤ p ≤ 0.05) decreased VEGF (2.8-fold) and IL-6 (1.6-fold) protein
expression in 4 h CYP-induced cystitis mice. VEGF protein expression was reduced to
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control levels in acute (4 h) CYP-induced cystitis mice pre-treated with imatinib (Fig.
3A). Although imatinib prevention significantly (p ≤ 0.05) reduced IL-6 expression in the
acute CYP condition, expression remained significantly (p ≤ 0.001) increased compared
to vehicle (6.6-fold) and imatinib (14.4-fold) controls (Fig. 3B). ELISAs for CCL2 and
BDNF were also conducted; however, sample values exceeded the upper limits of the
standard curves and assays could not be reported because of limited protein yield.
Transurethral Bladder Infusion of Imatinib Does Not Reduce Inflammatory
Mediator mRNA (LP) and Protein (Whole Bladder) Expression in Female Mice
with 4 h CYP-Induced Cystitis
Acute (4 h) CYP (200 mg/kg, i.p.) treatment significantly (0.0001 ≤ p ≤ 0.01)
increased CCL2, IL-6, and VEGF isoforms mRNA (2.3-5.7-fold) (Figs. 4A, B, 5C, D)
and CCL2, IL-6, NGF, and VEGF protein expression (1.8-11.1-fold) (Figs. 4C, D, 5F, G)
in the LP and urinary bladder, respectively, in mice that received saline intrabladder
infusion. However, 4 h CYP treatment did not affect BDNF or NGF LP mRNA
expression (Figs. 5A, B). BDNF urinary bladder protein expression was significantly (p ≤
0.05) increased in mice with 4 h CYP-induced cystitis that received saline (1.7-fold) or
imatinib (1.7-fold) intrabladder infusion, compared to imatinib infused controls (no
CYP), but was not significantly different from vehicle (saline) infused controls (Fig. 5E).
Imatinib treatment via transurethral bladder infusion did not significantly affect CCL2,
IL-6, BDNF, NGF, VEGFaa or VEGFab LP mRNA or urinary bladder protein expression
in female mice with 4 h CYP cystitis (Figs. 4, 5).
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Oral Gavage, but not Transurethral Bladder Infusion, of Imatinib Reduces Bladder
Weight
4 h CYP treatment significantly (0.0001 ≤ p ≤ 0.05) (1.2-1.8-fold) increased
bladder weight compared to vehicle and imatinib controls (Fig. 6). Imatinib prevention
significantly (p ≤ 0.05) (1.2-fold) reduced bladder weight in mice with 4 h CYP-induced
cystitis (Fig. 6A) whereas, imatinib treatment was without effect (Fig. 6B).
Oral Gavage or Transurethral Bladder Infusion of Imatinib Reduces pERK and
pAKT Expression in the Upper and Deeper LP in Mice with 4 h CYP-Induced
Cystitis
Two regions of the LP were analyzed: the upper LP (U. LP), directly underneath
the urothelium, sometimes called the suburothelium and the deeper LP (D. LP), defined
as the loosely distributed tissue between the U. LP and detrusor (Figs. 7-10). Separate
cohorts of mice were used in the following studies.
U. LP:
Prevention (gavage), pERK
In the prevention studies (gavage, 250 mg/kg, 5 days, 1X/day), pERK U. LP expression
is low in the vehicle controls and is dramatically increased in the vehicle pre-treated, 4 h
CYP condition (Figs. 7C, E). Imatinib control and imatinib pre-treated, 4 h CYP pERK
expression is greater than vehicle, but not to the same extent as the vehicle pre-treated, 4
h CYP condition (Figs. 7C-F). All groups display bell-shaped pERK intensity curves in
the U. LP (Fig. 7I). Most of the pixels within the U. LP exhibit a peak fluorescence
intensity (25-50 intensity unit; IU) for the vehicle, imatinib, and imatinib prevention with
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4 h CYP groups. The vehicle pre-treated, 4 h CYP group is also bell-shaped with a peak,
but exhibits broader fluorescence across a range of intensities (10-150 IU), producing a
flatter curve. The vehicle pre-treated, 4 h CYP group exhibits a rightward shift, with
more pixels fluorescing at greater intensities. Imatinib control and imatinib pre-treated, 4
h CYP groups also demonstrate rightward shifts compared to vehicle control, but lesser
than the vehicle, 4 h CYP group (Fig. 7I).
Acute (4 h) CYP treatment (200 mg/kg, i.p.) significantly (0.0001 ≤ p ≤ 0.001) increased
pERK fluorescence intensity in the U. LP of female mice compared to vehicle (1.9-fold)
and imatinib (1.5-fold) controls (Fig. 7J). Imatinib prevention via oral gavage
significantly (p ≤ 0.01) (1.5-fold) reduced pERK fluorescence intensity in the U. LP in
mice with acute (4 h) CYP-induced cystitis (Fig. 7J).
Prevention (gavage), pAKT
pAKT expression did not differ in the U. LP in mice 4 h CYP-induced cystitis, pretreated with vehicle or imatinib (Figs. 8C-F). Similar to pERK expression in the U. LP,
pAKT expression formed bell-shaped, high peak curves (Fig. 8I). The vehicle pre-treated,
4 h CYP group exhibits a small rightward shift (i.e., brighter intensities) (10-150 IU)
away from vehicle (10-100 IU). This shift is not different from the imatinib control and
imatinib pre-treated, 4 h CYP groups with many pixels from these groups falling within
the same fluorescence intensity range (Fig. 8I).
4 h CYP treatment significantly (p ≤ 0.05) (1.4-fold) increased pAKT fluorescence
intensity in the U. LP of female mice compared to vehicle control (Fig. 8J). Imatinib
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prevention via oral gavage did not affect pAKT fluorescence in the U. LP in mice with 4
h CYP-induced cystitis (Fig. 8J).
Treatment (intravesical infusion) pERK
pERK expression is not different in the U. LP in mice treated with imatinib or vehicle via
intravesical infusion, with or without 4 h CYP (Figs. 9C-F). In the U. LP, all groups
exhibit a wide range of fluorescence intensities, producing wide, flat curves. Although
wide, each group exhibits a peak intensity level (50, 60, 75 IU). Most pixels overlap
within similar intensity ranges for all groups (Fig. 9I).
U. LP pERK fluorescence intensity was not significantly different in mice with 4 h CYPinduced cystitis that received imatinib or saline intrabladder infusions, compared to saline
infused controls (Fig. 9J). Imatinib intrabladder infusion also did not significantly affect
U. LP pERK fluorescence in mice with 4 h CYP-induced cystitis (Fig. 9J).
Treatment (intravesical infusion), pAKT
pAKT expression in the U. LP in mice treated with 4 h CYP is increased compared to the
vehicle condition (Figs. 10C, E). Imatinib control and imatinib treated groups exhibit
greater pAKT expression than the vehicle control group, but less than the 4 h CYP,
vehicle treated group (Figs. 10C-F). These groups display bell-shaped, high peak pAKT
intensity curves (Fig. 10I). The vehicle treated, 4 h CYP group exhibits a flatter curve and
rightward shift (i.e., brighter intensities) (20-150 IU). Imatinib control and imatinib
treated, 4 h CYP groups also demonstrate rightward shifts (20-125 IU) compared to
vehicle control, but less than the vehicle, 4 h CYP group (10-125 IU) (Fig. 10I).
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4 h CYP treatment (200 mg/kg, i.p.) significantly (0.0001 ≤ p ≤ 0.001) increased pAKT
fluorescence intensity in the U. LP of female mice compared to vehicle (1.8-fold) and
imatinib (1.5-fold) controls (Fig. 10J). Intravesical imatinib treatment significantly (p ≤
0.01) (1.4-fold) reduced pAKT fluorescence intensity in mice with 4 h CYP-induced
cystitis (Fig. 10J).
D. LP:
Prevention (gavage), pERK
pERK expression in the D. LP was reduced in the imatinib pre-treated, 4 h CYP group
compared to the vehicle pre-treated, 4 h CYP group (Figs. 7E, F). Unlike the U. LP, the
D. LP produced variable rising intensity curves, possibly due to the more diffuse
organization of D. LP tissue. Pixel intensities from each group largely overlapped, but
imatinib control and imatinib pre-treated, 4 h CYP groups displayed more pixels at lower
(< 25 IU) intensities compared to the vehicle pre-treated, 4 h CYP group (25-100 IU)
(Fig. 7K). Imatinib prevention significantly (p ≤ 0.05) (1.6-fold) reduced pERK
fluorescence intensity in mice with 4 h CYP-induced cystitis (Fig. 7L).
Prevention (gavage), pAKT
pAKT expression in the D. LP is greater with 4 h CYP treatment than controls (Figs. 8CE). Imatinib prevention reduces pAKT expression in the 4 h CYP condition (Figs. 8E, F).
The imatinib control and vehicle pre-treated, 4 h CYP groups displayed many pixels
fluorescing across a broad range, producing very wide, flat curves (20-100 IU). The
vehicle control and imatinib pre-treated, 4 h CYP groups displayed sharper peaks, with
most pixels fluorescing at lower (< 25 IU) intensity levels (Fig. 8K).
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4 h CYP treatment significantly (p ≤ 0.05) (1.5-fold) increased pAKT fluorescence
intensity in the D. LP that was significantly (p ≤ 0.001) (2.2-fold) reduced by imatinib
prevention via gavage (Fig. 8L).
Treatment (intravesical infusion), pERK
pERK expression in the D. LP is greater in the vehicle treated, 4 h CYP group compared
to vehicle control (Figs. 9C, E). Imatinib treatment appears to reduce pERK expression in
the 4 h CYP condition (Figs. 9E, F). These groups exhibit peaked, variable intensity
curves. The imatinib controls and vehicle treated, 4 h CYP group display a rightward
shift compared to vehicle controls and the vehicle treated, 4 h CYP group (Fig. 9K).
4 h CYP treatment significantly (p ≤ 0.05) (1.5-fold) increased pERK fluorescence
intensity in the D. LP that was significantly (p ≤ 0.05) (1.3-fold) reduced by imatinib
treatment via intravesical infusion (Fig. 9L).
Treatment (intravesical infusion), pAKT
pAKT expression in the D. LP is greater with 4 h CYP treatment compared to vehicle
control (Figs. 10C-E). Imatinib treatment reduces expression comparable to control levels
in the 4 h CYP condition (Figs. 10C-F). Most pixels in the vehicle control, imatinib
control and imatinib treated, 4 h CYP groups coalesced around low (< 25 IU) intensity
levels, producing sharp, high peaks. The vehicle treated, 4 h CYP group demonstrated a
dramatic rightward shift (i.e., brighter intensities), with many pixels fluorescing across a
broad range (25-100 IU) (Fig. 10K).
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4 h CYP treatment significantly (p ≤ 0.001) (2.5-fold) increased pAKT fluorescence
intensity in the D. LP that was significantly (p ≤ 0.0001) (3.8-fold) reduced by imatinib
treatment via intravesical infusion (Fig. 10L).
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Discussion
We and others (Abrams et al., 2012; Biers et al., 2006; Deng et al., 2013; Giglio
et al., 2018; Kjell et al., 2015; Kubota et al., 2006; Kubota et al., 2004; Preis et al., 2015;
Sancho et al., 2017) have previously demonstrated LUT improvements with imatinib
administration in animal models of bladder dysfunction. These studies expand upon
previous reports (Abrams et al., 2012; Kjell et al., 2015) examining the effect of imatinib
on inflammatory mediators in the serum, spinal cord, and peripheral lymphoid organs
(i.e., spleen, bone marrow, thymus) in rats with contusion SCI. However, the effect of
imatinib on the urinary bladder inflammatory milieu and signaling kinases has not been
previously investigated in IC/BPS animal models. Our studies demonstrate that oral
administration of imatinib, but not intrabladder infusion, reduces urinary bladder
inflammatory mediator (e.g., VEGF, BDNF, CCL2, IL-6) mRNA and protein expression,
and kinase (pERK, pAKT) immunoreactivity in the bladder LP in female mice with acute
(4 h) CYP-induced cystitis.
Imatinib and other PDGFRα inhibitors have been used in a wide variety of
model systems and clinical studies (e.g., SCI, stroke, MS, retinal neovascularization,
fibrosis, CML, GI stromal tumors, glioblastoma) to address effects on the immune
response (Adzemovic et al., 2013; Buchdunger et al., 2002; Cohen et al., 2021; Hayashi
et al., 2012; Kjell et al., 2015; Ma et al., 2011; Roskoski, 2018). Here, we examine
inflammatory mediators (e.g., NGF, BDNF, VEGF, CCL2, IL-6) previously shown to
increase expression and exhibit functional effects in micturition pathways in rodent
models of CYP-induced cystitis (Arms et al., 2013; Cheppudira et al., 2008; Girard et al.,
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2011a; Girard et al., 2016; Hu et al., 2005; Malley and Vizzard, 2002; Tooke et al., 2019;
Vizzard, 2000; Zvara and Vizzard, 2007). Prevention by oral gavage of imatinib reduced
VEGFaa, VEGFab, BDNF, IL-6 and CCL2 mRNA, and VEGF and IL-6 protein
expression in the LP and whole bladder, respectively, in mice with acute CYP-induced
cystitis. However, imatinib did not affect NGF LP mRNA expression. Treatment with
imatinib by intravesical infusion in mice with acute CYP-induced cystitis did not
significantly affect mRNA or protein expression of the inflammatory mediators
examined.
Previously, we demonstrated bladder functional improvements (i.e., decreased
voiding frequency), with imatinib in a 1) prevention design (before CYP) by oral gavage,
or 2) treatment (after CYP) by transurethral intrabladder infusion in mice with 4 h CYPinduced cystitis (Perkins M, 2022). Imatinib may have affected these inflammatory
mediators with the prevention, but not treatment, design due to the frequency and
duration of imatinib administration. The pharmacokinetics of imatinib and previous
studies (Abrams et al., 2012; Buchdunger et al., 2002; Kjell et al., 2015; Peng et al.,
2005; Sancho et al., 2017) suggest daily, repeated dosing of imatinib like our prevention
design protocol (1X/day for 5 days) is effective in contrast to a single treatment (i.e.,
single intrabladder infusion). Our differential results may also be due to the delivery route
of imatinib (systemic vs. intrabladder). In addition to PDGFRα, imatinib also inhibits the
tyrosine kinases PDGFRβ, c-KIT, and ABL (Buchdunger et al., 2000; Buchdunger et al.,
1996; Capdeville et al., 2002). These tyrosine kinases are highly conserved across species
and widely expressed throughout the body on various cell types (Andrae et al., 2008;
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Colicelli, 2010; Lennartsson and Rönnstrand, 2012). With the prevention design, imatinib
was systemically delivered allowing the drug to act at bladder and non-bladder sites with
pervasive receptor expression.
When imatinib was delivered via intravesical infusion, improvements in bladder
function in CYP-treated mice were demonstrated within 30 min and persisted during the
entire recording period (Perkins M, 2022). In the present studies, no changes in the
inflammatory mediators examined were detected following intravesical imatinib infusion
in mice with acute CYP-induced cystitis. It is possible that intravesical effects of imatinib
on the inflammatory milieu may require more time to be detected and additional time
points should be examined. However, changes in inflammatory mediator expression in
the urinary bladder are unlikely to underlie the early bladder functional improvements in
mice with 4 h CYP-induced cystitis and other mechanisms of action for imatinib should
be considered.
Numerous reports in a variety of models (e.g., SCI, stroke, MS) suggest that
imatinib alters endothelial tight junction protein expression (e.g., claudin 5, occludin, ecadherin, connexin 43, beta-catenin) and improves vascular integrity (Abrams et al.,
2012; Adzemovic et al., 2013; Aman et al., 2012; Chislock and Pendergast, 2013; Langer
et al., 2019; Ma et al., 2011; Su et al., 2008; Vrekoussis et al., 2006; Wang et al., 2020;
Zhan et al., 2015). Tight junction proteins (e.g., occludins, claudins) are also expressed
by urothelial cells and contribute to the exceptionally high resistance of the urothelium
(Birder and Andersson, 2013; Chung et al., 2014; Rickard et al., 2008). Intravesical
imatinib may mediate functional improvements by altering urothelial barrier
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characteristics (e.g., tight junction, uroplakin, glycosaminoglycan protein expression).
Future studies should examine effects of imatinib on urothelium tight junction protein
expression and transepithelial resistance in control mice and in mice with CYP-induced
cystitis. In addition, when considering the effects of imatinib delivered intravesically, one
should consider the depth of penetration of intravesically infused substances and cell
types affected. Interstitial cells exhibit heterogeneous morphology and exhibit differential
receptor and channel expression, properties, and function according to tissue distribution
in the LP (upper vs. lower) and tissue (LP vs. detrusor) (Gevaert et al., 2014b; Neuhaus et
al., 2018; Steiner et al., 2018). Thus, effects of intravesical imatinib treatment may be
affected by frequency and duration of imatinib treatment and populations of interstitial
cells affected.
Increased NGF and BDNF expression in the urinary bladder with CYP-induced
cystitis has been demonstrated in preclinical animal models and human patients with
IC/BPS (Coelho et al., 2019; Girard et al., 2016; Vizzard, 2000). Unexpectedly in the
present study, NGF mRNA and BDNF mRNA and protein expression were not
significantly different in mice with 4 h CYP-induced cystitis that subsequently received
transurethral intravesical saline infusion compared to controls (no CYP, intravesical
saline infusion). The lack of effect of CYP on NGF and BDNF mRNA may be partially
due to solely examining the LP, without the urothelium or detrusor as previously
demonstrated. Our results suggest that distension or lavage of the bladder with saline
alone may affect NGF and BDNF expression. It is also interesting that the magnitude of
change observed for IL-6 and CCL2 mRNA expression with CYP-induced cystitis was
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dramatically reduced in LP samples with treatment (infusion) compared to LP samples
with prevention (gavage). Whether bladder distention or lavage reduced the IL-6 and
CCL2 mRNA LP expression in treatment groups is unknown but could be addressed in
future studies. Although this result was unexpected, it may not be entirely surprising
considering hydrodistension is a common treatment option for IC/BPS patients and may
reduce inflammatory mediator expression (Aihara et al., 2009; Chen et al., 2021;
Erickson et al., 2007; Hanno et al., 2015; Liu and Kuo, 2007).
The PDGFRα, c-KIT, and ABL kinases can each activate MAPK/ERK and
PI3K/AKT signaling pathways (Andrae et al., 2008; Colicelli, 2010; Lennartsson and
Rönnstrand, 2012) and we examined pERK and pAKT expression in the U. LP and D.
LP. In mice with 4 h CYP-induced cystitis, imatinib prevention via gavage: 1) reduced
pERK expression in both the U. LP and D. LP, and 2) reduced pAKT expression in the
D. LP, but not the U. LP. In mice with 4 h CYP-induced cystitis, imatinib treatment via
intravesical infusion: 1) reduced pERK expression in the D. LP, but not the U. LP and 2)
reduced pAKT expression in both the U. LP and D. LP. Our results suggest that imatinib
prevention or treatment, reduces MAPK/ERK and PI3K/AKT expression in the U. LP
and D. LP in female mice with 4 h CYP-induced cystitis. Imatinib inhibition of receptors,
such as PDGFRα, may differentially regulate tissue expression of downstream kinases in
inflammatory conditions depending on imatinib delivery route, frequency, and duration.
We previously demonstrated pERK and pAKT functional involvement and
expression in the micturition system in CYP-induced cystitis (Arms and Vizzard, 2011;
Corrow and Vizzard, 2007; Corrow and Vizzard, 2009). The MAPK/ERK and
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PI3K/AKT pathways regulate many processes including cell growth, proliferation,
migration, survival, angiogenesis, cell death, inflammatory mediator expression and
secretion (Brazil and Hemmings, 2001; Fernandes et al., 2016; Hers et al., 2011; Lavoie
et al., 2020; Li et al., 2006; Miranda et al., 2005; Sharma et al., 2020; Zegeye et al.,
2018). In rodent models of CYP-induced cystitis, functional and pharmacological studies
suggest pERK and pAKT may induce pCREB, mTOR, type 1 collagen, and cytokine
expression, including IL-6 (Kay et al., 2013; Qiao et al., 2014; Sun et al., 2015). In our
studies, the reduction in kinase expression with imatinib was most prominent with pAKT
and in the D. LP. A major downstream target of pAKT is mTOR (Manning and Toker,
2017) which may contribute to IC/BPS (Liang et al., 2016; Lin et al., 2015; Liu et al.,
2020; Xie et al., 2018; Yang et al., 2012). Intrathecal blockade of the PI3K/AKT-mTOR
pathway reduced bladder hyperactivity, somatic sensitivity, and spinal cord substance P
and CGRP protein expression in female rats with chronic CYP-induced cystitis (Liang et
al., 2016). Future studies concerning signaling mechanisms of PDGFRα+ interstitial cells
and their contribution to cystitis should examine downstream kinase targets including
mTOR.
In conclusion, our studies suggest that imatinib may affect the urinary bladder
inflammatory milieu and signaling kinases differently, depending on delivery route,
frequency, and duration of treatment. Imatinib is likely mediating effects through
multiple mechanisms (e.g., reducing inflammatory mediators, enhancing endothelial and
urothelial barriers) which may be dependent on frequency of delivery and delivery route.
Imatinib prevention via gavage may be improving functional urinary outcomes, in part,
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by affecting the bladder inflammatory milieu in female mice with acute CYP-induced
cystitis. Imatinib treatment via intravesical infusion in CYP-induced cystitis did not affect
urinary inflammatory mediator expression at the examined time point but could be
utilizing other mechanisms to mediate functional improvements including altering
urothelial barrier properties. Additionally, PDGFRα+ interstitial cell signaling may be
mediated by both pERK and pAKT pathways in cystitis. Future studies should examine
the effect of imatinib on urothelial barrier function and downstream kinase targets (e.g.,
mTOR), to further elucidate the mechanism(s) by which imatinib improves urinary
bladder function in CYP-induced cystitis.
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Abbreviations
IC/BPS, Interstitial Cystitis/Bladder Pain syndrome
OAB, Overactive Bladder
SCI, Spinal Cord Injury
LUT, Lower Urinary Tract
LP, Lamina Propria
U. LP, Upper Lamina Propria
D. LP, Deeper Lamina Propria
DRG, Dorsal Root Ganglia
WT, Wild Type
PDGFRα, Platelet-Derived Growth Factor Receptor Alpha
PDGFRβ, Platelet-Derived Growth Factor Receptor Beta
c-KIT, tyrosine-protein kinase KIT
BCR-ABL, Breakpoint Cluster Region-Abelson Murine Leukemia
TrpV4, Transient Receptor Potential Vanilloid-type 4 (Trpv4)
NGF, Nerve Growth Factor
BDNF, Brain-Derived Neurotrophic Factor
VEGF, Vascular Endothelial Growth Factor
IL-6, Interleukin-6
CCL2, C-C Motif Chemokine Ligand 2
MAPK/ERK, Mitogen-Activated Protein Kinase/Extracellular Signal-Related Kinase
PI3K/AKT, Phosphatidylinositol 3-Kinase/Protein Kinase B
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p, phosphorylated
IMI, Intermicturition Interval
IV, Infused Volume
CYP, Cyclophosphamide
i.p., intraperitoneal
s.c., subcutaneous
h, hour(s)
min, minutes
ANOVA, Analysis of Variance
qRT-PCR, quantitative Reverse Transcription-Polymerase Chain Reaction
ELISA(s), Enzyme-Linked Immunosorbent Assay(s)
IHC, Immunohistochemistry
IU, Intensity Units
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Table 1: Antibodies used for immunohistochemistry
pPDGFRα, phosphorylated platelet-derived growth factor receptor alpha; pERK, phosphorylated
extracellular signal-related kinase; pAKT, phosphorylated protein kinase B; FITC, fluorescein
isothiocyanate; CY3, sulfo-cyanine3.

Primary Antibody

Dilution

Source

Secondary

Dilution

Source

Antibody
Rabbit anti-pPDGFRα

1:250

Abcam,
Cambridge,
UK

FITC donkey
anti-rabbit

1:200

Jackson
Immunoresearch, West
Grove, PA, USA

Sheep anti-pERK

1:1000

Osenses,
Keswick, SA,
Australia

CY3 donkey
anti-sheep

1:500

Jackson
Immunoresearch

Sheep anti-pAKT

1:3000

Osenses

CY3 donkey
anti-sheep

1:500

Jackson
Immunoresearch

Table 2: Primer sequences for real time qRT-PCR
BDNF, brain-derived neurotrophic factor; NGF, nerve growth factor; VEGFaa, vascular endothelial growth
factor aa; VEGFab, vascular endothelial growth factor ab; IL-6, interleukin 6; CCL2, chemokine (C-C
motif) ligand 2; L32, ribosomal protein L32. U: upper; L: lower.
Primer
BDNF
NGF
VEGFaa
VEGFab
IL-6
CCL2
L32

Sequence
U: GTGACAGTATTAGCGAGTGGG
L: GGGTAGTTCGGCATTGC
U: AGTGAGGTGCATAGCGTAAT
L: AGTGGAGTCTCCGTTTCTTA
U: AGAGCGGAGAAAGCATTTGTTT
L: AGCATTTGTTTGTCCAAGATCC
U: TCACCGCCTTGGCTTGTCACAT
L: TTAATCGGTCTTTCCTTTGAGA
U: TTGCCTTCTTGGGACTGATG
L: GCCATTGCACAACTCTTTTC
U: AGCCAACTCTCACTGAAGC
L: GTGAATGAGTAGCAGCAGGT
U: CCTGGCGTTGGGATTGGTGA
L: GAAAAGCCATCGTAGAAAGA
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Figure 1: Experimental designs
(A) Prevention design. Mice were pre-treated with imatinib mesylate (250 mg/kg) or vehicle (water) via
oral gavage for 5 days, 1X/day. Mice received acute (4 h) cyclophosphamide (CYP) treatment (200 mg/kg,
i.p.) on the 5th day. (B) Treatment design. Mice received acute (4 h) CYP (200 mg/kg, i.p.) followed 4 h
later by imatinib (50 μM) or vehicle (saline) treatment via transurethral intravesical (intrabladder) infusion
(30 min). Upon completion of prevention or treatment design, urinary bladders were collected (4 h+ post
CYP) for real time qRT-PCR, ELISA or IHC experiments. qRT-PCR, quantitative reverse transcriptionpolymerase chain reaction; ELISA, enzyme-linked immunosorbent assay; IHC, immunohistochemistry.

204

205

Figure 2: Oral gavage of imatinib mesylate significantly affects inflammatory mediator mRNA
transcript expression in the lamina propria (LP) of the urinary bladder in an acute (4 h)
cyclophosphamide (CYP)-induced cystitis female mouse model
Acute (4 h) CYP treatment (200 mg/kg, i.p.) significantly (0.0001 ≤ p ≤ 0.001) increased (A) IL-6 (3794.4fold), (B) NGF (26.8-fold), (C) VEGFaa (4.4-fold), (D) CCL2 (142.2-fold), (E) BDNF (13.9-fold), and (F)
VEGFab (3.7-fold) mRNA transcript expression in the bladder LP in female mice pre-treated with vehicle
(water) via gavage, compared to vehicle (water gavage, no CYP) control. Imatinib prevention (250 mg/kg,
5 days, 1X/day) via oral gavage significantly (0.0001 ≤ p ≤ 0.05) decreased (A) IL-6 (3.1-fold), (C)
VEGFaa (1.6-fold), (D) CCL2 (6.5-fold), (E) BDNF (1.9-fold), and (F) VEGFab (2.1-fold), but did not
affect (B) NGF, mRNA transcript expression in the bladder LP of female mice with 4 h CYP-induced
cystitis. mRNA transcripts were measured by real time qRT-PCR. mRNA transcript expression was
normalized to expression of the house keeping gene, L32. Transcript values are displayed as fold change
values ± SEM with respect to the control group (vehicle, no CYP). n = 4-6. *p ≤ 0.05; **p ≤ 0.01; ***p ≤
0.001; ****p ≤ 0.0001 by two-way ANOVA with Tukey’s multiple comparisons test.
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Figure 3: Oral gavage of imatinib mesylate significantly decreases inflammatory mediator protein
expression the urinary bladder in an acute (4 h) cyclophosphamide (CYP)-induced cystitis female
mouse model
Acute (4 h) CYP treatment (200 mg/kg, i.p.) significantly (0.0001 ≤ p ≤ 0.001) increased (A) VEGF (2.4fold) and (B) IL-6 (10.2-fold) whole bladder protein expression in female mice pre-treated with vehicle
(water) via gavage, compared to vehicle (water gavage, no CYP) control. Imatinib prevention (250 mg/kg,
5 days, 1X/day) via oral gavage significantly (0.001 ≤ p ≤ 0.05) decreased (A) VEGF (2.8-fold) and (B) IL6 (1.5-fold) whole bladder protein expression in female mice with 4 h CYP-induced cystitis. Raw ELISA
values (pg/μg) are presented as fold change values ± SEM with respect to the control group (vehicle, no
CYP). n = 7-9. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way ANOVA with Tukey’s
multiple comparisons test.
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Figure 4: Transurethral bladder infusion of imatinib mesylate does not significantly affect CCL2 and
IL-6 mRNA transcript (lamina propria, LP) or protein (whole urinary bladder) expression in an
acute (4 h) cyclophosphamide (CYP)-induced cystitis female mouse model
Acute (4 h) CYP treatment (200 mg/kg, i.p.) significantly (0.0001 ≤ p ≤ 0.01) increased (A) CCL2 (4.4fold) and (B) IL-6 (5.7-fold) mRNA transcript expression in the bladder LP, and (C) CCL2 (4-fold) and (D)
IL-6 (11.1-fold) whole bladder protein expression in female mice that received vehicle (saline) intravesical
infusion 4 h post CYP injection, compared to vehicle infused control. Imatinib treatment via transurethral
intravesical infusion (50 μM, 30 min) 4 h post CYP administration, did not significantly affect (A) CCL2 or
(B) IL-6 mRNA transcript expression in the bladder LP, nor (C) CCL2 or (D) IL-6 protein expression in
whole bladder samples in female mice with 4 h CYP-induced cystitis. mRNA transcript and protein
expression were measured by real time qRT-PCR and ELISAs, respectively. mRNA transcript expression
was normalized to expression of the house keeping gene, L32. Raw mRNA transcript and ELISA values
(pg/μg) are presented as fold change values ± SEM with respect to the control group (vehicle, no CYP). n
= 7-10. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way ANOVA with Tukey’s multiple
comparisons test.
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Figure 5: Transurethral bladder infusion of imatinib mesylate does not significantly affect VEGF,
BDNF or NGF mRNA transcript (lamina propria, LP) or protein (whole urinary bladder) expression
in an acute (4 h) cyclophosphamide (CYP)-induced cystitis female mouse model
Acute (4 h) CYP treatment (200 mg/kg, i.p.) significantly (p ≤ 0.001) increased (C) VEGFaa (2.6-fold) and
(D) VEGFab (3.1-fold) mRNA but did not affect (A) BDNF or (B) NGF mRNA transcript expression in
the bladder LP, in female mice that received vehicle (saline) intravesical infusion 4 h post CYP injection,
compared to vehicle infused (no CYP) controls. 4 h CYP treatment significantly (0.0001 ≤ p ≤ 0.001)
increased (F) NGF (1.8-fold) and (G) VEGF (4.8-fold), but did not affect (E) BDNF whole bladder protein
expression, compared to vehicle controls. Imatinib treatment via transurethral intravesical infusion (50 μM,
30 min) 4 h post CYP administration, did not significantly affect (A) BDNF, (B) NGF, (C) VEGFaa, or (D)
VEGFab mRNA transcript expression in the bladder LP, nor (E) BDNF, (F) NGF, or (G) VEGF protein
expression in whole bladder samples in female mice with 4 h CYP-induced cystitis. mRNA transcript and
protein expression were measured by real time qRT-PCR and ELISAs, respectively. mRNA transcript
expression was normalized to expression of the house keeping gene, L32. Raw mRNA transcript and
ELISA values (pg/μg) are presented as fold change values ± SEM with respect to the control group
(vehicle, no CYP). n = 6-10. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way ANOVA
with Tukey’s multiple comparisons test.
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Figure 6: Oral gavage of imatinib mesylate, but not transurethral bladder infusion, significantly
reduces bladder weight in an acute (4 h) cyclophosphamide (CYP)-induced cystitis female mouse
model
Acute (4 h) CYP treatment (200 mg/kg, i.p.) significantly (0.0001 ≤ p ≤ 0.05) increased bladder weight in
(A) mice that received vehicle (water) via oral gavage for 5 days prior to CYP administration (1.8-fold) and
(B) mice that received transurethral vehicle (saline) intravesical infusion 4 h post CYP administration (1.3fold), compared to vehicle (no CYP) controls. (A) Imatinib prevention (250 mg/kg, 5 days, 1X/day) via
oral gavage significantly (p ≤ 0.05) (1.2-fold) reduced bladder weight in female mice with 4 h CYPinduced cystitis, but (B) imatinib treatment (50 μM, 30 min) via intravesical infusion did not affect bladder
weight. Raw values (g) are presented as fold change values ± SEM with respect to the control group
(vehicle, no CYP). n = 10-19. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way ANOVA
with Tukey’s multiple comparisons test.
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Figure 7: Oral gavage of imatinib mesylate reduces pERK expression in the upper lamina propria
(U. LP) and deeper lamina propria (D. LP), in an acute (4 h) cyclophosphamide (CYP)-induced
cystitis female mouse model
Representative (A-H) images, (I) upper LP and (K) deeper LP fluorescence intensity curves of pERK
immunoreactivity (CY3, red) in the urinary bladder (10 µm sections) in female mice with (E) acute (4 h)
cyclophosphamide (CYP)-induced cystitis (200 mg/kg, i.p.) and (C, D) controls (no CYP), (F) pre-treated
with imatinib mesylate via oral gavage (250 mg/kg, 5 days, 1X/day). (A, B, G, H) Bladder tissue was costained for pPDGFRα (FITC, green), and the corresponding images are displayed to provide orientation. 4
h CYP treatment significantly (p ≤ 0.0001) increased pERK expression in the (J) U. LP (2-fold) but not the
(L) D. LP, compared to vehicle controls. Imatinib prevention significantly (0.01 ≤ p ≤ 0.05) reduced pERK
expression in the (J) U. LP (1.5-fold) and the (L) D. LP (1.6-fold) in female mice with 4 h CYP-induced
cystitis. Raw IHC values (intensity units, 8-bit) are presented as fold change values ± SEM with respect to
the control group (vehicle, no CYP). n = 3-6. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by twoway ANOVA with Tukey’s multiple comparisons test. Tissues were processed simultaneously. Microscope
and camera settings were kept constant across all groups. Fluorescence intensity was measured using
Volumetry image analysis software (VolumetryG9a, Grant Hennig). 10 μm sections. Scale bar = 50 μm. U,
urothelium; U. LP, upper lamina propria; D. LP, deeper lamina propria; IU, intensity units.
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Figure 8: Oral gavage of imatinib mesylate reduces pAKT expression in the deeper lamina propria
(D. LP), but not upper lamina propria (U. LP), in an acute (4 h) cyclophosphamide (CYP)-induced
cystitis female mouse model
Representative (A-H) images, (I) upper LP and (K) deeper LP fluorescence intensity curves of pAKT
immunoreactivity (CY3, red) in the urinary bladder (10 µm sections) in female mice with (E) acute (4 h)
cyclophosphamide (CYP)-induced cystitis (200 mg/kg, i.p.) and (C, D) controls (no CYP), (F) pre-treated
with imatinib mesylate via oral gavage (250 mg/kg, 5 days, 1X/day). (A, B, G, H) Bladder tissue was costained for pPDGFRα (FITC, green), and the corresponding images are displayed to provide orientation. 4
h CYP treatment significantly (p ≤ 0.05) increased pAKT expression in the (J) U. LP (1.4-fold) and the (L)
D. LP (1.2-fold), compared to vehicle controls. Imatinib prevention significantly (p ≤ 0.001) reduced pAKT
expression in the (L) D. LP (2.2-fold), but not the (J) U. LP in female mice with 4 h CYP-induced cystitis.
Raw IHC values (intensity units, 8-bit) are presented as fold change values ± SEM with respect to the
control group (vehicle, no CYP). n = 4-6. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way
ANOVA with Tukey’s multiple comparisons test. Tissues were processed simultaneously. Microscope and
camera settings were kept constant across all groups. Fluorescence intensity was measured using
Volumetry image analysis software (VolumetryG9a, Grant Hennig). 10 μm sections. Scale bar = 50 μm. U,
urothelium; U. LP, upper lamina propria; D. LP, deeper lamina propria; IU, intensity units.
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Figure 9: Transurethral bladder infusion of imatinib mesylate reduces pERK expression in the
deeper lamina propria (D. LP), but not upper lamina propria (U. LP), in an acute (4 h)
cyclophosphamide (CYP)-induced cystitis female mouse model
Representative (A-H) images, (I) upper LP and (K) deeper LP fluorescence intensity curves of pERK
immunoreactivity (CY3, red) in the urinary bladder (10 µm sections) in female mice with (E) acute (4 h)
cyclophosphamide (CYP)-induced cystitis (200 mg/kg, i.p.) and (C, D) controls (no CYP), (F) treated with
imatinib mesylate via transurethral intravesical infusion (50 μM, 30 min). (A, B, G, H) Bladder tissue was
co-stained for pPDGFRα (FITC, green), and the corresponding images are displayed to provide orientation.
4 h CYP treatment significantly (p ≤ 0.05) increased pERK expression in the (L) D. LP (1.5-fold) but not
the (J) U. LP, compared to vehicle controls. Imatinib treatment significantly (p ≤ 0.05) reduced pERK
expression in the (L) D. LP (1.3-fold), but not the (J) U. LP in female mice with 4 h CYP-induced cystitis.
Raw IHC values (intensity units, 8-bit) are presented as fold change values ± SEM with respect to the
control group (vehicle, no CYP). n = 4-8. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way
ANOVA with Tukey’s multiple comparisons test. Tissues were processed simultaneously. Microscope and
camera settings were kept constant across all groups. Fluorescence intensity was measured using
Volumetry image analysis software (VolumetryG9a, Grant Hennig). Scale bar = 50 μm. U, urothelium; U.
LP, upper lamina propria; D. LP, deeper lamina propria; IU, intensity units.
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Figure 10: Transurethral bladder infusion of imatinib mesylate reduces pAKT expression in the
upper LP (U. LP) and deeper lamina propria (D. LP), in an acute (4 h) cyclophosphamide (CYP)induced cystitis female mouse model
Representative (A-H) images, (I) upper LP and (K) deeper LP fluorescence intensity curves of pAKT
immunoreactivity (CY3, red) in the urinary bladder (10 µm sections) in female mice with (E) acute (4 h)
cyclophosphamide (CYP)-induced cystitis (200 mg/kg, i.p.) and (C, D) controls (no CYP), (F) treated with
imatinib mesylate via transurethral intravesical infusion (50 μM, 30 min). (A, B, G, H) Bladder tissue was
co-stained for pPDGFRα (FITC, green), and the corresponding images are displayed to provide orientation.
4 h CYP treatment significantly (0.0001 ≤ p ≤ 0.001) increased pAKT expression in the (J) U. LP (1.8-fold)
and the (L) D. LP (2.5-fold), compared to vehicle controls. Imatinib treatment significantly (0.0001 ≤ p ≤
0.01) reduced pAKT expression in the (J) U. LP (1.4-fold) and the (L) D. LP (3.8-fold) in female mice with
4 h CYP-induced cystitis. Raw IHC values (intensity units, 8-bit) were converted to and are displayed as
fold change values ± SEM with respect to the control group (vehicle, no CYP). n = 4-7. *p ≤ 0.05; **p ≤
0.01; ***p ≤ 0.001; ****p ≤ 0.0001 by two-way ANOVA with Tukey’s multiple comparisons test. Tissues
were processed simultaneously. Microscope and camera settings were kept constant across all groups.
Fluorescence intensity was measured using Volumetry image analysis software (VolumetryG9a, Grant
Hennig). Scale bar = 50 μm. U, urothelium; U. LP, upper lamina propria; D. LP, deeper lamina propria; IU,
intensity units.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
4.1. General Summary
LUT dysfunction conditions, such as IC/BPS or OAB, are characterized by
storage symptoms (e.g., altered sensation, increased urinary urgency and frequency).
Pelvic pain and/or discomfort is a hallmark feature of IC/BPS (Hanno et al., 2015). LUT
dysfunction causes significant personal distress and is complicated to manage and treat.
The etiology for both IC/BPS and OAB remains unclear. Treatment options for IC/BPS
and OAB are few and not effective for all patients. In this dissertation, we propose
PDGFRα interstitial cells contribute to LUT IC/BPS outcomes, such as increased voiding
frequency and decreased bladder capacity. Our experiments characterize the functional
effects of imatinib mesylate, a tyrosine kinase inhibitor that inhibits PDGFRα and -β, cKIT and BCR-ABL kinases, in mice with CYP-induced cystitis and suggest potential
mechanisms by which imatinib mediates its effects (e.g., urinary inflammatory milieu,
intracellular signaling cascades).
4.2. Conclusions and Future Directions: The Effect of Imatinib Mesylate on LUT
Function in CYP-Induced Cystitis
Imatinib mesylate reduced LUT outcomes (e.g., voiding frequency and infused
volume) in female, but not male, mice with acute (4 h) CYP-induced cystitis, by a
prevention (i.e., pre-treatment of 250 mg/kg imatinib via oral gavage, pre-CYP, 1X/day,
5 days total) and treatment (i.e., treatment of 50 μM imatinib via intravesical bladder
infusion, post-CYP) experimental design. Imatinib did not affect LUT outcomes in
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female mice with intermediate (48 h) or chronic (8 day) CYP-induced cystitis.
Additionally, imatinib administration did not affect pelvic somatic sensitivity by the
prevention or treatment design, measured with the von Frey assay, in female mice with or
without acute (4 h) CYP-induced cystitis.
Of the models and designs tested, our studies suggest that imatinib administration
is most effective at improving LUT outcomes in female mice with acute (4 h) CYPinduced cystitis. Our studies suggest that imatinib did not affect LUT outcomes at later
time points. If we consider the translational relevance of our studies to human IC/BPS or
OAB patients, symptom duration should be considered, and timely diagnoses should be
emphasized. Imatinib treatment may also be relevant to patients who experience severe
symptom flares.
The lack of effect of imatinib on somatic sensitivity suggests that it may be a
better therapeutic option for OAB patients, as OAB patients do not experience pelvic pain
or discomfort. However, this speculation should be extensively explored further in OAB
animal models. The extent of improvements of LUT function in acute (4 h) CYP-induced
cystitis with imatinib administration by gavage or intravesical infusion were similar;
however, intravesical infusion of imatinib had less of an effect on bladder pressure. Thus,
treatment with imatinib via infusion may be a more ideal option, considering side effects.
Additionally, the translational value of a prevention design for IC/BPS or OAB patients is
debatable; however, this design primarily addresses basic science, rather than clinical
concerns. The prevention design may further inform our understanding of the
contribution of urinary bladder PDGFRα interstitial cells to the development of IC/BPS;
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albeit, with these designs, our conclusions are not fully PDGFRα specific and off target
effects are unavoidable.
4.2.1. Future Directions: The Effect of Imatinib Mesylate on Calcium Signaling in
Urinary Bladder Interstitial Cells
Calcium signaling is likely a primary mediator of urinary bladder interstitial cell
communication. Electrophysiological, immunohistochemistry and PCR techniques
suggest LP and detrusor interstitial cells generate and propagate calcium transients and
express cell surface and intracellular calcium channels (Deng et al., 2013; Drumm et al.,
2014; Fry et al., 2012; Gray et al., 2013; Heppner et al., 2017; Ikeda et al., 2007; Neuhaus
et al., 2020; Sui et al., 2008; Wu et al., 2004). Imatinib has been widely used in LUT
research as a PDGFRα or c-KIT inhibitor, yet our understanding of the effect of imatinib
on urinary bladder interstitial cells at the cellular level (e.g., calcium signaling) is limited.
Few studies have examined the effect of imatinib on interstitial cell calcium signaling in
the normal or pathological bladder (Deng et al., 2013; Fry et al., 2012; Sui et al., 2008).
Mucosal or detrusor strip preparations could be used to generally isolate
interstitial cell subpopulations. Interstitial cells could be identified by shape and location.
A transgenic murine line which constitutively expresses enhanced green fluorescent
protein in PDGFRα+ cells, due to the insertion of H2B-eGFP fusion gene downstream of
the PDGFRα promoter, could also be used to identify interstitial cells for calcium
signaling (Hamilton et al., 2003; Koh et al., 2012). Calcium signaling should be assessed
with multiple experimental designs in which imatinib is administered before dissection
and testing or directly applied to the bladder tissue during testing. Varying schedules,
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doses and delivery routes should be examined. It should be considered that imatinib may
inhibit L-type calcium channels (Kubota et al., 2006; Kubota et al., 2004) at high (> 50
μM) concentrations. These experiments would provide insight concerning the cellular
effects of imatinib on interstitial cells (e.g., extent of interstitial cell inhibition with
imatinib) and may clarify previous findings.
4.2.2. Future Directions: Targeting PDGFRα
Currently, techniques that specifically inhibit PDGFRα do not exist. The inability
to target or isolate PDGFRα+ cells presents a major obstacle to understanding the
function of PDGFRα interstitial cells in the normal and pathological bladder. It is
difficult to draw strong conclusions concerning the roles of bladder interstitial cells with
non-specific techniques. However, investigators should consider the available techniques
which target PDGFRα, albeit non-specifically. Additional lines of evidence using varied
techniques and methodologies, despite drawbacks, still add to the growing body of
interstitial cell literature and further our understanding of their role in the bladder.
Many PDGFRα inhibitors alternative to imatinib exist such as sunitinib or
nilotinib (Roskoski, 2018). Inhibitors such as tyrphostin AG 1296 (Kovalenko et al.,
1997), that demonstrate high potency for PDGFRs and low potency for related receptors
are ideal. However, the primary drawback of non-specific inhibition remains. PDGFRα
neutralizing antibodies have been previously used and demonstrate inhibition of receptor
autophosphorylation and autocrine growth (LaRochelle et al., 1993; Loizos et al., 2005;
Lokker et al., 1997; Matei et al., 2006). These studies are primarily conducted in vitro
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and in tumor cell lines, infrequently used, and are not therapeutic treatments. Thus,
therapeutic relevance to IC/BPS patients is debatable.
Transgenic techniques also offer an alternative approach to targeting PDGFRα.
Thus far, a transgene specific to bladder interstitial cells has not been developed.
However, multiple PDGFRα specific strains expressing transgenic systems (e.g., loxP,
cre, mutations) are available. PDGFRα signaling can also be studied with one strain that
carries a point mutation at the PDGFRα PI3K binding site (Klinghoffer et al., 2002).
PDGFRα Cre-mediated PDGFRα deletion or constitutive activation in certain cells and
tissues (e.g., kidney, heart; fibroblasts) can be produced when certain strains are
combined. For instance, a strain expressing a floxed PDGFRα allele (Jackson et al., 2006;
Tallquist and Soriano, 2003) could be crossed with strains expressing fibroblast (e.g.,
Col1α2, integrin α11) (Alam et al., 2020; Florin et al., 2004; Zheng et al., 2002),
myofibroblast (e.g., a-SMA) (LeBleu et al., 2013), or interstitial cell (e.g., Tcf21/pod1 –
kidney) (Maezawa et al., 2012) specific cre-recombinase, to more directly target
PDGFRα bladder interstitial cells (Swonger et al., 2016). However, PDGFRα bladder
interstitial cells may not express these markers and genetic manipulation would still not
be specific to the bladder. Controllability of PDGFRα manipulation is one advantage of
using transgenic techniques. Depending on strains crossed, transgenic offspring express
doxycycline- (Li et al., 2018) or tamoxifen-induced (Chung et al., 2018) cre-recombinase
in PDGFRα cells.
Although these techniques are not specific to PDGFRα or urinary bladder
interstitial cells, they may provide additional tools of manipulation and contribute to the
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growing body of evidence concerning the role of PDGFRα urinary bladder interstitial
cells.
4.2.3. Future Directions: Repeated and Combinational Treatment Approaches in
IC/BPS and OAB Animal Models
An additional dose of imatinib via intravesical infusion 4 h and 24 h post CYP,
improved LUT outcomes in female mice (Chapter 2, Figure 7). Treatment for IC/BPS is
often consistent and repeated. Continued repeated treatments of imatinib via intravesical
infusion past 24 h post CYP should be explored.
Stress is known to induce IC/BPS symptom flares in patients (Koziol, 1994; Nazif
et al., 2007; Rothrock et al., 2001; Whitmore, 1994) and animal models (Birder and
Andersson, 2018; Charrua et al., 2015; Girard et al., 2017; Matos et al., 2017; Merrill et
al., 2013; Mingin et al., 2015; Mingin et al., 2014) Our data in both experimental designs
suggests that imatinib does not prevent (i.e., 250 mg/kg, oral gavage, 1X/day, 5 days, preCYP) (Chapter 2, Figure 5) chronic CYP-induced cystitis, nor treat (i.e., 50 μM, 30 min,
post-CYP) (Chapter 2, Figure 6) chronic CYP-induced cystitis. Thus, imatinib may not
be effective in stress protocols with chronic CYP-induced cystitis. However, IC/BPS
stress induced, or exacerbated symptoms may be considered acute bouts of cystitis.
Examining the effect of imatinib on LUT outcomes with stress protocols, after full or
near recovery from CYP-induced cystitis, may be useful.
A hallmark feature of IC/BPS is pelvic discomfort and/or pain (Hanno et al.,
2015). The absence of effect of imatinib on pelvic somatic sensitivity (Appendix, Figures
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1, 2) in mice with acute CYP-induced cystitis may suggest that imatinib will not be an
effective treatment for IC/BPS patients. Thus, imatinib administration, via prevention or
treatment designs, should be further examined using OAB models, such as SCI-induced
or partial outlet obstruction-induced OAB.
Many IC/BPS patients receive combinational treatments (e.g., hydrodistension
with oral medication) (Hanno et al., 2015). It is possible that imatinib administration, in
addition to other therapeutic treatments, may be clinically relevant for IC/BPS patients
despite our somatic sensitivity results. Combinational approaches, such as imatinib
prevention via oral gavage with intravesical infusion of NGF inhibitors, should be
assessed in IC/BPS and OAB animal models.
4.2.4. Future Directions: PDGFRα+ Interstitial Cell Relation to Urinary Bladder
Afferent Nerves
Imatinib prevention or treatment did not affect pelvic somatic sensitivity in mice
with or without acute CYP-induced cystitis (Appendix, Figure 1, 2). Interstitial cells are
near nerve terminal endings (Koh et al., 2012) and suspected of neural signaling, as they
reportedly express purinergic (Fry et al., 2012; Heppner et al., 2017; Sui et al., 2006; Sui
et al., 2008; Wu et al., 2004), nitrergic (de Jongh et al., 2007; Gillespie et al., 2006; Smet
et al., 1996) and cholinergic (Grol et al., 2009; Mukerji et al., 2006) receptors or activity,
and demonstrate calcium transients in response to electrical field stimulation (Gray et al.,
2013). It is possible that interstitial cells communicate with Aδ fibers and contribute to
normal bladder sensation, but do not interact with C fibers responsible for noxious
sensation. Future studies could examine the relation of interstitial cells and bladder
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afferents (e.g., Aδ, C) using ex vivo preparations, in the normal and pathological bladder.
In this preparation, the bladder, urethra, ureters, major pelvic ganglia, postganglionic
nerves, and pelvic nerves are conserved and transferred into a recording solution and
chamber for physiological recordings. A remote-controlled syringe pump, connected to a
pressure transducer, is used to infuse substances into the bladder, empty the bladder, and
monitor bladder pressure. Electrodes are placed in the pelvic nerves to monitor
distension-evoked afferent activity. Aδ and C fibers cannot be distinguished by this
design. To target C fibers more selectively, inhibitors for receptors expressed in C fibers,
but not A fibers, such as TrpV1, could be used. However, TrpV1 is also expressed in
urothelial cells (Avelino and Cruz, 2006; Birder et al., 2002). We’ve previously
demonstrated successful results using this experimental design/model (Gonzalez et al.,
2016; Heppner et al., 2019).
In situ half bladder preparations are a recently developed technique (Aronsson et
al., 2014; Giglio et al., 2018) in which the bladder is exposed and completely separated
by a midline incision, from bladder to urethra, in an anesthetized animal. This preparation
allows for tension recordings on one side of the bladder, while the other side receives
afferent pelvic nerve stimulation, stretch to evoke afferent firing, or femoral intravenous
application of drugs. Aδ and C fibers have different stimulation thresholds thus, they can
be isolated depending on the stimulation protocol (Fujihara et al., 2011; Onda et al.,
2016; Sengupta and Gebhart, 1994) However, this protocol has not been widely used and
would likely be difficult to perform in mice, due to size.
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These preparations could be used to examine urinary bladder tension and afferent
nerve responses in the presence of PDGFRα inhibitors in IC/BPS, OAB, or PDGFRα
transgenic animal models. These studies could further our understanding of the role of
interstitial cells in the normal and pathological bladder.
4.2.5. Future Directions: Sex Differences
Our studies suggest the effect of imatinib on CYP-induced cystitis may differ
depending on sex. Imatinib prevention improved LUT outcomes in female, but not male,
mice with acute CYP-induced cystitis (Chapter 2, Figure 1). Imatinib treatment improved
LUT outcomes in both female and male mice with acute CYP-induced cystitis, however
the fold change was greater in females (Chapter 2, Figure 3). Sex differences were not
observed in control (no CYP) mice by the prevention (i.e., gavage) or treatment (i.e.,
intravesical infusion) design. This may suggest that sex differences are not present in
interstitial cells in the non-pathological bladder, however further research should be
conducted. In the literature, some studies include male and female human and/or animal
tissue (Gevaert et al., 2017a; Gevaert et al., 2017b; Gevaert et al., 2014; Heppner et al.,
2017; Neuhaus et al., 2020; Neuhaus et al., 2018; Steiner et al., 2018) and do not observe
overt sex differences. However, sample sizes in these studies, especially with human
tissue, do not allow definitive conclusions concerning sex differences. Most interstitial
cell reports examine one sex; thus, it is difficult and inappropriate to conclude sex
differences based on the literature. Females are predominantly used in studies examining
interstitial cells in the pathological bladder (e.g., IC/BPS, OAB), while males are
typically used in studies examining interstitial cells in the normal bladder. Investigating
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sex differences in interstitial cells may further our understanding of their role in the
normal bladder and help explain and treat sex differences observed in patient populations.
4.2.6. Future Directions: Mechanosensitive Ion Channel (MSC) Considerations
Mechanosensitive, calcium permeable channels such as TrpV4 (Heppner et al.,
2017; Lee et al., 2017; Zhao et al., 2021), TrpA1 (Steiner et al., 2018; Zhao et al., 2021),
and Piezo1 (Dalghi et al., 2019; Liu et al., 2018; Zhao et al., 2021) expression has been
transcriptionally and functionally demonstrated in PDGFRα+ and Vim+ bladder
interstitial cells, in multiple species including human. Reports suggest that these receptors
likely contribute to stretch-induced sensation, in the normal and pathological bladder
(Andersson, 2019; Merrill et al., 2016).
TrpV4 agonists increase ATP release in cultured urothelial cells (Mochizuki et al.,
2009). TrpV4 genetic deletion or antagonists increase void volumes and IMIs, and reduce
ATP release (Gevaert et al., 2007; Girard et al., 2019), suggesting a reduced afferent
response and/or increased threshold to bladder filling. LUT TrpV4 expression increases
and TrpV4 blockade improves LUT outcomes in rodent models of bladder overactivity
(e.g., NGF-overexpression, CYP-induced cystitis, stress-induced LUT dysfunction) (Beča
et al., 2021; Girard et al., 2019; Girard et al., 2013; Merrill et al., 2012; Merrill and
Vizzard, 2014). The role of TrpV4 in urinary bladder interstitial cells has also been
assessed in a few studies. TrpV4 agonists evoke slow propagating calcium waves
throughout interstitial cells in the U. LP of the bladder, yet TrpV4 antagonists are without
effect (Heppner et al., 2017). Electrophysiological experiments demonstrate TrpV4
channel activation reduces detrusor contractions and hyperpolarizes PDGFRα+ detrusor
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interstitial cells via SK3 activation (Lee et al., 2017). These studies indicate TrpV4+ may
mediate sensory signaling in the LP (Heppner et al., 2017; Neuhaus et al., 2020; Zhao et
al., 2021) and contribute to regulation of SMC excitability in the detrusor (Lee et al.,
2017).
TrpV4 may also play a role in underactive bladder. Rats with detrusor
underactivity demonstrate increased TrpV4 mRNA transcript expression and increased
voiding frequency with TrpV4 agonists (Deruyver et al., 2018; Takaoka et al., 2018;
Young et al., 2013). TrpV4 deficient mice exhibit an underactive bladder phenotype (e.g.,
increased IV and IMI) (Gevaert et al., 2007; Thorneloe et al., 2008) and altered sensation
compared to wild type mice (Suzuki et al., 2003). A combinational approach of
interstitial cell inhibition using a PDGFRα inhibitor (e.g., imatinib) in TrpV4 null mice
should be further assessed at higher doses and varying schedules, and in female mice.
These experiments could have implications for the role of TrpV4/PDGFRα interstitial
cells in the underactive bladder.
LUT DRG cells demonstrate increased calcium transients in response to TrpA1
agonists (DeBerry et al., 2014) and increased TrpA1 expression (Chen et al., 2016) with
chronic CYP-induced cystitis. TrpA1 antagonists reduce mechanical hyperalgesia, reduce
non-voiding contractions, and increase IMI in rodents with chronic CYP-induced cystitis
(Chen et al., 2016; DeBerry et al., 2014; Meotti et al., 2013).
Piezo1 agonists increase voiding frequency and decrease IMI in control, female
rats (Beča et al., 2021). Piezo1 expression increases in the urothelium, LP and detrusor in
female rats with chronic, but not acute, CYP-induced cystitis (Beča et al., 2021; Liu et
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al., 2018). Peizo1 agonists increase calcium activity in urothelial cells in acute and
intermediate-CYP induced cystitis (Beča et al., 2021) and antagonists reduce bladder
hyperactivity (Liu et al., 2018). Additionally, a piezo1 antagonist significantly reduced
hypotonic stress-induced calcium and sodium influx in cultured urinary bladder
interstitial cells from female rats with and without chronic CYP-induced cystitis (Liu et
al., 2018).
The role of mechanosensitive ion channels in interstitial cells could be further
assessed using CYP-induced cystitis, OAB, or transgenic (e.g., TrpV4-/-) mouse models.
Combinational approaches using channel agonists and antagonists, in the presence or
absence of PDGFRα inhibitors, could be assessed. Such studies would shed light
concerning the function and mechanisms of action of urinary bladder interstitial cells in
normal and pathological conditions.
4.3. Conclusions and Future Directions: The Effect of Imatinib Mesylate on the
Urinary Bladder Inflammatory Milieu and Intracellular Signaling Cascades
Imatinib mesylate reduced inflammatory mediator expression (i.e., BDNF,
VEGF, IL-6, CCL2), in the whole urinary bladder and LP by the prevention (i.e., pretreatment of 250 mg/kg imatinib via oral gavage, pre-CYP, 1X/day, 5 days total)
experimental design in female mice with acute CYP-induced cystitis, but was without
effect by the treatment (i.e., treatment of 50 μM imatinib via intravesical bladder
infusion, post-CYP) design. NGF was the only mediator assessed that was not affected by
imatinib administration. We cannot conclusively determine where imatinib is acting with
the prevention design. Thus, reductions in inflammatory mediators may be due to urinary
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bladder PDGFRα inhibition and/or off-target effects (e.g., c-KIT mast cell inhibition).
The absence of effect of imatinib treatment on inflammatory mediators may suggest that
imatinib does not improve LUT outcomes in mice with acute CYP-induced cystitis via
the inflammatory milieu, but rather faster mechanisms, such as gene transcription.
Additionally, it is possible that imatinib may influence the urothelium; however, our
studies do not address this topic.
Imatinib administration reduced downstream pERK and pAKT expression in the
U. LP and D. LP by the prevention and treatment designs in female mice with acute
CYP-induced cystitis. Immunohistochemistry results were nuanced which may indicate
that downstream signaling effects of imatinib inhibition are differential, depending on the
drug delivery route, frequency and dose, and interstitial cell type (e.g., U. LP vs. D. LP
interstitial cells). For instance, imatinib treatment may primarily reduce pAKT in the U.
LP and D. LP, while imatinib prevention may reduce pERK in U. LP and pAKT in D.
LP. These results may also reflect expressional and functional differences in urinary
bladder interstitial cells.
4.3.1. Future Directions: pERK and pAKT Considerations
In our studies, both pERK and pAKT were significantly reduced in either the U.
LP or D. LP, with imatinib prevention and treatment in female mice with acute CYPinduced cystitis (Chapter 3, Figures 7-10). pAKT was more affected than pERK with
imatinib prevention and treatment, particularly in the D. LP. PDGFRα signals via
numerous pathways including MAPK/ERK, PI3K/AKT, and PLCγ/PKC (Andrae et al.,
2008). However, PI3K is the primary downstream effector of PDGFRα. mTOR is a major
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target of the PI3K/AKT cascade (Saxton and Sabatini, 2017). mTOR may contribute to
cystitis (Liang et al., 2016; Lin et al., 2015; Liu et al., 2020; Xie et al., 2018; Yang et al.,
2012). One study that examined the role of mTOR in CYP-induced cystitis found that
blockade with intrathecally delivered inhibitors of mTOR or of PI3K increased IMI, IV,
and hind paw withdrawal thresholds in female rats with chronic CYP-induced cystitis
(Liang et al., 2016). Phosphorylated mTOR, downstream mTOR effectors (e.g., p70
S6K1), substance P and CGRP protein expression was significantly increased in the
dorsal horn of lumbar (L4-L6) spinal cord in these rats. This effect was attenuated by
PI3K and mTOR inhibition.
These signaling cascades, secondary effectors, and potential transcription factors,
should be further explored to better understand the mechanism of action of imatinib
inhibition and interstitial cell intracellular signaling pathways.
4.3.2. Future Directions: c-KIT Considerations
Imatinib is a non-specific tyrosine kinase inhibitor and effectively inhibits
PDGFRα, c-KIT and BCR-ABL tyrosine kinases (Buchdunger et al., 2000; Buchdunger
et al., 1996; Capdeville et al., 2002). Thus, we were not able to explicitly target PDGFRα
in our studies, especially with the prevention design due to systemic delivery of imatinib.
The LUT improvements and reductions in inflammatory mediator, pERK and pAKT
expression may be partially due to c-KIT mast cells, and/or other off target effects of
imatinib inhibition. This hypothesis could be partially tested using loss-of-function c-KIT
mutants (Arguello et al., 1992; McCloskey et al., 2009; Reis et al., 2000). If c-KIT
mutant mice with acute CYP-induced cystitis demonstrate improved LUT outcomes and
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reduced urinary bladder mediator and LP kinase expression, this could suggest that
imatinib may, in part, act via c-KIT receptors.
Detrusor preparations from loss-of-function c-KIT mutants (W/WV) and wild-type
mice exhibit similar, not significantly different electrical and contractile properties
(McCloskey et al., 2009). The only major difference observed was that detrusor muscle
from c-KIT mutant mice, unlike wild-types, demonstrated electrical filed stimulationinduced contractions that were atropine-resistant. Rats with loss-of-function c-KIT
mutations (WsRCWs/Ws) do not exhibit significantly different cystometric outcomes
compared to wild-type rats (Okada et al., 2011). This may suggest that loss of c-KIT,
does not contribute to overall bladder functioning. By extrapolation, these results may
indicate that the effects of imatinib on control mice observed in our study (Chapter 2,
Figures 1, 3) may not be due to c-KIT inhibition.
Interestingly, c-KIT mutant rats (WsRCWs/Ws) treated with CYP (100 mg/kg,
i.p., 48 h) exhibit reduced IMIs and increased non-voiding contractions compared to cKIT+ controls, which may suggest that c-KIT contributes to LUT functioning in rats with
CYP-induced cystitis (Okada et al., 2011). By extrapolation, these results may indicate
that imatinib improves LUT function in mice with acute CYP-induced cystitis partially
via c-KIT inhibition.
Although these studies are interesting and their results are worth consideration,
they are not directly comparable to the studies presented in this dissertation and
extrapolated conclusions cannot be assumed due to differences in experimental subject
(e.g., rat) and design.
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4.3.3. Future Directions: The Effect of Imatinib Mesylate on the Urothelium
Imatinib treatment via intravesical infusion did not affect examined inflammatory
mediators in LP mRNA or whole bladder protein expression (e.g., NGF, BDNF, VEGF,
IL-6, CCL2) in female mice with acute CYP-induced cystitis (Chapter 3, Figures 4, 5).
This may indicate that imatinib treatment acts by a non-inflammatory mechanism(s) to
mediate LUT functional improvements in acute CYP-induced cystitis. It is possible that
imatinib treatment via intravesical infusion may affect urothelial integrity. To test this
hypothesis, the transepithelial electrical resistance of the urothelium can be measured in a
mucosal preparation in which the mucosa is mounted between two halves of a Ussing
chamber, substances (e.g., imatinib) are washed over the urothelium, and electrical
resistance is measured to determine urothelial permeability (Lavelle et al., 2002; Studeny
et al., 2008; Truschel et al., 1999). Urothelial permeability could be assessed during
imatinib washes, with varying doses and exposure times, as well as in IC/BPS or OAB
animal models previously treated with imatinib. Tight junction mRNA and protein
expression in the urothelium (e.g., claudins, zona occludins, cadherins) should also be
examined. These studies would provide additional mechanistic insight concerning the
process(es) by which imatinib treatment via intravesical infusion improves LUT function
in female mice with acute CYP-induced cystitis. These experiments may also provide
more support for further assessment of the therapeutic potentials of imatinib if urothelial
enhancements are observed with imatinib treatment in the presence of inflammation.
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APPENDIX A

Figure 1: PDGFRα inhibition with imatinib mesylate pre-treatment via oral gavage does not affect
pelvic somatic sensitivity in an acute (4 h) cyclophosphamide (CYP)-induced cystitis female mouse
model
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Somatosensitivity of the pelvic region was determined with calibrated von Frey filaments in control (no CYP)
and acute, 4 h CYP-induced cystitis mice pre-treated with imatinib mesylate via oral gavage. Stimulation
was specific to the abdominal-pelvic region, overlying the urinary bladder. (A) Acute (4 h)
cyclophosphamide (CYP)-induced cystitis experimental schedule for imatinib mesylate pre-treatment via
oral gavage somatic sensitivity studies. Imatinib or vehicle (water) was administered (250 mg/kg, oral
gavage) daily for 5 days. Acute cystitis (200 mg/kg, 4 h, i.p.) was induced on the last day, followed by
mechanical sensitivity testing. Mice were acclimated to the testing environment on days 3, 4 and 5. (B)
Imatinib mesylate pre-treatment via gavage does not significantly affect pelvic somatic sensitivity in acute
(4 h) CYP-induced cystitis female mice. Imatinib mesylate pre-treatment significantly reduces the 50%
withdrawal threshold in control (no CYP) female mice. n = 5-6. Values are means ± SEM. *P ≤ 0.05; **P ≤
0.01; ***P ≤ 0.001; ****P ≤ 0.0001 by two-way ANOVA with Bonferroni’s multiple comparisons test.
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Figure 2: PDGFRα inhibition with imatinib mesylate treatment via intravesical infusion does not
significantly affect pelvic somatic sensitivity or behavior in an acute (4 h) cyclophosphamide (CYP)induced cystitis female mouse model
Somatosensitivity of the pelvic region was determined with calibrated von Frey filaments in control (no
CYP) and acute, 4 h CYP-induced cystitis mice treated with imatinib mesylate via intravesical bladder
infusion. Stimulation was specific to the abdominal-pelvic region, overlying the urinary bladder. (A) Acute
(4 h) cyclophosphamide (CYP)-induced cystitis experimental schedule for imatinib mesylate treatment via
intravesical infusion, somatic sensitivity studies. Acute, 4 h CYP-induced cystitis mice received a
transurethral instillation of imatinib or vehicle (saline) for 30 mins, followed by mechanical sensitivity and
behavioral testing. (B) Imatinib mesylate treatment via bladder infusion does not significantly affect pelvic
somatic sensitivity in acute (4 h) CYP-induced cystitis mice nor in control (no CYP) mice. (C, D) Total
time moving, and total licking behaviors were also analyzed in each infusion treatment cohort. Mice were
adequately acclimated to the testing environment and observation cages. Imatinib mesylate infusion does
not significantly affect behavioral measures in 4 h CYP-induced cystitis mice nor in control (no CYP)
mice. All behavioral results were analyzed by a blinded evaluator. n = 8-10. Values are means ± SEM. *P ≤
0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001 by two-way ANOVA with Bonferroni’s multiple
comparisons test.
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